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Abstract 
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of clinically 
aggressive malignancies derived from mature (post-thymic) T-cells or Natural Killer cells, 
which comprise approximately 10-15% of all non-Hodgkin lymphomas. In contrast to 
aggressive B-cell malignancies, which are often curable and for which advances in 
understanding disease biology have resulted in new targeted treatment approaches, the 
treatment of PTCL remains inadequate. Apart from those with ALK-positive anaplastic 
large cell lymphoma (ALCL), patients presenting with PTCL have a poor outcome with 
only approximately 25% cured of their disease. The pathogenesis of T-cell lymphoma is 
poorly understood and few new targeted therapies are emerging. 
The transcription factors BCL6, IRF4 and BLIMP1 function in a regulatory network 
to direct mature B-cell differentiation. They are genetically altered and dysregulated in 
B-cell malignancy, and BCL6 and IRF4 represent potential therapeutic targets. These 
transcription factors also interact to regulate T-cell differentiation and emerging data 
indicated genetic alteration in some PTCL. This project investigated the importance of 
BCL6, IRF4, and BLIMP1 in the regulation of PTCL cell line proliferation and survival using 
ALCL cell lines in vitro as a model.  
Lentiviral-mediated knockdown of BCL6 and IRF4, and overexpression of BLIMP1, 
each resulted in reduced proliferation / survival of some, but not all, ALCL cell lines 
tested, and no clear pattern of response emerged. These effects were associated with 
small changes in cell cycle progression and induction of apoptosis. Modulation of each 
of the transcription factors had small effects on the expression of the others, again with 
variable patterns between cell lines. IRF4 knockdown revealed a positive interaction 
with c-MYC aŶd BLIMPϭα iŶ Ϯ/ϯ ALK+ ALCL cell lines. Intriguingly, ALK inhibition with 
crizotinib revealed different patterns of NPM-ALK mediated dysregulation of the 
transcription factors across the cell lines. These data support a positive role for BCL6 and 
IRF4 in the maintenance of ALCL, and an inhibitory / tumour suppressor role for BLIMP1, 
but show variability in dependencies between cell lines which could reflect clinically 
important disease heterogeneity which must be considered when targeting this 
transcription factor axis therapeutically. 
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1. Introduction 
1.1 The immune system 
The key to the immune response in humans is the diverse nature of the 
lymphocytes present (figure 1.1). Lymphocytes are broadly divided into B-cells and T-
cells; each cell type plays a specific role required for successful, adaptive immune 
response.  
1.1.1 B-cell development 
B and T-cells are produced in the bone marrow from progenitor 
haematopoietic stem cells. B-cells progress through a number of stages to reach a 
functional effector cell: pro-B-cell, large pre-B-cell, mature naïve B-cell, activated B-
cell, Germinal Center (GC) B-cell, plasma cell/memory B-cell.  
  
Figure 1.1: Differentiation of B and T-cells upon stimulus by Antigen Presenting Cell 
The presence of a foreign antigen on the cell surface of antigen presenting cells (APCs) stimulates activation and 
differentiation of B-cells circulating the blood and T-cell precursors. GC = Germinal Centre, TH = T helper cell, TReg = 
Regulatory T helper cell, TFH = Follicular T helper cell. Dashed lines indicate where the T-helper cells presence is required 
for the formation of other cells of B-cell lineage. 
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To produce functional immunoglobulin (Ig) proteins on B-cell membranes, B-
cell precursors interact with stromal cells and cytokine signals to stimulate Ig heavy 
and light chain locus rearrangements. The combination of rearranged light and heavy 
chain genes produce an antibody which is unique to the cell. Now a mature naïve B-
cell, it is released into the blood.  
Upon encountering a pathogen, antigen presenting cells (APCs), such as 
macrophages and dendritic cells, engulf and digest the pathogen to present foreign 
antigens on their cell surface via Major Histocompatibility Complexes (MHC). The 
antigens stimulate activation of B-cells and T-cells (figure 1.1) (Tangye and Tarlinton, 
2009, Dudley et al., 2005). With help from antigen-activated T-cells naïve B-cells 
become activated and form or traffic to germinal centers where they differentiate into 
GC B-cells. Here, the GC B-cells undergo affinity maturation for their cognate antigen. 
There are two main processes undertaken by a GC B-cell to generate a mature 
antibody, Somatic Hypermutation (SHM) and Class-switch recombination (CSR). SHM is 
a process by which mutations are introduced into the coding sequence of 
immunoglobulin heavy and light chain genes. Mutations enhancing the affinity of 
immunoglobulin for antigen are positively selected within the germinal center 
microenvironment resulting in outgrowth of B-cells with high affinity antibody 
production. CSR is a process whereby deletional recombination changes the constant 
region segment used by a rearranged immunoglobulin gene to produce an 
immunoglobulin of a different isotype (figure 1.2). 
Upon achieving affinity maturation, the GC B-cell will then differentiate into 
either a long-lived memory B-cell or an effector antibody-secreting Plasma cell. Central 
to this pathway is the regulation of the BCL6-IRF4-BLIMP1 transcription factor axis 
which governs progression through the GC maturation phases (figure 1.3) (De Silva and 
Klein, 2015). 
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Figure 1.2: Germinal Center B-cell maturation 
Prior to entry to the lymph node, naïve B-cells detect antigen and receive co-stimulatory signals from T-helper cells 
and enter the dark zone of the Germinal Center (GC). The B-cell, now termed a centroblast, undergoes one or more 
rounds of proliferation and somatic hypermutation (SHM) through upregulation of Activation Induced Deaminase 
(AID). After this, the centroblast migrates to the light zone of the GC and are subjected to Follicular Dendritic Cells 
(FDCs) with target antigen present on their cell surface. At this point the mutated B-cell Receptor (BCR), a product of 
SHM, will bind the antigen. If binding affinity is too low the centrocyte undergoes apoptosis due to lack of survival 
signals from the FDCs. At this point, B-cells are defined as centrocytes. Centrocytes then undergo another round of 
selection by interaction of CD40 with CD40L found on follicular B-helper T-cells (TFH).  A small subset of centrocytes 
which do not achieve the required affinity can recirculate into the dark zone to undergo further SHM. In addition, 
light zone centrocytes may undergo immunoglobulin class-switch recombination (CSR) before recirculating into the 
dark zone before undergoing further proliferation and SHM. Finally, the centrocytes can either leave the germinal 
center as a mature plasma cells or memory B-cells. 
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1.1.2 T-cell development 
Like B-cells, T-cells pass through a number of intermediate cell stages to 
produce a mature T-cell: Pre-thymic precursor, early thymic precursor, double negative 
thymocyte (CD4-CD8-), double positive thymocyte (CD4+CD8+), single positive 
thymocyte (CD4+CD8- or CD4-CD8+), and finally a single positive CD4+ or CD8+ T-cell 
(Godfrey and Zlotnik, 1993) (figure 1.4).  
CD4+ T-cells regulate the mammalian immune response, facilitating adaptive 
immunity of the host. CD4+ T-cells can differentiate into one of many T helper cell 
types, which function to aid other lymphocytes in their specialisation through the 
production of cytokines (table 1.1). Helper T-cells are not necessarily terminally 
differentiated; further differentiation to other subsets can be achieved. T-helper cell 
plasticity is controlled by the presence of certain cytokines and expression of specific 
genes (figure 1.5) (Luckheeram, 2012). CD4+ T-cells also have the ability to 
differentiate into memory CD4 T-cells characterised by expression of BCL6 (Choi et al., 
2013). Memory CD4+ T-cells remain a controversial topic with regards to which T-
helper cells can contribute (Hale and Ahmed, 2015). Multiple studies have 
demonstrated long-term retention of both TH1 and TFH cells for up to 150 days post-
infection clearance which, upon reinfection, rapidly proliferated and recall the TFH 
Table 1.1: CD4 T-helper cell subsets and roles of each 
 
T-helper subset 
Interleukins 
required 
Master 
regulator Role 
Follicular B Helper T-cell 
(TFH) 
IL6, IL21  BCL6 Involved in the development of antigen-specific 
B-cell immunity through germinal center 
production and antibody maturation induction 
(Bollig et al., 2012, Breitfeld et al., 2000, Vinuesa 
et al., 2005). 
T-helper 2 (TH2) IL2, IL4 GATA3 Maintain the persistence of allergies through B-
cell interaction (Del Prete, 1992, Sokol et al., 
2009). 
T-helper 9 (TH9) TGF-β, ILϰ RBPJ Maintain the persistence of allergies through B-
cell interaction (Staudt et al., 2010). 
T-helper 1 (TH1) ILϭϮ, IFNɶ T-bet Enhance macrophage activity and produce 
opsonising antibodies (Murray et al., 1985, 
Afkarian et al., 2002, Lugo-Villarino et al., 2003). 
T-helper 17 (TH17) IL6, TGF-β RORɶT Mount immune responses against extracellular 
pathogens (Annunziato et al., 2007, Ivanov et al., 
2006, Weaver et al., 2006). 
Regulatory T-cell (Treg) TGF-β, ILϭϮ FOXP3 Suppression of the immune system (Jutel and 
Akdis, 2008). 
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Figure 1.5: Effect of cytokines upon the differentiation of CD4+ T-cells. 
Black arrows indicate the differentiation of the naïve CD4+ T-cell to the helper T-cell subsets in the presence of 
particular cytokines (red text). Orange arrows and text indicates the cytokine produced by the specific T-helper 
subset which promotes self-aŵplifiĐatioŶ. Blue teǆt iŶdiĐates the ͞ŵasteƌ ƌegulatoƌ͟ of eaĐh T-helper subset. 
Green arrows indicate the further differentiation T-helper cells can undergo when stimulated by specific cytokines 
(green text). Although the transcription factor, RBPJ, has been found to be upregulated in Th9 cells (van den Ham 
et al., 2010) it has not yet been verified as the regulator of Th9 cells.  
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phenotype (Luthje et al., 2012, Pepper et al., 2011, Hale et al., 2013). In another study, 
TH2 cells derived from mice infected with N.brasiliensis, transferred into an 
immunocompromised mouse recipient and rested for 30 days before reinfection with 
the parasite, were sufficient to clear infection (Zaph et al., 2006). Therefore, currently 
it is believed that TH1, TH2, and TFH cells are able to form long lived memory CD4+ T-
cells. 
Naïve CD8+ T-cells undergo a large proliferative stage upon detection of foreign 
antigen; this clonal expansion gives rise to differentiated CD8+ T-cells which can either 
develop into cytotoxic T-cells with a short lifespan or longer-living memory T-cells. If 
another encounter with the corresponding antigen occurs, then memory cells can 
rapidly proliferate and differentiate into cytotoxic T-cells (Harty and Badovinac, 2008, 
Williams and Bevan, 2007) (figure 1.6). 
Cytotoxic CD8+ T cell populations are defined by the ability to secrete 
interferon-ɶ ;IFNɶͿ aŶd to pƌoduĐe ĐhaƌaĐteƌistiĐ effeĐtoƌ ŵoleĐules used iŶ Đell lǇsis 
such as Granzyme B and Perforin (Belz and Kallies, 2010). Memory CD8+ T cell 
populations, conversely, are divided into two subgroups, categorised by the expression 
of specific markers. The two groups are defined as Central memory T-cells (TCM) and 
Effector memory T-cells (TEM). TCM express high levels of the chemokine receptor, 
CCR7 as well as CD62L whereas TEM express these proteins at a lower level whilst 
producing cytokines and cytolytic molecules (Sallusto et al., 1999). Interestingly, TEM 
are very similar to cytotoxic CD8+ T-cells in their features but differ in the ability to 
exist once foreign antigen has been removed (Gebhardt et al., 2009, Hikono et al., 
2007). Therefore, it is generally accepted that TEM are the long-lived effector T-cells 
whilst TCM require further differentiation to achieve their cytotoxic potential, 
suggesting a longer-lived memory T-cell subset. The co-ordination of these cell types 
allows for an efficient defensive system against invading pathogens and facilitates a 
more effective clearance of the disease should it arise again.
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1.2 Lymphoma 
 Most cancers are believed to adhere to specific hallmarks outlined by Hanahan 
and Weinberg, namely: the ability to evade growth suppressors, ability to activate 
invasion and metastasise to other tissue types, to reproduce indefinitely, to induce 
angiogenesis, to escape cell death, and to sustain proliferation (Hanahan and 
Weinberg, 2000). Lymphomas are neoplasms of lymphoid cells which form solid 
tumours in lymph nodes or extranodal tissues and may be present as indolent or 
aggressive disease (Swerdlow et al., 2008). As lymphocytes circulate around the body, 
lymphomas do not necessarily need to acquire new invasive qualities. Like all cancers, 
lymphomas are genetic diseases, typically being caused by multiple genetic lesions 
such as translocations, point mutations, and deletions which target similar pathways. 
Generally, genetic lesions associated with lymphoma dysregulate genes involved in 
cancer hallmark pathways critical for lymphocyte development, proliferation, 
differentiation and survival. 
 According to the World Health Organisation (WHO) Classification of 
lymphomas, these neoplasms can be sub-divided into categories. Firstly, lymphomas 
are defined as Hodgkin or Non-Hodgkin Lymphoma (NHL), somewhat arbitrarily and 
based on the early historical characterisation of Hodgkin lymphoma defined by the 
presence of Reed-Sternberg cells, a multinucleated CD30+CD15+ B-cell (Kuppers et al., 
2012). Non-Hodgkin lymphomas are then subdivided according to origin from B-cells or 
T/Natural-Killer (NK)-cells and subsequently sub-classified based upon clinical, 
pathologic and genetic features (Swerdlow et al., 2008). The incidence of each subclass 
can be found in figure 1.7. 
1.3 B-cell Non-Hodgkin lymphoma 
 The most common B-cell Non-Hodgkin Lymphomas (B-NHL) subtypes are 
Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). DLBCL accounts 
for approximately 30% of all NHL whilst FL also accounts for 30% of all NHL in the 
Western World (Ott and Rosenwald, 2008, Hartmann et al., 2008). Investigation into 
DLBCL through gene expression profiling has allowed further subdivision of the group. 
DLBCLs with strong expression of GC gene signatures are categorised into Germinal 
Center B-cell Diffuse Large B-cell Lymphoma (GCB-DLBCL), whilst those with gene 
signatures relating to activated B-cells give rise to lymphomas which resemble post- 
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Figure 1.7: Incidence of lymphomas (adapted from (Smith et al., 2015)) 
Crude incidence of lymphoma subtypes per 100,000 people in the UK from data 
collected from the UK’s Haematological Malignancy Research Network. PTCL 
NOS = Peripheral T-cell lymphoma, Not otherwise specified, AITL = 
Angioimmunoblastic T-cell lymphoma, ALK = Anaplastic Lymphoma Kinase, 
ALCL = Anaplastic Large Cell Lymphoma 
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germinal center B-cells, regarded as Activated B-cell Diffuse Large B-cell Lymphoma 
(ABC-DLBCL). Finally, a third group of DLBCL is defined as neoplasms arising from 
thymic B-cells and are termed Primary Mediastinal B-cell lymphoma (PMBL). 
 GCB-DLBCL typically exhibit amplifications of the MIHG1 gene on chromosome 
13, which harbours the miR-17-92 microRNA, gains of a 7.6Mb region of 12q, and 
amplification of REL on chromosome 2, together with losses of PTEN on chromosome 
10 by array CGH (Lenz et al., 2008b). ABC-DLBCLs are typically characterised by trisomy 
3, gains of 18q and a 9Mb gain of 19q, as well as 6q losses and deletion of the 
INK4α/ARF locus of 9p (Lenz et al., 2008b). PMBLs exhibit gains of 9p24 (encompassing 
the JAK2 gene) and 20p as well as monosomy 10 (Lenz et al., 2008b). In addition, 
DLBCLs often carry translocations of BCL2, c-MYC, and/or BCL6 singly, or in 
combiŶatioŶ as aggƌessiǀe ͞douďle-hit͟ oƌ ͞tƌiple-hit͟ (Snuderl et al., 2010). These 
translocations give rise to aberrant gene expression through promoter/enhancer 
substitution, often with immunoglobulin genes. BCL6 (3q27) translocations have been 
reported to be present in 19.5% of DLBCL cases giving rise to constitutive expression of 
B-cell Lymphoma (BCL6) protein (Shustik et al., 2010). The t(14;18)(q32;q21) 
translocation involving IGH and BCL2 is present in 10-40% of DLBCL cases (Tsujimoto et 
al., 1985) whilst translocations involving c-MYC (8q24) are rarer, present in up to 14% 
of DLBCL cases (Barrans et al., 2010). BCL6 is highly expressed in GCB-DLBCL, as the cell 
of origin naturally expresses high levels of BCL6, however translocations of BCL6 occur 
in both GCB- and ABC-DLBCL (Thieblemont and Briere, 2013). BCL6 may also be 
dysregulated in DLBCL by other means. Loss of 6q across DLBCL is of particular interest 
in this regard as this region contains PRDM1, the gene encoding B Lymphocyte-
Induced Maturation Protein 1 (BLIMP1), a transcriptional repressor of BCL6 (Bea et al., 
2005). ABC-DLBCLs typically demonstrate high Nuclear Factor kappa-light-chain-
enhancer of Activated B-cells (NF-kB) activation, in many cases brought about by 
constitutively active B-cell Receptor (BCR) signalling (Lenz et al., 2008a). In one study, 
approximately 10% of ABC-DLBCL and 4% of GCB-DLBCL harboured mutations in 
CARD11, a gene required for NF-kB transcription via BCR stimulation (Lenz et al., 
2008a). In addition to CARD11, activating mutations in MYD88, CD79A/B, and 
inactivating mutations in TNFAIP3 give rise to constitutive NF-kB activity in ABC-DLBCL 
(Pasqualucci and Dalla-Favera, 2014). 
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Generally, FL is a less-aggressive lymphoma than DLBCL but does have the 
ability to transform into a more aggressive lymphoma (Ott and Rosenwald, 2008). 
Approximately 80-90% of FL cases contain the t(14;18)(q32;q21) translocation 
juxtaposing BCL2 with the IGH promoter region (Ott and Rosenwald, 2008). Despite 
this, published data suggests that the translocation alone is not sufficient to produce 
FL (Liu et al., 1994, McDonnell et al., 1989). Therefore, other genetic aberrations are 
believed to contribute to the transformation of these cells. The genetics of the disease 
are quite variable. A recent publication demonstrated, through use of whole-exome 
sequencing,  that FL harbour genetic lesions such as copy number variations and single 
nucleotide mutations in genes required for apoptosis, chromatin remodelling, cell 
cycle and immune evasion such as FAS, CREBBP, c-MYC, TP53, and B2M (Pasqualucci et 
al., 2014). 
1.4 Peripheral T-cell lymphoma  
Peripheral T-cell lymphomas (PTCL) are neoplasms of NK cells or mature T-cells 
;eitheƌ αβ oƌ ɶɷ T-cells) which account for approximately 12% of all non-Hodgkin 
Lymphoma (Piccaluga et al., 2011).   
The World Health Organisation (WHO) classification of PTCL recognises a 
number of PTCL subtypes (figure 1.8A and 1.8B, (Swerdlow et al., 2008)), the most 
common of which are:  
- PTCL not otherwise specified (PTCL-NOS) 
- Angioimmunoblastic T cell Lymphoma (AITL) 
- ALK+ (Anaplastic Lymphoma Kinase) Anaplastic Large Cell Lymphoma (ALCL) 
- ALK- ALCL  
These lymphomas are clinically, genetically and pathologically heterogeneous and, 
from a pathological perspective, are often difficult to classify. Clinical behaviour and 
prognosis of PTCL is highly variable but systemic (as opposed to cutaneous) PTCL are 
generally aggressive in nature as shown in figures 1.8C and 1.8D (Pileri and Piccaluga, 
2012, Vose et al., 2008). Most systemic PTCL are initially treated with the same CHOP 
chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisolone) but 
relapse is common and despite aggressive second-line chemotherapy treatment, long-  
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term disease-free survival is not achievable for most patients. Novel therapeutic 
approaches to the treatment of PTCL are desperately needed. Recently, the Histone 
Deacetylase (HDAC) inhibitors Belinostat and Romidepsin, and the antifolate agent 
Prelatraxate, have been approved for use for relapsed or refractory PTCLs due to the 
reasonable sensitivity to these drugs demonstrated in clinical trials (Bates et al., 2015, 
McDermott and Jimeno, 2014). It is unknown why PTCLs exhibit high sensitivity to 
HDAC inhibition as gene expression changes of PTCLs treated with these drugs vary 
widely between samples. However, down-regulation of the NF-κB pathǁaǇ is pƌeseŶt 
in many samples which could be indicative of potential mechanism of action (Bates et 
al., 2015). 
1.4.1 Peripheral T-cell Lymphoma – Not otherwise Specified 
PTCL-NOS are a group of mature T-cell lymphomas which do not show features 
of any other PTCL subgroup as defined by the WHO and are primarily nodal neoplasms 
(Vose et al., 2008). Typically, PTCL-NOS presents at a median age of 50-60 years with 
50-70% of patients being male (Weisenburger et al., 2011, Schatz et al., 2015). The 5-
year overall survival rate of PTCL-NOS is currently 30% (figure 1.8C) (Weisenburger et 
al., 2011). Of all PTCL-NOS patients, most receive combination chemotherapy with 
anthracycline treatment (80%) or combination chemotherapy without anthracycline 
(7%) (Weisenburger et al., 2011). However, studies have revealed no overall benefit to 
5-year overall survival with the addition of anthracycline (Vose et al., 2008).  
Until recently, the genetic changes underlying PTCL-NOS genetics have 
remained largely unknown but, in the last few years, studies have begun to identify 
recurrent alterations in the tumours. Studies have reported recurrent gains across 
7q22-ter harbouring the CDK6 gene and losses of 6q21, 9p21, and 17p13 regions 
encompassing PRDM1, CDKN2A and CDKN2B, and TP53 tumour suppressor genes 
respectively (Fujiwara et al., 2008, Zettl et al., 2004).  
Despite the low incidence of the t(5;9)(q33;q22) SYK-ITK translocation in PTCL-
NOS (Streubel et al., 2006), it has been reported that expression of the proliferative 
gene, SYK, is high across PTCL-NOS presenting a potential therapeutic avenue for this 
group of lymphoma (Fujiwara et al., 2008). More recently, recurrent translocations 
involving TP63 in PTCL-NOS have been identified (Vasmatzis et al., 2012). The clinical 
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relevance of this translocation is unknown to date, but it is currently believed to cause 
dysregulation of the P53 pathway in order to promote lymphomagenesis (Vasmatzis et 
al., 2012). 
Mutations are common in PTCL-NOS and multiple studies have confirmed a 
number of mutated targets. In one study of 28 diagnostic PTCL-NOS, a novel set of 
recurrently mutated genes were found across multiple pathways (Schatz et al., 2015), 
most harboured mutations in one or more genes involved in epigenetic modification 
such as TET1, TET2, MLL2, KDM6A, MLL, and CREBBP (Schatz et al., 2015). Another 
study confirmed the presence of TET2 mutations in 38% of PTCL-NOS cases (Palomero 
et al., 2014). In addition, recurrent frameshift/missense mutations in DNMT3A have 
been identified in 48.5% of PTCL-NOS (Sakata-Yanagimoto et al., 2014) and, in some 
rare cases, present simultaneously in TET2-mutated PTCL-NOS (Couronne et al., 2012). 
These mutations are believed to give rise to inactivation of both Tet methylcytosine 
dixogygenase (TET)2 and DNA (cytosine-5)-methyltransferase 3A (DNMT3A) as knock-
out mouse studies have demonstrated that deficiency of both genes results in 
increased self-renewal capabilities of haematopoietic stem cells (Challen et al., 2012, 
Quivoron et al., 2011). 
Recently the presence of a recurrent RHOA c.G50T gene mutation, giving rise to 
a Rho GTPase A (RHOA) G17V protein mutation, was identified in both AITL and PTCL-
NO“. This ŵutatioŶ leads to iŶhiďitioŶ of the ρ-signalling pathway as well as 
upregulation of the NF-κB, pϯϴ ŵitogeŶ-activated protein kinase, and mitogen-
activated protein kinase kinase/extracellular signal-regulated kinase pathways 
(Palomero et al., 2014, Manso et al., 2014). The authors surmise that PTCL-NOS 
patients presenting with this mutation could benefit from NF-κB iŶhiďitoƌs. AŶotheƌ 
study demonstrated the presence of a recurrent PLCG1 mutation, giving rise to a 
PLCG1 S345F protein mutation, in PTCL-NOS (Manso et al., 2015). PLCG-mutated PTCL-
NOS neoplasms exhibited lower overall survival rates compared to non-mutated 
counterparts. In addition, this mutation was associated with increased CD30-staining 
by immunohistochemistry (Manso et al., 2015). Therefore, it is believed that these 
tumours may benefit from CD30-targeted treatments.  
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1.4.2 Angioimmunoblastic T-cell lymphoma 
AITL is a lymphoma believed to be derived from follicular helper T-cells (TFH) 
based upon the expression of PD1, CXCL13, ICOS, CD57, CD10, BCL6 and other antigens 
similar to that of TFH present in the germinal center (Piccaluga et al., 2007, de Leval et 
al., 2007, Grogg et al., 2007).  
Patients presenting with AITL typically appear at a median age of 69 years with 
a 5-year overall survival rate of 33% (Xu and Liu, 2014). The treatment regimens for 
AITL are not standardised, as a result patients are treated with combination 
chemotherapy, steroids, or immunomodulators (Mosalpuria et al., 2014). However, 
AITL patient survival has not improved in the last 20 years (Xu and Liu, 2014). 
Cytogenetic and SNP array analysis of AITL has demonstrated recurrent 
trisomies of chromosome 21 and 19, as well as gains of 5q, 11q13, 20q13, 22q, and 3q. 
In addition, recurrent losses of 6q, 13q22-q23, 8p22, and 9p21 were reported 
(Fujiwara et al., 2008, Lepretre et al., 2000, Nelson et al., 2008). Of particular interest is 
the loss of 9q21, harbouring the tumour suppressor gene CDKN2A, highlighting a 
potential mechanism of transformation of AITL (Fujiwara et al., 2008). AITL has been 
linked with viral associations which contribute to homeostasis of the AITL 
microenvironment. Epstein-Barr Viruses (EBV) are found in the B-cells of almost half of 
all AITL cases and, whilst the mechanism has not been defined, the viruses are believed 
to control cytokine/chemokine production (Foss et al., 2011). 
Three independent gene expression studies of AITL have highlighted a set of 
genes involved in vascular biology as upregulated in AITL, most notably Vascular 
Endothelial Growth Factor (VEGF), which has been suggested to be a potential 
therapeutic avenue for AITL treatment (Piccaluga et al., 2007, Zhao et al., 2004, Iqbal 
et al., 2014). 
Many mutations have been identified in AITL recently. One study 
demonstrated, through targeted sequencing of 219 candidate genes, that 76% of AITLs 
harboured mutations in TET2, 33% exhibited mutations in DNMT3A, and 20% exhibited 
mutations in IDH2 (Odejide et al., 2014). Further, albeit less frequent, mutations were 
found in TP53, CCND3, EP300, JAK2, and STAT3 (Odejide et al., 2014). As previously 
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mentioned in PTCL-NOS, AITL also harbour mutations in RHOA although at a higher 
frequency. The most common mutation identified in RHOA is the RHO G17V mutation. 
Multiple studies have confirmed the presence of this mutation in AITL (Palomero et al., 
2014, Sakata-Yanagimoto et al., 2014, Yoo et al., 2014). In normal T-cells, RHOA is 
required for T-cell migration and motility, as well as adhesion and cell-cell interactions 
(Heasman et al., 2010). Investigation into this mutation in AITL has revealed it exhibits 
a dominant-negative phenotype resulting in loss of RHOA function (Sakata-Yanagimoto 
et al., 2014, Yoo et al., 2014). This effect is believed to improve motility of the TFH cell 
to the follicular environment whereby it can drive proliferation (Ahearne et al., 2014). 
1.4.3 Anaplastic Large Cell Lymphoma 
ALCL are tumours of large pleomorphic cells which express CD30 (previously 
termed Ki-1). HistologiĐallǇ, ŵost ALCLs aƌe defiŶed ďǇ the pƌeseŶĐe of ͞hallŵaƌk͟ Đells 
which have enlarged nuclei with a characteristic horseshoe shape (Swerdlow et al., 
2008). However, the ALCL histotype encompasses multiple morphological variants: 
common, giant cell-rich, Hodgkin-like, small-cell type, and lympho-histiocytic defined 
in table 1.2 (Piccaluga et al., 2010).  
Cumulatively, ALCL encompass 3 separate subgroups as defined by the WHO 
(Swerdlow et al., 2008): 
- Systemic ALCL, divided into: 
o ALK+ ALCL 
o ALK- ALCL 
- Primary Cutaneous Anaplastic Large Cell Lymphoma (C-ALCL) 
Variant Specific Histological Features 
Common Cohesive neoplastic cells found predominantly in lymph node sinuses 
Giant-cell rich Presence of large multi-nucleated cells with Reed-Sternberg characteristics 
Hodgkin-like 
CD30+ anaplastic cells surrounded by sclerotic bands, typically with ALK protein 
expression  
Small-cell type Variable neoplastic cell sizes with irregular nuclei, can contain sheets of CD30+ blasts 
Lympho-histiocytic 
Variable neoplastic cell sizes with irregular nuclei with abundance of reactive 
histiocytosis containing irregular nuclei 
 
Table 1.2: The Histological subgroups of ALCL as defined by the WHO Classification of Haematological 
Malignancies 
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Accounting for 10-15% of all paediatric NHL, systemic ALK+ ALCLs typically 
present at a median age of 10-11 years with a predominance towards males (Kinney et 
al., 2011). ALK- ALCLs are more common in adults, typically presenting at a median age 
of 40-65. Multiple studies have detailed the observation that the 5 year overall survival 
of ALCL varies between ALK+ (80%) and ALK- (48%) subgroups (Falini et al., 1999, 
Gascoyne et al., 1999, Lechner et al., 2012). The reason for the favourable prognosis of 
ALK+ ALCL is unclear, however it may be attributed to the younger age and relatively 
lower genetic complexity of ALK+ ALCL compared to ALK- ALCLs. Typically ALK+ ALCLs 
demonstrate few genetic lesions aside from the characteristic ALK translocation whilst 
ALK- ALCLs harbour lesions across multiple regions (Boi et al., 2013).  
C-ALCL, conversely, present as nodular, often ulcerated, tumours of the skin 
which are typically CD30+ and granzyme B-positive but lack ALK expression, with a 
median age of 60 years (Stein et al., 2000, Su et al., 1997, Wood et al., 1996). C-ALCL 
accounts for approximately 9% of all cutaneous T-cell lymphoma (CTCL) and has a 
much better prognosis than systemic ALCL counterparts with a 5 year overall survival 
of 90-95% (Querfeld et al., 2010). 
Patients presenting with systemic ALCL are typically given the standard 
combination chemotherapy, CHOP. Intensive chemotherapy in combination with stem-
cell transplant may be prescribed for patients with a poorer prognosis (Armitage, 
2012).  
Despite being well studied, the cell-of-origin for ALCLs has not been elucidated. 
Independent of histological subtype, most ALCLs demonstrate strong expression of 
membranous CD30 (Falini et al., 1995, Gascoyne et al., 1999). CD30 is a 120kDa protein 
which is required for regulation of apoptosis and induction of NF-κB eǆpƌessioŶ iŶ 
activated B and T-cells (Wright et al., 2007). Expression of CD30 is not exclusive to ALCL 
however, with reported cases of DLBCL also expressing the glycoprotein (Piccaluga et 
al., 2010). Therefore, other common markers are used to distinguish ALCL such as 
granzyme B, perforin, and TIA-1 (Piccaluga et al., 2010). 
 Recent work has focused on profiling the molecular signature for ALCLs. 
Recently, two independent groups have attempted to define ALCL at the molecular 
level (Agnelli et al., 2012, Iqbal et al., 2014). Through gene expression profiling, ALCLs 
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demonstrate high expression of CD30, BATF3 and TMOD1 with low expression of T-cell 
receptor genes: LCK, FYB, and CSK1 (Iqbal et al., 2014).  
1.4.3.1 Genetics of ALK+ ALCL 
 Genetically, ALK+ ALCL typically exhibit gains of 12p and 17q24-qter, and losses 
of 4q13-q21 and 11q14 (Salaverria et al., 2008). However, the most common 
aberration is the ALK translocation. ALK is a gene, located at chromosome 2p23, that 
encodes a receptor tyrosine kinase of 177kDa which, after post-translational 
modifications, can increase to 220kDa in size (Stoica et al., 2001). ALK contains several 
domains: an extracellular ligand-binding domain, a transmembrane domain, and a 
cytoplasmic kinase catalytic domain (Stoica et al., 2001, Stoica et al., 2002). Part of the 
insulin-receptor superfamily, ALK shares homology with Leukocyte Tyrosine Kinase 
(LTK) (Stoica et al., 2001). The exact role of ALK in normal tissues has yet to be 
definitively identified but restricted expression of ALK in the nervous system during 
foetal development suggests a physiological role in this context. The putative ALK 
ligands Pleiotropin (PTN) and Midkine (MK) are similarly expressed in the foetal 
nervous system but specific interactions between ALK and these ligands in human cells 
has yet to be demonstrated (Moog-Lutz et al., 2005, Motegi et al., 2004, Mourali et al., 
2006, Mathivet et al., 2007).  
Recurrent translocations involving ALK were originally observed in the 1980s 
(Benz-Lemoine et al., 1988, Fischer et al., 1988) however the translocation partners 
were not identified until 1994 by two separate groups (Morris et al., 1994, Shiota et al., 
1994). ALK translocations, producing ALK fusion genes have been observed across 
many types of cancer such as: Inflammatory Myofibroblastic Tumours, DLBCLs, Renal 
Medulla Carcinoma, Serous Ovarian Carcinoma, and non-small-cell lung cancer (NSCLC) 
(Hallberg and Palmer, 2013). The most common chromosomal translocation of ALK in 
ALCL, is the t(2;5)(p23;q35) accounting for up to 80% of all ALK+ ALCL cases (Amin and 
Lai, 2007, Stein et al., 2000). Hoǁeǀeƌ, otheƌ tƌaŶsloĐatioŶ paƌtŶeƌs fusiŶg to the ϱ’ eŶd 
of ALK have been identified including: RNF213 (Cools et al., 2002), ATIC (Colleoni et al., 
2000, Cools et al., 2002, Ma et al., 2000), TFG (Hernandez et al., 1999), MSN (Tort et 
al., 2001), TPM3 (Lamant et al., 1999, Siebert et al., 1999), TPM4 (Meech et al., 2001), 
MYH9 (Lamant et al., 2003), and CLTCL(Touriol et al., 2000) (summarised in table 1.3). 
All ALK fusion genes share common features; each partner is highly expressed in 
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normal cells and is the cause of constitutive fusion gene expression. In addition 
partners contain, either complete or in part, an oligomerisation domain which is 
believed to mediate auto-associative interactions of ALK by mimicking ligand-mediated 
activation of the tyrosine kinase (Hernandez et al., 1999, Lamant et al., 1999, Lamant 
et al., 2003). Critically, each translocation also retains the complete tyrosine kinase 
domain of ALK.  
 Constitutively active, ligand-independent ALK, derived from fusion genes 
mediates its activity through a number of important signalling pathways. ALK interacts 
with the RAS-ERK, PI3K-AKT, and the Janus Kinase (JAK)-Signal Transducer and 
Activator of Transcription (STAT)3 pathways to promote expression of transcription 
factors involved in cellular growth, differentiation, and anti-apoptotic pathways such 
as Jun Proto-Oncogene ;JUNͿB, C/EBPβ, BCLϮAϭ, MMPϵ, INKϰA, aŶd Hypoxia Inducible 
Factor 1a (HIF1A) (Hallberg and Palmer, 2013). Of particular interest is the JAK-STAT3 
pathway, as this is believed to play a key role in survival of ALCL. STAT3 is activated 
through phosphorylation either by ALK directly, or via JAK3 signalling (Chiarle et al., 
2008). Activated STAT3 induces the expression of many targets, most importantly 
BCL6, IRF4, PRDM1α, BCL2, BCL-XL, C/EBPβ, Survivin, and MCL1 (Chiarle et al., 2008, 
Kwon et al., 2009, Walker et al., 2013). In agreement with this, ChIP-Seq analysis of 
phosphorylated STAT3 (p-STAT3) demonstrates binding to BCL6 in the breast cancer 
cell line, SK-BR-3, resulting in increased expression of BCL6 mRNA (Walker et al., 2013). 
Furthermore, knockout of Irf4 in normal murine T-cells abolishes a STAT3-dependent 
PRDM1 luciferase reporter construct signal compared to wild-type controls suggesting 
Interferon Regulatory Factor (IRF)4 is also a direct p-STAT3 target (Zamo et al., 2002). 
Table 1.3: Documented cases of translocations involving ALK in ALCL 
Gene name Gene symbol Translocation 
Nucleophosmin NPM t(2;5)(p23;q35) 
Ring finger protein 213 RNF213 (ALO17) t(2;17)(p23;q25) 
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP 
cyclohydrolase ATIC inv(2)(p23;q35) 
TRK-fused gene TFG t(2;3)(p23;q21) 
Moesin MSN t(2;X)(p23-q11-12) 
Tropomyosin 3 TPM3 t(1;2)(p23;q35) 
Tropomyosin 4 TPM4 t(2;19)(p23;p13.1) 
Myosin Heavy Chain 9 MYH9 t(2;22)(p23;q11.2) 
Clathrin Heavy Chain CLTCL t(2;17)(p23;q23) 
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Taken together these data, with the observation that p-STAT3 is highly expressed in 
ALK+ ALCLs (Khoury et al., 2003, Zamo et al., 2002), suggests that STAT3 is vital for 
cellular survival and presents an attractive therapeutic target for ALK+ ALCLs. 
 Inhibition of ALK as a therapeutic avenue has gained popularity in recent years 
due to the large spectra of cancers which harbour an ALK translocation. The only Food 
and Drug Administration approved drugs currently available for ALK are Crizotinib and 
Ceritinib. Crizotinib is a dual ALK and c-Met inhibitor which is approved for use in 
NSCLC patients harbouring an ALK translocation (Sahu et al., 2013). Crizotinib and 
Ceritinib can bind ALK and inhibit the phosphorylation of the tyrosine kinase (Cui et al., 
2011, Sahu et al., 2013, Friboulet et al., 2014). Recently, Crizotinib has entered clinical 
trials for treatment of patients with relapsed or refractory ALCL (Mosse et al., 2013). 
Despite initial good response for patients, there is worry that resistant-forms of the 
cancer will arise with prolonged treatment. One study demonstrated the generation of 
resistance to Crizotinib in vitro by subjecting Karpas-299 cells to low levels of drug 
(Zdzalik et al., 2014). Interestingly, sequencing of the resistant Karpas-299 cells 
revealed an activating ALK mutation, specifically I1171T, which was believed to confer 
resistance (Zdzalik et al., 2014). Another study performed sequencing of NPM-ALK 
gene mutations in ALK+ ALCL tumours which received standard chemotherapy 
regimens and detected two missense mutations in the gene across the ALCL tumour 
panel (Lovisa et al., 2015). The mutations detected in this study however, did not result 
in activation of ALK. The c.872G>A (corresponding to a R291Q protein mutation) 
resulted in autophosphorylation of NPM-ALK, comparable to wild-type NPM-ALK, 
when introduced into HEK-293T cells (Lovisa et al., 2015). However the second 
mutation detected, c.1004G>A (corresponding to a R335Q protein mutation), markedly 
reduced NPM-ALK autophosphorylation as well as STAT3 phosphorylation and resulted 
in increased sensitivity to Crizotinib (Lovisa et al., 2015). However, in other ALK-driven 
malignancies such as Neuroblastoma as well as accelerated mutagenesis screens, 
activating ALK mutations have been detected which confer resistance to Crizotinib 
(Bresler et al., 2011, Zhang et al., 2011). Therefore taken together, these studies 
demonstrate that, although rare, mutations in NPM-ALK are a possibility in ALK+ ALCLs 
and therefore novel therapeutic alternatives are required. Currently, novel inhibitors 
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of ALK, HSP90, or mTOR are under investigation to attempt to overcome resistance 
(Zdzalik et al., 2014).  
Specific gene signatures have been defined for ALK+ and ALK- ALCLs from gene 
expression profiling. According to one study, ALK+ ALCLs are enriched for gene 
signatures involved in cellular proliferation and survival, such as HIF1A, Interleukin (IL)-
10, and K-RAS target genes compared to ALK- ALCLs (Iqbal et al., 2014). Previously 
published data from this group also revealed that ALK+ ALCLs are enriched for cytokine 
signalling regulators of STAT3, IL-26 and IL-31R (Iqbal et al., 2010). Other gene 
expression profiling studies have found that BCL6, PTPN12, CEBPB, SERPINA1 and GAS 
are overexpressed in ALK+ ALCL. In addition, ALK+ ALCLs demonstrated high levels of 
BCL6, C/EBPbeta, and SERPINA1 protein by tissue microarray staining (Lamant et al., 
2007). Another independent study has demonstrated that ALK+ ALCLs also over-
express signal transduction molecules such as SYK, LYN, and CDC37 (Thompson et al., 
2005). 
In addition to changes in protein-coding genes, microRNAs have now been 
implicated in the pathogenesis of many malignancies. MicroRNAs are important for 
normal T-cell development as well as regulation of cancer biology. These RNAs bind to 
processed mRNA and lead to the degradation or inhibition of translation (Lawrie, 
2013). Recently, through use of a transgenic-ALK mouse models in combination with 
primary ALCL tumours, microRNA profiles for ALCL have been established (Merkel et 
al., 2010). Specifically, ALK+ ALCLs express high levels of different miR-17-92 cluster 
members: miR-20b, miR106a, miR-20a, miR-886-3p, and miR-17 (Merkel et al., 2010). 
Common to both ALCL subgroups, miR-101 is downregulated and, interestingly over-
expression of the microRNA in ALK+ ALCL cells reduced proliferation of these cells 
(Merkel et al., 2010). In addition, a separate independent study also revealed that 
ALK+ ALCLs down-regulate miR15A/16-1, which is known to regulate HIF1A and VEGF 
expression in ALCL (Dejean et al., 2011).  
As a whole, these data highlight the common gene expression and microRNA 
alterations that occur across ALCL suggesting that ALCLs may share a common 
precursor. Important variances between gene expression profiles of the subsets would 
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not only allow tailored treatment but highlight the differences in transforming 
mechanism.  
1.4.3.2 Genetics of ALK- ALCL 
ALK- ALCLs are genetically less well characterised than ALK+ ALCLs, but by 
definition they lack the ALK translocation (Swerdlow et al., 2008). ALK- ALCLs typically 
exhibit gains of 1q and 6p21 as well as losses of 17p13 and 6q21 (encompassing TP53 
and PRDM1 respectively) (Boi et al., 2013, Zettl et al., 2004).  
Translocations have been observed in a small number of ALK- and c-ALCL cases, 
specifically the t(6;7)(p25.3;q32.3) translocation involving DUSP22 and IRF4 leading to 
downregulation of DUSP22 mRNA expression (Feldman et al., 2011). The clinical 
relevance of this lesion has yet to be determined, but those harbouring the 
translocation exhibit an overall survival rate of 90%, higher than the average for ALK- 
ALCLs (Parrilla Castellar et al., 2014). Another exclusive ALK- ALCL rearrangement 
involving the TP63 gene has also been identified. In this study, it was revealed that 
TP63 rearrangements give rise to fusion proteins homologous to a dominant-negative 
foƌŵ of Pϲϯ ;ΔNPϲϯͿ ǁhiĐh is ďelieǀed to ďe oncogenic (Vasmatzis et al., 2012). The 
most common translocation partner was TBL1XR1. The study also revealed that TP63 
rearranged neoplasms resulted in significantly lower overall survival rates than non-
rearranged counterparts (Vasmatzis et al., 2012). 
A transcriptional profiling meta-analysis of 309 PTCLs has identified a number 
of genes which allow specific identification of ALK- ALCL from other PTCL. In this study, 
ALK- ALCL is defined by expression of TNFRSF8, BATF3, TMOD1, TMEM158, MSC and 
POPDC3 (Agnelli et al., 2012). Further gene signature studies have allowed the 
reclassification of some PTCL-NOS as ALK- ALCL. In one study, ALK- ALCLs exhibit 
enriched expression of c-Myelocytomatosis Viral oncogene (c-MYC) and IRF4 gene 
signatures compared to PTCL-NOS (Iqbal et al., 2014). Other studies have 
demonstrated that ALK- ALCLs overexpress CCR7, CNTFR, IL-22, and IL-10 (Lamant et 
al., 2007, Piva et al., 2010), as well as the anti-apoptotic proteins BCL2, BIC, and BIRC6 
(Thompson et al., 2005). 
 Whole exome sequencing of ALK- ALCL has revealed the sub-group exhibits 
recurrent activating mutations of JAK1 and STAT3 genes and inactivating mutations of 
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PRDM1, TP53, and CSMD2 (Crescenzo et al., 2015). In this study, mutations in STAT3 
clustered in the SH2 domain whilst JAK1 mutations clustered primarily in the kinase 
domain. Recurrent missense mutations of STAT3 included Y640F, N647I, D661Y, and 
A662V. The result of these mutations is constitutive activation of the JAK/STAT3 
pathway with p-STAT3 levels comparable to ALK+ ALCL (Crescenzo et al., 2015). This 
mechanism is believed to be oncogenic for ALK- ALCL. Furthermore, cell lines 
harbouring these mutations exhibited reduced cellular growth upon JAK/STAT3 
pathway inhibition (Crescenzo et al., 2015). 
MicroRNAs are also believed to play a key role in ALK- ALCLs as overexpression 
of miR155 is present in these lymphomas (Merkel et al., 2010). Further investigation 
into miR155 demonstrated that the microRNA is specifically oncogenic in ALK- ALCL 
(Merkel et al., 2015).  In this study, high levels of promoter methylation were detected 
in ALK+ ALCL cell lines compared to ALK- ALCL and resulted in low expression of 
miR155. Furthermore, subcutaneous injection of Mac1 and Mac2a ALK- ALCL cell lines, 
transfected with pre-miR155 RNA, into mice resulted in increased tumour growth 
compared to controls (Merkel et al., 2015). Thus, miR155 is deemed important for ALK- 
ALCL proliferation. In addition, a specific microRNA signature consisting of 4 
upregulated microRNAs: miR-210, miR-197, miR-191, and miR-512-3p and 7 
downregulated microRNAs: miR-451, miR-22, miR-146a, miR455-3p, miR455-5p, miR-
494, and miR-143 has been identified to allow delineation of ALK- ALCL from other 
PTCLs (Liu et al., 2013). 
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1.5 B-cell Lymphoma 6 (BCL6) 
1.5.1 BCL6 Structure 
BCL6 is a gene, located at chromosome 3q27, which encodes a zinc finger 
transcriptional repressor (figure 1.9A). BCL6 encodes three transcripts, two of which 
produce the full-length BCL6 protein whilst the third encodes a truncated form of the 
protein (BCL6S) lacking exon 7, encoding the RD2 domain (Shen et al., 2008). The BCL6 
protein comprises three main domains: the C-terminal zinc finger domain, the RD2 
domain, and the N-terminal POZ/BTB domain. The zinc finger domain comprises six 
zinc fingers which facilitate precise binding to BCL6 binding motifs (core sequence 
TTCCTA/CCGGA) within the regulatory regions of BCL6 target genes. The role of the 
RD2 domain has only recently been discovered and is currently believed to involve 
repressive activity of specific targets genes, which allows progression through GC B-cell 
development. The RD2 domain interacts with HDAC2, MTA3/NuRD complex, as well as 
CtBP (Bereshchenko et al., 2002, Fujita et al., 2004, Huang et al., 2014, Mendez et al., 
2008). By recruiting HDAC2, gene transcription of targets such as: EBI2, S1PR1, and 
S1PR2 are silenced (Huang et al., 2014). The POZ/BTB domain is vital to allow BCL6 to 
form homodimers and heterodimers with other POZ/BTB domain-containing 
transcription factors such as Myc-Interacting Zinc Finger Protein-1 (MIZ-1) and 
Figure 1.9: Structure of BCL6 and the effect of inhibitors on the protein function 
A) Structure of BCL6 protein with binding partners. B) Mechanism of BCL6 inhibition. All available BCL6 inhibitors, 
79-6, RI-BPI, Rifamycin SV, and Apt48 bind and prevent interactions of the POZ/BTB domain with co-repressor 
molecules rendering the repressive activity of domain non-functional.  
 
A) B) 
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Promyelocytic Leukaemia Zinc Finger (PLZF) (Dhordain et al., 2000, Phan et al., 2005). 
The formation of these complexes creates 2 lateral grooves through which, the domain 
recruits co-repressor molecules such as BCL6 Corepressor (BCoR), Nuclear receptor 
corepressor (NCoR), and Silencing mediator for retinoid and thyroid hormone 
receptors (SMRT), amongst others, to facilitate the recruitment of HDACs to target 
genes and thereby effect transcriptional repression (Ahmad et al., 2003, Dhordain et 
al., 1997, Dhordain et al., 1998, Huynh et al., 2000). For example, when BCoR interacts 
with the BCL6 BTB domain, it can create characteristic repression complexes with both 
class I and class II HDACs that allow histone deacetylation and ultimately silencing of 
genes (Huynh et al., 2000, Polo et al., 2004). All three co-repressor proteins bind the 
lateral groove via a BCL6 binding domain (BBD). The BBD domain of SMRT and BCoR 
share high homology with only 3/17 residues differing between the molecules whereas 
BCoR possess low homology, harbouring a completely different sequence (Ahmad et 
al., 2003, Ghetu et al., 2008).  
Genetically, BCL6 contains an autoregulatory binding site within the first exon 
of the gene which allows suppression of its own transcription (Kikuchi et al., 2000, 
Pasqualucci et al., 2003). This occurs via recruitment of CtBP and, subsequently, the 
corepressor Zinc finger E-box binding homeobox 1 (ZEB1) to this site (Mendez et al., 
2008, Papadopoulou et al., 2010). Other BCL6 regulatory elements have been detected 
upstream of the transcription start site (Tang et al., 2002) and, more recently, in intron 
1 of the BCL6 gene, which can be bound by CCCTC-binding factor (CTCF) (Kikuchi et al., 
2000, Saito et al., 2007, Batlle-Lopez et al., 2015).  
Post-translational modifications of BCL6 are also utilised to regulate BCL6 
activity. Phosphorylation of BCL6 by Mitogen-Activated Protein Kinase (MAPK) 
pathways results in degradation of the transcription factor, whilst BCL6 can also be 
targeted for ubiquitination directly by F-box protein 11 (FBX011) (Niu et al., 1998, Saito 
et al., 2007, Duan et al., 2012). The PEST domain overlapping the RD2 domain of BCL6 
can also undergo p300-mediated acetylation resulting in inactivation of transcriptional 
suppressive activity by blocking HDAC association (Bereshchenko et al., 2002). 
 
 
49 
 
1.5.2 BCL6 in B-cells 
With the introduction of gene expression profiling it has been possible to 
investigate in detail the expression and activity of BCL6 in B-cells. This technology has 
led to the discovery that BCL6 suppresses genes involved in lymphocyte activation, 
differentiation, and apoptosis by recruiting HDACs to silence target genes (Shaffer et 
al., 2012).  
Although not fully elucidated, expression of BCL6 is believed to be initiated by 
MEF2B, IRF8, and IRF4 within naïve B-cells interacting with T-cells and antigen (Basso 
and Dalla-Favera, 2015). At the centroblast stage of lymphocyte development, BCL6 
fine-tunes its own expression via an autoregulatory mechanism (Pasqualucci et al., 
2003, Mendez et al., 2008) and inhibits differentiation of the GC B-cells through 
interaction with other transcription factors (figure 1.4A) (Saito et al., 2007). In addition, 
BCL6 blocks the expression of inflammation genes such as IL-10, CCL3 and STAT1 
(Barish et al., 2010, Toney et al., 2000); this may also explain why BCL6 deficient mice 
in these studies developed fatal inflammatory diseases.   
BCL6 is critical for GC-formation. BCL6 mutant mice, expressing a truncated 
form of BCL6 which lacks DNA-binding activity, displayed a failure to form germinal 
centres during a T-cell-dependent immune response and developed a fatal systemic 
inflammatory disease characterised by the presence of TH2 cells (Dent et al., 1997, Ye 
et al., 1997). Recently, the RD2 domain of BCL6 has shown to be important in early GC-
cell development (Huang et al., 2014). The domain has been demonstrated to directly 
bind the co-repressor MTA3 via coimmunoprecipitation assays (Bereshchenko et al., 
2002, Fujita et al., 2004, Huang et al., 2014) and exert repressive functions on target 
genes through recruitment of HDAC2 (Huang et al., 2014). Mutation of a critical lysine 
residue in the RD2 domain abolishes this repressive activity resulting in aberrant GC B-
cell formation (Huang et al., 2014). In addition, RD2-mutant mice failed to produce 
detectable levels of GC B-cells after immunisation with Sheep Red Blood Cells (SRBCs) 
(Huang et al., 2014). 
Genomic instability is believed to be maintained by BCL6 activation due to 
repression of specific B-cell targets in GC B-cells. It is believed that in order for GC B-
cells to tolerate the high rates of DNA damage brought about by CSR and SHM, BCL6 
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represses genes encoding regulators of the DNA damage response (namely TP53, ATR, 
CHEK1, GADD45A, PC4 as well as CDK inhibitors P21 and P27KIP1) (Phan and Dalla-
Favera, 2004, Ranuncolo et al., 2008a, Ranuncolo et al., 2008b).  In particular, the 
interactions between Tumour Promoter 53 (TP53) and BCL6 are important. TP53 
requires suppression by BCL6 in GC B-cells as the TP53 pathway would induce 
apoptosis due to the large-scale genomic aberrations occurring from SHM. 
Interestingly, the pathways involved in activation of TP53 as a transcription factor 
(ATM-mediated phosphorylation and PIN1 interactions) are important for the 
degradation of BCL6 (Phan et al., 2007, Zacchi et al., 2002, Zheng et al., 2002). The 
actions of these pathways may help to ensure that healthy B-cell proliferation and cell 
death is controlled and that constitutive BCL6 expression does not result in 
tumorigenesis.   
BCL6 facilitates cell-cycle progression by repressing inhibitors of cyclin 
dependent kinases (CDKs) such as P21 and P27KIP1 (Phan et al., 2005, Shaffer et al., 
2000). Cell cycle progression is key for GC B-cells to allow rapid proliferation and 
expansion of centroblasts before migration and selection. 
A well-established target of BCL6 is BLIMP1 and interactions between the 
transcription factors have been studied extensively. BCL6 prevents plasma cell 
differentiation through inhibition of PRDM1 (figure 1.4A). Initially, it was shown, using 
DNaseI footprinting that PRDM1 contained two binding sites for BCL6 (Tunyaplin et al., 
2004) and that there was a two-fold increase in the number of antibody secreting cells 
(a characteristic of BLIMP1 expression) in Bcl6-/- mice compared to Bcl6+/- controls, 
suggesting that expression of the PRDM1 gene was repressed by BCL6. Further studies 
have confirmed the antagonistic interactions between BLIMP1 and BCL6 (Cimmino et 
al., 2008, Crotty et al., 2010, Shaffer et al., 2002, Shaffer et al., 2012, Shapiro-Shelef 
and Calame, 2005, Tunyaplin et al., 2004, Alinikula et al., 2011, Basso et al., 2010).  
Although it has been postulated that BCL6 may bind and repress PRDM1 directly, other 
studies have suggested alternate mechanisms (Alinikula et al., 2011, Basso et al., 
2010). One study found, through ChIP-on-ChIP screening, that PRDM1 was not the sole 
BCL6 target gene (Basso et al., 2010). In agreement with this, another study (Alinikula 
et al., 2011) found that BCL6 exerts its effects indirectly on PRDM1 through activation 
of BACH2 (basic region-leucine zipper (bZip) factor BTB and CNC homology 2) and MITF 
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(microphthalmia-associated transcription factor) in DT40 cells. BACH2 has been found 
to inactivate BLIMP1 expression via interaction with two Maf Recognition Elements 
(MARE-elements) present on the PRDM1 gene (Ochiai et al., 2006). MITF has also been 
found to inactivate IRF4 (Lin et al., 2004). It is for these reasons that BCL6 is believed to 
repress BLIMP1 activity by a number of pathways: by directly repressing the 
transcription of PRDM1, by increasing inhibition of PRDM1 via BACH2 expression, and 
by repressing activators of PRDM1, such as IRF4, through MITF expression. More 
recent studies into BCL6-BACH2 interactions have suggested the dependency of BACH2 
on BCL6 foƌ BLIMPϭα iŶhiďitioŶ (Huang et al., 2013a). In this study, through ChIP-Seq 
PRDM1α, but not PRDM1β, binding sites of BCL6 and BACH2 overlapped in the DLBCL 
cell line OCI-Ly7. Furthermore, knockdown of each protein individually caused 
increased levels of BLIMP1 mRNA with further increase in a double knockdown (Huang 
et al., 2013a). The authors suggest BACH2 protein may recruit BCL6, or vice versa, 
allowing repressive activity on PRDM1α, whereas PRDM1β may be inhibited by BCL6 
alone. 
1.5.3 BCL6 in B-cell lymphoma 
BCL6 plays a central role in the pathogenesis of several types of B-cell 
lymphoma (Basso and Dalla-Favera, 2012, Shaffer et al., 2012, Shaffer et al., 2000). The 
proto-oncogene was first identified as the target of chromosome 3q27 translocation, 
which is found in approximately 40% of all Diffuse Large B-cell Lymphoma (DLBCL) (Ye 
et al., 1993, Butler et al., 2002). In addition, BCL6 was found to be highly expressed in 
germinal center B-cells (Cattoretti et al., 1995). This suggested that B-cell lymphomas 
derived from germinal centers may in fact be a result of aberrant BCL6 expression. 
BCL6 translocations are associated with the Ig loci in approximately 50% of all B-cell 
cases, with 75% of these locating to the Ig heavy chain locus (Akasaka et al., 2000), as 
well as non-Ig loci (such as the IL-21 locus) in approximately 40% of B-cell cases (Ueda 
et al., 2002). BCL6 tƌaŶsloĐatioŶs Đlusteƌ iŶ the ϱ’UTR of the geŶe ƌesultiŶg iŶ the 
substitution of the BCL6 promoter region, causing subsequent overexpression of the 
gene (Butler et al., 2002, Ye et al., 1997, Chen et al., 1998). In addition, studies into 
BCL6 translocations revealed that the event leads to loss of autoregulation by BCL6, as 
well as regulation by other targets by disruption of the promoter binding site (Gearhart 
et al., 2006, Mendez et al., 2008). 
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In addition to translocations, the BCL6 promoter region undergo SHM to 
dysregulate BCL6 regulation. The BCL6 exon 1 region and the 696 base pair sequence 
downstream is subject to SHM in normal GC B-cells, however the majority of 
mutations do not cause alteration in transcriptional activity (Zan et al., 2000). One 
study demonstrated that introduction of GC B-cell-generated BCL6 mutants, 
harbouring mutations in the BCL6 regulatory region present within exon 1 of BCL6, into 
DLBCL cell lines gave rise to increased expression of BCL6 mRNA which was not found 
in BL, FL, or B-cell chronic lymphocytic leukaemia (Pasqualucci et al., 2003). In 
agreement with this, a second independent study demonstrated that introduction of 
BCL6 constructs, lacking the DNA-binding domain, into mice deficient in BCL6 protein 
resulted in marked increase in BCL6 mRNA levels compared to full-length counterparts 
(Wang et al., 2002). Furthermore, approximately 15% of DLBCL harbour mutations in 
BCL6 in this autoregulatory sequence. Collectively, these data demonstrate that BCL6 
can escape autoregulation via SHM of its own regulatory elements during the GC B-cell 
reaction. 
BCL6 is also dysregulated in B-cell lymphoma through inactivation of histone 
acetyltransferases (HATs). One study demonstrated, by ChIP analysis, that the p300 
lysine acetyltransferase gene (EP300) and its cofactors gene, HLA-B-associated 
transcript 3 (BAT-3), are physically bound by BCL6 (Cerchietti et al., 2010b). 
Furthermore, inhibition of BCL6 via a peptide inhibitor, resulted in increased lysine-
acetyltransferase activity of P300 in DLBCL cell lines as well as increase EP300  and 
CREBBP mRNA levels suggesting BCL6 repressed EP300 and CREB-binding protein 
(CREBBP) acetyltransferase activity (Cerchietti et al., 2010b). Importantly, P300-
mediated acetylation of heat-shock protein 90 (HSP90) regulates its chaperone activity 
(McClellan et al., 2007). In normal GC B-cells, CREBBP acetylates and subsequently 
inactivates BCL6 (Andersen et al., 2012). Thus, it is currently hypothesised that BCL6 
maintains HSP90 activity via inhibition of P300-mediated acetylation as well as 
downregulating CREBBP expression to promote survival (Cerchietti et al., 2010b, 
Andersen et al., 2012).  
In B-cell biology orphan F-box protein (FBXO11) is required for BCL6 
ubiquitylation and degradation, however in DLBCL inactivating mutations or deletions 
of FBXO11 are present (Duan et al., 2012). In one study, deletions/mutations of 
53 
 
FBXO11 in DLBCL cell lines exhibited greater stability of BCL6 protein levels (Duan et 
al., 2012). Furthermore, introduction of FBXO11 into FBXO11-null cells resulted in 
ubiquitylation and degradation of BCL6 (Duan et al., 2012). Therefore, BCL6 expression 
and stability is believed to be maintained in some DLBCL via FBXO11 inactivation. 
Normal BCL6 functions allow for cancer development. For example, aberrant 
constitutive activation of BCL6 facilitates survival and proliferation of cancerous cells, 
genomic instability, and the blocking of GC B-cell differentiation through repression of 
PRDM1, in DLBCL (Shaffer et al., 2000). Furthermore, transgenic mice mimicking a 
t(3;14)(q27;q32) translocation, common to human DLBCL, facilitates production of B-
cell and T-cell lymphomas  and upon administration of N-ethyl-N-nitrosourea caused a 
marked increase in the incidence of T-cell lymphomas (Baron et al., 2004). 
In recent years several inhibitors of BCL6 have been created, a synthetic 
peptide inhibitor (Cerchietti et al., 2009), a peptide aptamer (Chattopadhyay et al., 
2006), and a small molecular inhibitor (Cerchietti et al., 2010a). These inhibitors rely on 
specifically binding and blocking the BTB domain of the BCL6 protein (figure 1.8B),  
preventing the recruitment of co-repressors mandatory for biological activity (Ahmad 
et al., 2003, Cerchietti et al., 2010a, Cerchietti et al., 2010b, Cerchietti et al., 2009). 
Retro-inverted BCL6 peptide inhibitor (RI-BPI) is a 41 amino acid long peptide designed 
specifically to target the lateral groove of the BCL6 BTB/POZ domain (Cerchietti et al., 
2009). The inhibitor was able to induce apoptosis in DLBCL cell lines and primary DLBCL 
patient samples in vitro (Cerchietti et al., 2009, Cerchietti et al., 2010b, Polo et al., 
2004), and in addition could reduce the proliferation of xenografted DLBCL cell lines, 
SUDHL4 and SUDHL6, in SCID mice with no obvious side effects (Cerchietti et al., 2009, 
Cerchietti et al., 2010b). The small molecular inhibitor, 79-6, was also shown to 
seleĐtiǀelǇ kill ͞BCLϲ-depeŶdeŶt͟ DLBCL Đell liŶes aŶd adŵiŶistƌatioŶ at loǁ 
ĐoŶĐeŶtƌatioŶs upƌegulated a Ŷuŵďeƌ of kŶoǁŶ BCLϲ taƌget geŶes iŶ ͞BCLϲ-
depeŶdeŶt͟ DLBCL Đell liŶes “UDHLϰ aŶd “UDHLϲ ďut Ŷot iŶ the ͞BCLϲ-iŶdepeŶdeŶt͟ 
cell line Toledo (Cerchietti et al., 2010a). Another BCL6 inhibitor is a peptide aptamer 
(Apt48), produced from a library of randomly generated peptides and able to bind the 
BCL6 BTB/POZ domain in a manner distinct from the BCL6-SMRT interaction 
(Chattopadhyay et al., 2006). Specifically, this peptide could even bind a mutated 
BTB/POZ domain which could not be bound by SMRT. In addition, treatment of cell 
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lines in vitro with Apt48 lead to upregulation of a BCL6-repressed luciferase reporter as 
well as increasing mRNA levels of BCL6-repressed targets, BLIMP1, CD69, and CyclinD2 
(Chattopadhyay et al., 2006). Furthermore, this peptide aptamer facilitated IL-2 and IL-
5-mediated suppression of growth of cells expressing BCL6 (Chattopadhyay et al., 
2006). Recently, through use of X-ray crystallography, the antibiotic Rifamycin SV has 
also been shown to bind to the BCL6 lateral groove, by a similar mechanism to RI-BPI 
and 79-6 (Evans et al., 2014), suggesting a novel foundation for the development of 
new BCL6 inhibitors. Collectively these data demonstrate the potential to inhibit BCL6 
through the BTB/POZ domain suggest a means to BCL6 therapeutically. 
Other mechanisms for BCL6 inhibition can also be postulated. In addition to the 
BTB domain, the RD2 domain mediates transcriptional repression of some BCL6 target 
genes and has been implicated in DLBCL. Gene Set Enrichment Analysis (GSEA) of GCB-
DLBCL cells harbouring a BCL6 knockdown and rescued with BCL6 containing a mutant 
RD2 domain revealed RD2 domain-dependent repression of a number of genes known 
to be BCL6 targets in B-cell lymphoma (Huang et al., 2014, Shaffer et al., 2000) 
suggesting that RD2 domain inhibition may also be useful in DLBCL.  
BCL6 could also be inhibited indirectly. For example, one study (Ying et al., 
2013) found that somatic mutations of MEF2B in DLBCL cell lines resulted in 
deregulated overexpression of BCL6. Introduction of mutated MEF2B or BCL6 via viral-
transduction into SUDHL4 cells caused marked reduction in the proliferative activity of 
these cells as well as reduced BCL6 expression. The study suggests that MEF2B, and 
perhaps other BCL6 regulators, may represent alternative targets for indirectly 
blocking BCL6 activity.  
1.5.4 BCL6 in T-cells 
BCL6 is vital for normal T-cell differentiation and maturation, with roles 
identified in T-helper cell specification, effector T-cell differentiation and T-cell 
memory. There are multiple hypotheses for the mechanism of BCL6 action in effector 
CD4+ T cells. One well documented hypothesis is that each CD4+ T-cell subset has a 
known master regulator transcription factor (figure 1.5), which, for TFH cells is believed 
to be BCL6 (Johnston et al., 2009).  Expression of BCL6 is normally regulated by IL-6 and 
IL-21, however, constitutive overexpression of BCL6 has been shown  to promote the 
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expression of TFH-related genes (Nurieva et al., 2009), whilst in contrast, CD4+ cells 
lacking BCL6 fail to differentiate into TFH cells (Johnston et al., 2009, Nurieva et al., 
2009, Yu et al., 2009).  In addition, BCL6 mRNA has been shown, by real-time reverse 
transcription polymerase chain reaction (RT-PCR), to be significantly upregulated in 
naïve CD4+ cells upon administration of IL-6 and IL-21 (Nurieva et al., 2009). Another 
hypothesis for the involvement of BCL6 in T-Đell diffeƌeŶtiatioŶ is the ͞ďalaŶĐed 
ŵodel͟ ǁheƌeďǇ the fate of CDϰ+ T-cells is determined by strict regulation of a gene 
expression profile (Inghirami et al., 2015). In this model, CD4+ T-cells initially develop 
into TH1 or TH2 cell types as determined by their master regulators (T-bet and GATA3 
respectively), however maintenance of this differentiation fate is mediated via 
expression of other master regulator genes (Inghirami et al., 2015). Therefore, a TH cell 
committed to TH1 lineage may activate expression of a BCL6 gene expression profile, 
leading to terminal differentiation to a TFH cell subset. 
 Therefore, BCL6 has been implicated as the key regulator of TFH cell 
differentiation, a process which has been shown to be antagonised by BLIMP1 (Crotty 
et al., 2010, Johnston et al., 2009). Intriguingly, the only CD4+ cell type which has high 
expression of BCL6 is the TFH cell, the remaining groups (TH1, TH2, TH17, and TReg) show 
a high expression of BLIMP1 (Crotty et al., 2010, Fazilleau et al., 2009, Johnston et al., 
2009, Cimmino et al., 2008). In Blimp1-deficient murine CD4+ cells, Bcl6 mRNA was 
shown to have a two-fold increase against wild-type controls (Cimmino et al., 2008).  
This evidence suggests that respective expression and inhibition of either BLIMP1 or 
BCL6 is the key to determining CD4+ cell fate decision (figure 1.10). 
A recent study into targets of BCL6 in TFH cells has also demonstrated that BCL6 
represses a number of targets involved in T-cell differentiation, signalling, and 
migration. These targets include: STAT4, IFNGR1, GIMAP1, RORA and GATA3 (Hatzi et 
al., 2015). In addition, this study demonstrated that BCL6 can bind to Activator Protein 
1 (AP1) motifs in TFH cells, in conjunction with AP1, to repress AP1-mediated activity on 
these targets (Hatzi et al., 2015).  
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A certain threshold of BCL6 is believed to be required to achieve CD8+ 
differentiation into memory T-cells (figure 1.8). BCL6-deficient mice exhibited lower 
detectable levels of CD44 and Ly6C (CD8+ memory T –cell surface markers) than wild-
type mice (Ichii et al., 2004). In agreement with these findings, overexpression of BCL6 
in the transgenic Ick-BCL6 mouse model resulted in elevated levels of memory T-cells 
compared to wild type mice (Ichii et al., 2002, Ichii et al., 2004). However, in the 
spleens of Bcl6-deficient mice phenotypic memory T-cells were still detectable (Ichii et 
al., 2004) suggesting that the formation of memory T-cells is not wholly reliant upon 
BCL6 expression. 
Recently, BCL6 has been shown to repress the glycolytic pathway in primary 
CD4+ and CD8+ murine T-cells (Leavy, 2014, Man and Kallies, 2014, Oestreich et al., 
2014). In this study, a BCL6 expression construct was shown to inhibit the expression 
of luciferase reporter constructs for a number of glycolytic molecules (Oestreich et al., 
2014). Furthermore qPCR analysis of glycolytic pathway member mRNAs, in CD4+ T-
cells cultured in TH1 conditions with a BCL6 expression construct, revealed that BCL6 
represses a number of targets, including SLC2A1, SLC2A3, PKM, and HK2 (Oestreich et 
Figure 1.10: Interaction of the BCL6-IRF4-BLIMP1 axis in CD4+ cells 
BCL6 activity promotes differentiation to follicle helper T-cell [TFH] whilst BLIMP1 activity promotes differentiation 
to the remaining T-helper [TH] cells. Both BCL6 and BLIMP1 activity is facilitated by IRF4; however the interaction 
between IRF4 and either transcription factor is poorly understood. Cells overexpressing BCL6 will favour TFH 
specialisation but in BCL6 deficient cells, TFH differentiation is not possible. BCL6 has also been implicated as 
important for memory CD4 T-cell development. BLIMP1 expression is present in all remaining TH subsets. BCL6 
aŶd BLIMPϭ ĐaŶ phǇsiĐallǇ ďiŶd eaĐh otheƌ’s pƌoŵoteƌ aŶd aĐtiǀelǇ pƌeǀeŶt tƌaŶsĐƌiptioŶ (Cimmino et al., 2008, 
Johnston et al., 2009). 
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al., 2014). In addition, ChIP-PCR also revealed that BCL6 specifically bound the 
promoter region of SLC2A3 (Oestreich et al., 2014). The data as a whole suggests that 
BCL6 is responsible for the maintenance of glycolytic pathway repression exhibited in 
memory CD8+ T-cells.  
Interestingly, BCL6 may not utilise the BTB/POZ domain in T-cells as it does in B-
cells. Recent evidence shows that a knock-in mouse model containing BCL6 with a non-
functional BTB domain did not produce fatal inflammatory responses found within 
Bcl6-/- mice (Huang et al., 2013b). In addition, TFH cells containing this mutated BCL6 
gave rise to normal GC responses whilst normal T-helper cell differentiation was 
achieved with the same construct (Huang et al., 2013b). Thus, BCL6 may exert its 
actions through a different domain, such as RD2. In agreement with this, mice 
harbouring BCL6 with an inactivated RD2 domain resulted in a 40% reduction of GC-TFH 
cell formation in comparison to wild type mice suggesting the domain is important for 
TFH cell formation (Huang et al., 2014). 
1.5.5 BCL6 in T-cell lymphoma 
From our current understanding of BCL6 functions in B-cells, it is logical to 
assume it may act as a pro-tumour factor in some PTCL. In fact, BCL6 overexpression 
results in the overproduction of TFH cells and contributes to TFH  cell-derived 
lymphomas as well as other T-cell lymphomas (de Leval et al., 2007, Duy et al., 2011, 
Kerl et al., 2001). Indeed, deficiency of BCL6 in CD8+ T-cell reduces the proliferation of 
these cells (Ichii et al., 2002) and a further study found that cytotoxic T-cell 
proliferation correlates with Bcl6 expression in mice (Ichii et al., 2004).  
BCL6 has been shown to be vital for pre-B-cell renewal in B-cell leukaemias due 
to its inhibitory effect on DNA damage response genes (Duy et al., 2011, Hurtz et al., 
2011) and it is plausible that the same process may be occurring within T-cell 
lymphomas, although the BCL6 target genes of B-cells have not been confirmed in T-
cells as of yet. Importantly, BCL6 promotes the formation of long-lived memory T-cells 
with self-renewal capabilities; equally it represses terminal effector T-cell 
differentiation associated with low proliferative potential providing evidence of 
potential oncogenic effect in PTCL. 
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In ALK+ ALCL, deregulation of BCL6 appears prominent. It has been suggested 
this deregulation is mediated through the constitutive activation of ALK driven by the 
t(2;5)(p23;q35) NPM-ALK translocation. In agreement with this, gene expression 
profiling and IHC staining of systemic ALCLs demonstrated that BCL6 expression is 
higher in ALK+ ALCL (Saglam and Uner, 2011, Lamant et al., 2007).  
A study investigating overexpression of a construct containing full length NPM-
ALK under the control of a CD4 promoter in transgenic mice, restricting NPM-ALK 
expression to the T-cell lineage only, revealed mice expressing the cassette developed 
spontaneous thymic lymphomas, strongly reinforcing the fusion genes role in 
lymphomagenesis (Chiarle et al., 2003). Another study investigating overexpression of 
full-length NPM-ALK in HEK-293T cells resulted in increased phosphorylation of STAT3 
compared to inactive NPM-ALK (Chiarle et al., 2005, Zamo et al., 2002). Furthermore, 
ALK+ ALCL cell lines expressed considerably more phosphorylated STAT3 in contrast to 
ALK- cell lines (Zamo et al., 2002). Collectively, the data suggests that NPM-ALK drives 
ALK+ ALCL to phosphorylate, and thus activate, STAT3.  Phosphorylated STAT3 has 
been shown to activate the expression of a number of targets, most importantly BCL6. 
Induction of phosphorylated STAT3 expression in the breast cancer cell line, SK-BR-3, 
resulted in increased expression of BCL6 mRNA (Walker et al., 2013). In addition, ChIP-
Seq analysis of human cells revealed STAT3 binding directly to the BCL6 gene (Walker 
et al., 2013) suggesting STAT3 directly drives the expression of BCL6. Taken together, 
the data suggests that the initial transforming mechanism, NPM-ALK fusion could 
result in the constitutive expression of BCL6 and therefore may constitute potential 
therapeutic targets in these lymphomas. 
1.6 Interferon Regulatory Factor 4 (IRF4) 
1.6.1 IRF4 structure 
Located at chromosome 6p25.3, IRF4 was initially characterised by the 
generation of Irf4-/- mice (Mittrucker et al., 1997) which lacked GCs and plasma cells 
and could not generate cytotoxic T-cell responses. This finding was reinforced with 
immunohistochemistry analysis of human and mouse lymphoid tissue for IRF4 protein 
which showed high expression in plasma cells, but a lack of expression in most, but not 
all, GC B-cells (Falini et al., 2000). 
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IRF4 is a member of the IRF family of transcription factors. Most members of the IRF 
family consist of a tryptophan-rich DNA-binding domain coupled to a regulatory 
domain and an IRF-associated domain (IAD), the exception being IRF6 which lacks an 
IAD (Shaffer et al., 2009). IRF4 is unique in that it is one of two IRF family members 
expressed solely in lymphocytes, the other being IRF8 (Shaffer et al., 2009).  IRF4 
possesses poor DNA binding ability despite containing a DNA binding domain. This is 
currently believed to be the result of an autoinhibitory domain present at the C-
terminal of the protein (Brass et al., 1996). However, through binding of a co-factor, 
such as SPI1/PU.1 (Spleen Focus Forming Virus (SFFV) Proviral Integration Oncogene), 
SPIB, STAT3, or Basic Leucine zipper transcription factor, ATF-like (BATF) the 
autoinhibitory effect can be alleviated allowing IRF4 to exert DNA-binding activity to 
ETS-IRF composite elements (EICEs) or AP1-IRF4 composite elements (AICEs) (Brass et 
al., 1996, Escalante et al., 2002, Li et al., 2012) (figure 1.11). IRF4 can exert inhibitory 
effects on target genes through binding of interferon-stimulated response elements 
(ISREs) present in the promoters of genes (Brass et al., 1996, Yamagata et al., 1996). 
IRF4 successfully bound ISREs coupled to a GAL4 reporter construct and repressed 
IRF1-mediated expression of the reporter (Brass et al., 1996). Therefore it is 
hypothesised that IRF4 prevents the binding of other IRF family members to target 
genes through interaction with ISREs, in the absence of PU.1, and acts to inhibit 
transcriptional activation.  
1.6.2 IRF4 in B-cells 
Although it is required during early B-cell development, IRF4 also performs a 
vital part in late B-cell differentiation. During selection of GC B-cells, increased 
expression of IRF4, brought about by CD40 signalling and subsequent activation of NF-
κB (Gupta et al., 1999), alters the balance of TFs (figure 1.4B) causing repression of 
BCL6 transcription and activation of BLIMP1 transcription (De Silva et al., 2012). 
Activation of the NF-κB pathǁaǇ stiŵulates the foƌŵatioŶ of NF-κB heteƌodiŵeƌs upoŶ 
promoter regions of IRF4, activating IRF4 transcription (Gupta et al., 1999, Saito et al., 
2007, Shaffer et al., 2006, Sharma et al., 2000). In addition to CD40, IRF4 expression 
can also be induced by IL-4, mediated by STAT6 (Grumont and Gerondakis, 2000, 
Gupta et al., 1999). In agreement with previous findings, evidence shows low levels of 
NF-κB 
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Figure 1.11: Structure and function of IRF4 with binding partners 
A) Protein structure of IRF4 protein. IRF4 consists of four domains: a DNA-binding domain containing five 
tryptophan repeats, a regulatory domain, an IRF-associated domain (IAD), and a C-terminal inhibitory domain. 
Whilst IRF4 is not interacting with binding partners, the C-terminal domain exerts inhibitory activity on the 
DNA-binding domain preventing efficacious binding to IRF4 consensus sequences. B) Effect of binding of PU.1 
by the IRF-associated domain. Interaction of PU.1 with the IAD allows the PEST domain of PU.1 to inhibit C-
terminal domain inhibitory activity. IRF4 can now bind consensus sequences with 5-fold greater avidity and 
activate transcriptional activity (Escalante et al., 2002).  
A) 
B) 
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within GC B-cells (Shaffer et al., 2001) as well as IRF4, whilst expression of IRF4 is 
highest within plasma cells. 
The positive feedback loop of IRF4, and the inhibition by IRF4 of BCL6, 
maintains the plasma cell in the differentiated form (Sciammas et al., 2006, Shaffer et 
al., 2008) (figure 1.4C). Studies investigating the distribution of B-cell populations in 
Irf4-/- mice  show that, in comparison to wild type mice, there was a dramatic decrease 
in the number of plasma cells present (Klein et al., 2006, Mittrucker et al., 1997), 
suggesting a vital role of IRF4 in inducing terminal differentiation.  
IRF4 has also been shown to be required for CSR (Klein et al., 2006, Sciammas 
et al., 2006). In these studies, loss of IRF4 in B-cells resulted in poor expression of AID. 
Upon restoration of IRF4, CSR was restored, indeed more so than restoring AID alone 
(Sciammas et al., 2006), thus suggesting that IRF4 is important for CSR, both 
independently and through AID expression.  
The levels of IRF4 differ between B-cell development stages (figure 1.4). As well 
as being promoted by STAT6 and NF-κB, IRFϰ is ďelieǀed to ďe ƌepƌessed ďǇ MITF (Lin 
et al., 2004). Loss of MITF resulted in high rates of B-cell activation and differentiation 
into plasma cells, which promoted an autoimmune response (Lin et al., 2004). 
Currently however, no further studies into MITF/IRF4 interactions have been 
published. Nonetheless the data as a whole suggests IRF4 regulation plays an 
important role in B-cell maturation. 
As well as affecting plasma cell differentiation, IRF4 in conjunction with IRF8, 
promotes the rearrangement of Ig light-chain genes during early B-cell development 
(Johnson et al., 2008). In non-transformed pre-B-cells with IRF4-/- IRF8-/- geŶotǇpe, κ 
light-chain recombination does not occur but can be induced by re-introducing IRF4 
(Inlay et al., 2002, Johnson et al., 2008, Lu et al., 2003). IRF4 has also been shown to 
upregulate CXCR4, a receptor for the chemokine SDF-1 (Tokoyoda et al., 2004). It is 
proposed that this encourages pre-B-cells in the bone marrow to preferentially migrate 
towards stromal cells expressing SDF-1 rather than IL-7. As IL-7 represses light-chain 
gene rearrangement (Johnson et al., 2008), IRF4 expression tends to promote light 
chain gene rearrangements. Due to the observation that immature B-cells recognising 
self-antigen upregulate their IRF4 expression (Pathak et al., 2008), one study 
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concluded that IRF4 allow these B-cells further Ig gene alterations in order to escape 
apoptosis. 
1.6.3 IRF4 in B-cell lymphoma 
 IRF4 has been implicated in the development and maintenance of ABC-DLBCL, 
Multiple Myeloma, Hodgkin lymphoma, Primary effusion Lymphoma, and Chronic 
lymphocytic leukaemia. As a result, therapeutic intervention targeting IRF4 has 
become an attractive prospect in these malignancies. 
Studies have found that, using RNA-interference-based genetic screens, loss of 
IRF4 was toxic to myeloma cell lines irrespective of the transforming mechanism of the 
myeloma (Shaffer et al., 2008). In addition, chromosomal translocations bringing IRF4 
under control of the Ig heavy-chain regulatory regions have been identified in MM 
cases (Iida et al., 1997, Tsuboi et al., 2000). A particularly important target gene of IRF4 
in MM is c-MYC. Regulation of the c-MYC gene is commonly lost in MM (Dib et al., 
2008) and IRF4 also binds to the c-MYC promoter, activating its expression. Expression 
of c-MYC also increases IRF4 expression by binding a conserved intronic region of IRF4, 
effectively creating a positive autoregulatory feedback loop (Shaffer et al., 2008). In 
agreement with this, levels of IRF4 and c-MYC expression correlate well in MM 
patients (Shaffer et al., 2008). c-MYC is an important target as the protein is known to 
regulate the expression of vital cell cycle regulators such as P27, as well as cyclins and 
CDKs (Eilers, 2008, Dang et al., 2006). In mouse T-cells, deficiency of c-MYC resulted in 
a reduced induction of cyclin A, CDKs 2 and 4, and CDC25A however P27 remained 
unaffected (Wang et al., 2011b). These data collectively highlights the importance of 
an IRF4/c-MYC interaction for tumour proliferation and survival. 
Additionally, in approximately 2% of all MM cases, a common amino acid 
substitution is found amongst the DNA binding domain (specifically K123R) (Chapman 
et al., 2011). Although the implication of the mutation has not yet been discovered, 
the frequency of recurrence suggests it may provide a selective advantage. 
In another study, a role for IRF4 in mantle cell lymphoma (MCL) has been 
discovered. MCL cell lines which had selected resistance to bortezomib (a proteasome 
inhibitor which induces remission in 30-50% of MCL patients) showed elevated 
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expression of both IRF4 and BLIMP1 (Perez-Galan et al., 2011). However, knockdowns 
of IRF4 in the bortezomib-resistance MCL cell lines sensitised them to the drug, 
implicating IRF4 as an important factor for cancer mortality. IRF4 has also been 
targeted for therapies for ABC-DLBCL, by using the drug Ibrutinib which targets the B-
cell receptor/NF-κB sigŶalliŶg pathǁaǇ iŶ these Đells aŶd, iŶ ĐoŶjuŶĐtioŶ ǁith aŶotheƌ 
drug Lenalidomide, causes them to undergo apoptosis (Yang et al., 2012).  These drugs 
have been used in other lymphomas, such as chronic lymphocytic leukaemia (Herman 
et al., 2011) with promising results as well as MM (Li et al., 2011, Lopez-Girona et al., 
2011, Zhu et al., 2011, McCarthy et al., 2012). Thus reinforcing the importance IRF4 
plays in the transformation of lymphocytic cells. 
1.6.4 IRF4 in T-cells 
IRF4 has also been implicated as a regulator of T-helper cell differentiation, 
playing roles in the development of several TH cell subsets (Bollig et al., 2012, Brustle 
et al., 2007, Honma et al., 2008, Lohoff et al., 2002). It appears to play an 
accommodating role to both BLIMP1 and BCL6, and other master regulators, in 
determining T-cell differentiation but the exact mechanism of this is not well defined 
(figure 1.10). 
IRF4 is important in mature CD4+ T-cell function. Initial studies demonstrated 
that whilst Irf4-/- mice did not have abrogated T-cell development, the proliferation of 
these CD4+ T-cells was diminished when stimulated with CD3, concanavalin A, or 
staphylococcal enterotoxin A antibodies compared to Irf4+/+ mice (Mittrucker et al., 
1997). Furthermore, these cells lacked the ability to produce IL-2, IL-4, and IFN-ɶ 
(Mittrucker et al., 1997). Further studies into IRF4s involvement in IL-2, IL-4, and IFN-ɶ 
production demonstrated that IRF4 exerts T-helper cell-specific regulation of these 
interleukins (Honma et al., 2008).  
Deficiency of IRF4 in vitro and in vivo demonstrated that IRF4 was required for 
TH2 differentiation (Honma et al., 2008, Lohoff et al., 2002, Rengarajan et al., 2002, 
Tominaga et al., 2003). Intriguingly, effector/memory CD4+ T-cells obtained from Irf4-/- 
mice produced lower levels of IL-2, IL-4, and IL-5 compared to wild-type cells (Honma 
et al., 2008). In addition, Irf4-deficient mice failed to sustain TH2 immune responses to 
infections (Honma et al., 2008, Lohoff et al., 2002, Tominaga et al., 2003). Therefore, it 
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is believed that IRF4 is critical for the differentiation and function of CD4+ T-cells to TH2 
cells. In agreement with this, CD4+ T-cells derived from Irf4-deficient mice fail to 
produce TH2 cytokines (IL-4, IL-5, IL-13, and IL-21) when stimulated with TH2-promoting 
factors (Lohoff et al., 2002, Rengarajan et al., 2002, Tominaga et al., 2003).  
The role of IRF4 in the determination of TH1 cells remains difficult to ascertain. 
Studies of CD4+ T-cells in Irf4-deficient mice demonstrated that these cells exhibited 
higher expression of IFN-ɶ, a TH1 cytokine, compared to wild type controls (Rengarajan 
et al., 2002, Tominaga et al., 2003). However, a separate study into murine Irf4-/- CD4+ 
T-cells stimulated with TCR antigen demonstrated that these cells exhibited lower 
expression of IFN-ɶ than wild-type CD4+ T-cells (Honma et al., 2008). Furthermore, in 
an infectious model utilising Leishmania major, Irf4-/- mice failed to produce both TH1 
and TH2 responses (Sacks and Noben-Trauth, 2002).  
In addition to promoting TH2, and potentially TH1 responses, IRF4 is important 
in TH17 differentiation. CD4+ T-cells deficient in IRF4 lose the ability to differentiate 
into TH17 cells and produce IL-17 under stimulation (Brustle et al., 2007, Chen et al., 
2008, Huber et al., 2008). IRF4 activity on IL-17 expression is strictly controlled by IRF4-
binding protein (IBP). It has been demonstrated that deficiency of IBP resulted in 
enhanced IRF4 binding to IL-17 and IL-21 regulatory regions suggesting IBP typically 
inhibits IRF4 binding (Chen et al., 2008). Inhibition of IRF4 has been implicated as a 
potential therapy in TH17-mediated inflammatory diseases as loss of the gene confers 
resistance to mouse models of some TH17-associated diseases such as multiple 
sclerosis (Brustle et al., 2007). Furthermore, IRF4-/- T-helper cells fail to express the 
THϭϳ ƌegulatoƌ, RORɶt, ǁheŶ pƌiŵed ǁith IL-6 and TGF-β ;TH17 conditions) (Brustle et 
al., 2007). Further investigation into IRF4 revealed the protein can bind to the TH17 
cytokine promoter, IL-21, and activate its expression in conjunction with Nuclear 
Factor of Activated T-cells (NFAT)c2 (Chen et al., 2008). IRF4 has been revealed to play 
an important role in the differentiation of CD4+ T-cells via interaction with a variety of 
binding partners (figure 1.11). Recently, through genome wide ChIP analysis, IRF4s role 
in TH17 differentiation has been explored further (Ciofani et al., 2012). Interactions 
between IRF4 and BATF facilitate chromatin remodelling and, along with STAT3, allow 
access to a transcriptional program resulting in the differentiation of TH17 cells.  
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Figure 1.12: Interaction of IRF4 with binding partners in T-helper cell subsets 
TCR stimulation upregulates NF-κB in T
H
 responses resulting in upregulation of IRF4 expression. Associations of 
IRF4 with different molecules results in localisation to different transcriptional target regulatory regions. T
Reg
 
responses are believed to be mediated through IRF4s interaction with FOXP3, however little is known about the 
exact mechanisms of this action. IRF4 and BLIMP1 are required for IL-10 production in T
Reg
 cells and are believed 
to contribute to T
Reg
 response. T
H
1 responses remain undetermined, however data currently suggests IRF4 
facilitates differentiation through IFN-ɶ. 
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Moreover, through ChIP-Seq analysis, IRF4 binding sites overlapped with BATF binding 
sites in approximately 54% of all IRF4 targets, most notably PRDM1 and interleukin 
genes: IL21, Il17a, and IL10 in CD4+ and TH17 cells (Li et al., 2012). IRF4 also interacts 
with AP1 binding sites in pre-activated T-cells as a method of overcoming the 
intrinsically low levels of PU.1 protein (Li et al., 2012, Kwon et al., 2009, Murphy et al., 
2013), the partner required in B-cells for IRF4 activity (Brass et al., 1996, Escalante et 
al., 2002). Through Electophoretic Mobility Shift Assays (EMSAs) the authors show that 
IRF4, via interaction with AP1 sites, required the BATF-JUN complex to bind target sites 
within the IL10 gene within transfected 293T cells suggesting that BATF-JUN is required 
for IRF4 to exert transcriptional activity within the T-cell lineage (Li et al., 2012). It is 
therefore generally accepted that IRF4 mediates the differentiation of TH17 cells as 
well as TH2.  
Another member of the BATF family is BATF3. Through deficiency studies, 
BATF3 has been demonstrated to be required for CD8+ dendritic cell development 
(Hildner et al., 2008). Furthermore, BATF3 and IRF8 have overlapping targets in these 
cells suggesting a possible interaction (Bachem et al., 2010). Direct interaction of IRF8 
and BATF3 has been suggested, but never proven (Murphy et al., 2013). Despite this, 
due to the similarities between IRF4 and IRF8 structures (Jo et al., 2010) and the 
potential for IRF8 to bind BATF (Murphy et al., 2013), it is plausible that IRF4 may 
interact with BATF3 for T-cell development as well. In addition to BATF, IRF4 has also 
been demonstrated to bind NFATc2 in transfected HEK 293T cells (Rengarajan et al., 
2002). Introduction of NFATc2 to these cells in combination with immunoprecipitation 
for IRF4 demonstrated a strong interaction between the two transcription factors 
(Rengarajan et al., 2002). Furthermore, IRF4 knockout TFH cells failed to induce IL-4 
expression, an NFATc2 target (Rengarajan et al., 2002). Further studies have revealed 
that IRF4 interacts with NFATc2 to drive the expression of multiple interleukins such as 
IL-21, IL-5, and IL-13 in the CD4+ T-cell compartment (Hermann-Kleiter and Baier, 2010, 
Rengarajan et al., 2002). IRF4 is also believed to be important for the development of 
TReg cells. Whilst interaction of IRF4 and endogenous FOXP3 has not been 
demonstrated, the two transcription factors are believed to share common TReg-
related gene targets (Zheng et al., 2009). In addition, GFP-tagged FOXP3 gave rise to 
strong binding affinity between itself and IRF4 (Zheng et al., 2009); however, further 
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study is required to elucidate if this interaction occurs with endogenous FOXP3. In 
addition, reports have shown that TReg-specific IRF4 deficiencies lead to an 
autoimmune syndrome in mice (Chen et al., 2008, Zheng et al., 2009), suggesting IRF4 
is critical for TReg cell functions. 
However, due to the large repertoire of interactions IRF4 exhibits, it has also 
been found to affect the formation of other T-helper cells. Lohoff et. al show that Irf4-/- 
mice fail to generate TFH cells and, in addition, showed dramatic loss of BCL6 
expression in Irf4-/- CD4+ T-cells strongly implicating a positive interaction between 
IRF4 and BCL6 (Lohoff et al., 2002); a striking contrast to B-cells where IRF4 is 
responsible for suppression of BCL6 transcription (figure 1.4) (Saito et al., 2007).  
Moreover, IRF4 has been shown to physically bind BCL6 (Gupta et al., 1999). 
Therefore, IRF4 may also direct differentiation of TFH cells as well as TReg, TH2 and TH17 
cells (figure 1.12). 
IRF4 expression is also required for the differentiation of TH9 cells. Murine Irf4-/-
CD4+ T-cells fail to induce IL-9 production under TH9-stimulating conditions (Staudt et 
al., 2010). Furthermore, in a mouse model for allergic asthma, Irf4-/- mice were 
resistant to induction of the disease strongly implicating TH9 involvement. Further 
investigation, using microarray studies, demonstrated that BATF is specifically enriched 
in TH9 cells (Jabeen et al., 2013). In addition, T-cells deficient in either BATF or IRF4 
exhibited poor expression of IL-9. Re-introduction of either BATF or IRF4 separately to 
these cells promoted a 2-fold increase in IL-9 production, however re-introduction of 
both resulted in dramatically larger increases in IL-9 production (Jabeen et al., 2013). 
Thus, it is believed that both IRF4 and BATF are required for efficient TH9 responses 
(figure 1.12). 
Multiple studies have confirmed the importance of IRF4 in the expansion and 
function of cytotoxic CD8+ T-cells (Man et al., 2013, Raczkowski et al., 2013, Yao et al., 
2013). One study found that IRF4-deficient CD8+ T-cells expanded poorly in comparison 
to wild-type controls in vitro when stimulated with dendritic cells and alpha-CD3 (Yao 
et al., 2013). IRF4-deficienct CD8+ T-cells in mice also incorporated less BrdU than wild-
type mice when infected with influenza virus indicating the importance of IRF4 for 
proliferation in vivo (Yao et al., 2013). In agreement with this finding, another study 
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found IRF4-/- T-cells proliferated slower than wild-type counterparts and were 
outcompeted within a 5-day period in competitive transfer experiments against wild-
type T-cells (Raczkowski et al., 2013). In addition to slowing proliferation, IRF4 is 
important in preventing apoptosis. T-cell cultures of IRF4-/- CD8+ T-cells induced 
apoptosis to a greater frequency than IRF4+/+ CD8+ T-cells (Man et al., 2013). Though it 
is not understood how IRF4 prevents apoptosis, the data reinforces the notion that 
IRF4 is critical for CD8+ T-cell survival and proliferation. 
IRF4 has also been implicated in the metabolic activity of CD8+ T-cells. ChIP-Seq 
analysis of murine Irf4-/- T-cells stimulated with N4 antigen yielded two important 
targets in regulation of T-cell metabolism, Forkhead Box Protein 01 (Foxo1) and Hif1a 
(Man et al., 2013). In addition, loss of IRF4 in these cells reduced the rate of oxygen 
consumption, decreased ATP production, and exhibited lower glycolytic activity than 
Irf4+/+ T-cells (Man et al., 2013), all hallmarks of mitochondrial respiration. Currently, it 
is believed that IRF4 interacts with a number of key targets to regulate CD8+ T-cell 
differentiation. In addition to upregulation of BLIMP1 expression, another independent 
study confirmed that IRF4-/- CD8+ T-cells exhibit lower expression of T-bet (Tbx21) and 
Hif1a, as well as disrupting the binding of T-bet protein to targets (Yao et al., 2013), 
genes which are known to be important in CD8+ T-cell differentiation (Finlay et al., 
2012). This suggests that IRF4 regulates the expression of these targets in order to 
sustain activated CD8+ T-cell differentiation. 
Recent work has identified IRF4 associations with BLIMP1. IRF4 is believed to 
directly bind to sites within and around the PRDM1 locus and subsequently increase 
transcriptional activity of BLIMP1 in both CD4+ and CD8+ T-cells (Kwon et al., 2009, 
Man et al., 2013, Raczkowski et al., 2013, Yao et al., 2013). It has been found that IRF4 
indirectly affects the PRDM1 geŶe thƌough ďiŶdiŶg of a ƌespoŶse eleŵeŶt ϯ’ to the 
gene, in conjunction with STAT3 (Kwon et al., 2009), which caused greatly increased 
levels of BLIMP1 mRNA in CD4+ cells. Whilst loss of IRF4 in these cells did not affect 
STAT3 phosphorylation, it did result in a striking reduction in STAT3 binding activity 
(Kwon et al., 2009), suggesting a requirement of IRF4 for STAT3 activity. In CD8+ T-cells, 
IRF4 was able to bind multiple sites within the PRDM1 gene, including the promoter 
region (Yao et al., 2013). In congruence with this data, a separate study found that 
IRF4-/- CD8+ T-cells, when stimulated with T-cell activating cytokines, had lower BLIMP1 
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protein expression than IRF4+/+ counterparts (Raczkowski et al., 2013). However, when 
IRF4 was reintroduced retrovirally, BLIMP1 mRNA levels increased in these cells 
(Raczkowski et al., 2013). 
Taken together the studies described indicate an important role for IRF4 in 
many aspects of T-cell function and differentiation. Our understanding of the 
interactions between IRF4 and its targets in T-cells however, and thus the mechanisms 
by which IRF4 acts in these cells, is still incomplete. 
1.6.5 IRF4 in T-cell lymphoma 
IRF4 has an ambiguous part to play within PTCL currently. Although 
translocations involving the gene do exist in some PTCL (Feldman et al., 2011, Feldman 
et al., 2009, Karai et al., 2013); the oncogenic nature of the translocation has yet to be 
shown. Initial investigation into these translocations revealed that they are 
predominantly present in c-ALCL, but were also found in PTCL-NOS and ALK- ALCL 
cases. In this study, 2 PTCL-NOS cases exhibited a t(6;14)(p25;q11.2) IRF4-TCRA 
translocation whilst partners for the remaining cases were undetermined (Feldman et 
al., 2009). However, further investigation into 6p25.3 translocations in ALK- ALCL 
revealed a recurrent translocation, specifically t(6;7)(p25.3;q32.3) (Feldman et al., 
2011). Interestingly, the majority of ALK- ALCL cases did not involve IRF4 but DUSP22, 
the gene adjacent and telomeric to IRF4. However, all cases shared a common 
breakpoint adjoining to the FRA7H fragile site on 7q32.3. Specifically, 8/29 ALK- ALCL 
cases exhibited translocations involving IRF4 whilst 15/29 cases involved DUSP22, with 
the remaining undetermined (Feldman et al., 2011). Despite the translocation, IRF4 
mRNA expression was found to be constant between 6p25.3 rearranged and non-
rearranged samples (Feldman et al., 2011). Recently, a case of PTCL-NOS with marked 
splenomegaly has been reported to harbour a t(6;14)(p25;q11.2) IRF4-TRCA 
translocation suggesting the translocation may be a determinant of aggressive PTCL. In 
addition, this tumour exhibited high expression of IRF4 by immunohistochemistry 
staining suggesting IRF4 could be the driver of the aggressive lymphoma (Somja et al., 
2014). 
Translocations involving 6p25.3 have not been reported in ALK+ ALCL however 
IRF4 expression is still high (Feldman et al., 2009). It has been suggested that STAT3 
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may drive the expression of IRF4 in ALK+ ALCL. As previously mentioned, NPM-ALK  
drives the phosphorylation and activation of STAT3 (Chiarle et al., 2005, Zamo et al., 
2002). STAT3 and IRF4 interactions are pivotal for normal T-cell function. IRF4-/- mice, 
stimulated with IL-21, failed to induce the expression of a STAT3-dependent PRDM1 
response element coupled to a luciferase reporter compared to IRF4+/+ counterparts 
strongly implicating interactions between IRF4 and STAT3 (Kwon et al., 2009). 
In human malignancies involving oncogenic viruses such as Human T-cell 
leukaemia virus type 1 (HTLV-I) and EBV, IRF4 may play a vital role in maintaining the 
adult T-cell leukaemia (ATL) malignancy (Wang et al., 2011a, Sharma et al., 2000). The 
HTLV-I virus transforms cells by activating the NF-κB pathǁaǇ aŶd suďseƋueŶtlǇ Đauses 
overexpression of IRF4, in a manner similar to EBV-transformed lymphoblastoid cells 
(Xu et al., 2008). Furthermore, IRF4 can transactivate IL-ϭϱ ƌeĐeptoƌ α-chain gene 
(Mariner et al., 2002) and in some ATL, IL-15 has been associated as a growth factor 
(Kukita et al., 2002). Further investigation into IRF4 in ATL demonstrated that 
constitutive expression of IRF4 in Jurkat cells results in downregulation of a number of 
targets involved in cell cycle regulation, DNA repair, apoptosis, immune recognition 
and metastasis including: Cyclin B1, EB1, RHOA, GRB2, PCNA, RP-A, NIP3, GRB2, and 
LFA-1 (Mamane et al., 2002). These targets are believed to contribute to HTLV-I-
mediated transformation and promote cell survival (Mamane et al., 2005). 
In recent studies, IRF4 has been demonstrated to promote its own expression 
via a novel positive-feedback loop (Boddicker et al., 2015). ChIP-analysis of ALCL cell 
lines revealed that IRF4 binds to c-MYC, TNFRSF8 (CD30), P52, and RELB promoters 
(Boddicker et al., 2015). In addition, knockdown of NF-kB subunits, P52 and RELB, 
resulted in decreased IRF4 expression in ALCL cell lines suggesting NF-κB diƌeĐtlǇ 
targets IRF4 in ALCL (Boddicker et al., 2015). Stimulation of CD30 with ligand also 
resulted in activation of NF-κB aŶd suďseƋueŶt iŶĐƌease iŶ IRFϰ eǆpƌessioŶ (Boddicker 
et al., 2015). Taken together, the data suggests that in ALCL, IRF4 promotes its own 
expression via upregulation of CD30 and NF-κB suďuŶits. 
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1.7 B-lymphocyte Induced Maturation Protein 1 (BLIMP1) 
1.7.1 BLIMP1 structure 
PRDM1 is a gene located at chromosome 6q21 which encodes the BLIMP1 
protein. The protein contains five zinc-finger motifs which allows sequence-specific 
DNA binding activity (Keller and Maniatis, 1992, Tunyaplin et al., 2000). There are two 
kŶoǁŶ pƌoteiŶ isofoƌŵs of BLIMPϭ: BLIMPϭα aŶd BLIMPϭβ. BLIMPϭα results from a full 
length transcript of the PRDM1 geŶe ǁhilst BLIMPϭβ laĐks aŵiŶo aĐids ϭ-101 at the N-
terminus of the protein (Gyory et al., 2003) (figure 1.13). A third, naturally occurring 
variant of BLIMP1 has been described recently in NK-cells and lymphoblastoid cell lines 
ǁhiĐh laĐks eǆoŶ ϲ ;teƌŵed BLIMPϭΔϲͿ (Smith et al., 2010, Vrzalikova et al., 2012). This 
BLIMP1 isoform has been poorly characterised to date however. 
BLIMP1 contains three domains which are required for the function of the 
protein: the PR-domain, the proline-rich region, and the zinc-finger domain. The PR-
domain exhibits homology to SET domains within histone methyltransferases (HMTs) 
(Bellefroid et al., 1989, Huang et al., 1998). The proline-rich region has been 
demonstrated to recruit corepressor molecules, such as HDAC1, HDAC2, as well as 
GROUCHO proteins (Ren et al., 1999, Yu et al., 2000). The zinc-finger domain is 
Figure 1.13: Structure of BLIMP1 proteins 
BLIMP1 is comprised of two isoforms: BLIMP1α and BLIMP1β. BLIMP1 contains three primary domains: the PR-
domain, proline rich region, and the zinc finger domain. BLIMP1α and BLIMP1β are transcribed from alternative 
promoters giving rise to a full length BLIMP1α and a BLIMP1β with a truncated PR-domain. BLIMP1 exerts its 
repressive activity through recruitment of co-repressors. 
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required for the binding of BLIMP1 protein to DNA-binding sites. Through DNase 
fingerprinting it was revealed that only a portion of the zinc-finger domain is required 
for adequate binding to the BLIMP1 target sites, PRDI (Keller and Maniatis, 1992). 
Through use of a luciferase reporter gene construct coupled to the DNA binding 
doŵaiŶs of BLIMPϭα aŶd BLIMPϭβ, it has ďeeŶ deŵoŶstƌated that BLIMPϭβ eǆhiďited 
loǁeƌ ƌepƌessiǀe aĐtiǀitǇ ǁheŶ Đoŵpaƌed to BLIMPϭα (Gyory et al., 2003). 
1.7.2 BLIMP1 in B-cells 
Differentiation of plasma cells critically relies upon the expression of BLIMP1 as 
well as the inhibition of BCL6 (Shapiro-Shelef and Calame, 2005). The role of BLIMP1 
was first unearthed by demonstrating antibody secretion occurring in the immature B-
cell line, BAL17, when transfected with a BLIMP1 construct (Turner et al., 1994). This 
role was reinforced with deletions of Prdm1 in mice, which showed dramatic loss of Ig 
secretion in plasma cells in response to appropriate stimuli (Shapiro-Shelef et al., 2003) 
suggesting BLIMP1 is also vital for maturation of B-cells. In addition, studies confirmed 
that forced expression of BLIMP1 in the DLBCL cell line, SUDHL4, and in the Burkitt 
lymphoma cell line, Raji, is sufficient to drive differentiation of B-cells to Ig secreting 
cells (Shaffer et al., 2002). 
The BLIMP1 protein exerts its effects by inhibiting transcription of multiple 
effector pathways (Cimmino et al., 2008, Shaffer et al., 2002). Of most interest, BLIMP1 
represses genes involved in regulating B-cell receptor signalling such as SPIB and ID3, 
as well as inhibiting Ig class-switching by blocking the expression of AID, KU70, KU86, 
DNA-PKCS, and STAT6 proteins (Shaffer et al., 2002).   
Importantly, BLIMP1 also inhibits the expression of genes involved in 
proliferation, most notably BCL6 (Cimmino et al., 2008) and c-MYC (Lin et al., 1997).  
Ectopic expression of BLIMP1 in B-cells, transformed with the Abelson murine 
leukaemia virus, repressed endogenous c-MYC expression and induced apoptosis (Lin 
et al., 1997). It is these inhibitory effects of BLIMP1 which, in conjunction with IRF4 
self-promotion, contribute to maintaining the differentiated plasma cell (figure 1.4C). 
Taken together, these data ĐoiŶed the teƌŵ ͞ŵasteƌ ƌegulatoƌ of plasŵa Đell 
diffeƌeŶtiatioŶ͟ foƌ BLIMPϭ. 
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BLIMP1 has also been found to indirectly regulate expression of BACH2 in 
plasma cells via repression of PAX5 (Muto et al., 2010, Ochiai et al., 2008). Much like 
BCL6, BACH2 and BLIMP1 have antagonistic roles. BACH2 also inhibits expression of 
BLIMP1 in follicular B-cells (Ochiai et al., 2008). In BACH2 deficient cells, BLIMP1 is 
prematurely expressed and, subsequently, antibody secreting cell differentiation is 
enhanced. In addition, CSR and SHM rates are decreased in these cells (Muto et al., 
2010).  
1.7.3 BLIMP1 in B-cell lymphoma 
BLIMP1 is well established as a tumour suppressor gene in DLBCL. Initial studies 
into ABC-DLBCL revealed that PRDM1 was inactivated in 24% of all cases, on both 
alleles, through gene truncations, nonsense mutations, or splice site mutations, giving 
ƌise to aďeƌƌaŶt BLIMPϭα aŶd BLIMPϭβ pƌoteiŶs (Pasqualucci et al., 2006, Tam et al., 
2006). A more recent study demonstrated that PRDM1 is inactivated by homozygous 
deletions, mutations, or constitutive BCL6 expression in 53% of ABC-DLBCL 
(Mandelbaum et al., 2010). In this study, it was shown that the PRDM1 gene was 
genetically inactivated in 31% of ABC-DLBCL cases but a further 22% of cases, which 
did not harbour PRDM1 inactivation, also contained a BCL6 translocation 
(Mandelbaum et al., 2010). Furthermore, lentiviral-mediated knockdown of BCL6 in 
the RCK8 ABC-DLBCL cell line resulted in upregulation of BLIMP1 mRNA and protein 
(Mandelbaum et al., 2010). The data suggests that PRDM1 is either physically 
abrogated or mutated, or BLIMP1 expression is suppressed by constitutive BCL6 
expression as a mechanism of transformation through suppression of GC B-cell 
differentiation. 
As well as the repressive roles BLIMP1 has been shown to have, evidence has 
found that the protein may also be required for MM activity. An immunohistological 
study of B and T-cell lymphomas showed 100% of MM tumours were positive for 
BLIMP1 (Garcia et al., 2006), whereas other subsets of lymphomas showed lower or 
occasional positivity for BLIMP1. In agreement with this, a study into mice with a 
deficiency of BLIMP1 expression, brought about by the truncated Blimp1gfp/gfp gene 
(Kallies et al., 2004), revealed that lack of BLIMP1 expression prevented the formation 
of plasmacytomas (D'Costa et al., 2009). Specifically, this study demonstrated that 
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deficiency of BLIMP1 did not abrogate plasma cell formation but resulted in reduction 
in plasma cell transformation. Some mice reconstituted with Blimp1gfp/gfp however, 
developed tumours which were not plasma cell-based.  
BLIMP1 depletion in chronic myeloid leukaemia is believed to be important to 
the transformation of these neoplasms due to interactions with BACH2. The inhibition 
of BLIMP1 alongside its interactions with CSR and SHM (Muto et al., 2004), makes 
BACH2 another potential tumour promoter. Indeed, in chronic myeloid leukaemia, the 
resulting BCR-ABL fusion gene targets and upregulates BACH2 expression (Vieira et al., 
2001), thus loss of regulation by BLIMP1 may be sufficient to increase genomic 
instability. 
1.7.4 BLIMP1 in T-cells 
Originally, it was believed that the sole purpose of BLIMP1 in lymphocytes was 
to allow the terminal differentiation of antibody-producing plasma cells. However, 
more recently, BLIMP1 expression has been suggested to be crucial in T-cell 
homeostasis. Multiple studies have demonstrated that the overexpression of BLIMP1 
resulted in the accumulation of T-cells, within the CD8 lineage, with an effector 
phenotype through suppression of memory cell differentiation potential (Kallies et al., 
2006, Kallies et al., 2009, Martins et al., 2006, Rutishauser et al., 2009, Shin et al., 
2009).  
BLIMP1 is important for limiting T-cell responses. One well annotated 
mechanism of BLIMP1 function is through repression of IL-2 production during T-cell 
activation (Gong and Malek, 2007, Martins and Calame, 2008). Naïve T-cells, upon 
activation, express IL-2 which in turn causes potent transcription of BLIMP1 mRNA 
(Gong and Malek, 2007). However, ectopic expression of BLIMP1 in activated T-cells in 
vitro resulted in marked reduction of IL-2 after 24 hours suggesting BLIMP1 inhibited 
IL-2 (Gong and Malek, 2007). Thus, IL-2 appears important for initial proliferation upon 
T-cell activation before suppression by BLIMP1 expression. 
Studies into BLIMP1 expression revealed that the protein is expressed in only a 
subset of effector and memory CD8+ T-cells. Loss of BLIMP1 expression in mice led to 
the accumulation of large numbers of CD4+ and CD8+ memory T-cells in comparison to 
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wild type counterparts (Kallies et al., 2006, Martins et al., 2006). This evidence 
suggested BLIMP1 regulated the numbers of CD8+ T-cells as well as the number of 
CD4+ T-cells. In agreement with these findings, it was also found that CD8+ T-cells 
express high levels of BLIMP1 mRNA (Intlekofer et al., 2007) suggesting a suppressive 
role for BLIMP1 in CD8+ T-cell proliferation. Recent evidence has revealed that BLIMP1 
deficient CD8+ cells preferentially differentiate into a memory T-cell phenotype (Kallies 
et al., 2009, Rutishauser et al., 2009, Shin et al., 2009). Virus-mediated BLIMP1-
deficient CD8+ cells lose the ability to differentiate into KLRG1hiIL-7Rlo cells (a 
phenotype associated with effector T-cell properties which have a characteristically 
limited ability to survive and undergo memory cell conversion (Kaech and Wherry, 
2007)) and instead differentiate into KLRG1loIL-7Rhi cells (a memory CD8+ precursor cell 
phenotype) (Kallies et al., 2009, Rutishauser et al., 2009). In agreement with these 
findings, these cells also exhibited a lower expression of granzyme B, an important 
effector molecule required for cytotoxic T-cells (Kallies et al., 2009, Rutishauser et al., 
2009, Shin et al., 2009). However, the effect was not substantial enough to abolish 
effector functions of these T-cells as they could still clear acute infections with 
lymphocytic choriomeningitis or influenza viruses (Kallies et al., 2009, Rutishauser et 
al., 2009). The loss of granzyme B is thought to be caused by constitutive expression of 
BCL6 (Yoshida et al., 2006), arising from the lack of BLIMP1 expression. BCL6-/- CD8+ 
cells overexpress large quantities of granzyme B (Yoshida et al., 2006) (figure 1.7), 
therefore, the data signifies the antagonistic interaction between BCL6 and BLIMP1 in 
the CD8+ cell lineage too. 
Recent studies have elucidated that BLIMP1 expression is promoted, at least in 
part, by IRF4 expression to determine cytotoxic T-cell fate (Man et al., 2013, 
Raczkowski et al., 2013, Yao et al., 2013). One study demonstrated that deficiency of 
Irf4 in murine CD8+ T-cells resulted in abrogation of cytotoxic T-cell formation upon 
infection with L.monocytogenes concurrent with loss of BLIMP1 protein expression 
(Raczkowski et al., 2013). This effect was been confirmed by another independent 
study demonstrating IRF4 directly promoted the expression and function of BLIMP1 
and that ablation of Irf4 in murine T-cells abrogated antiviral CD8+ T-cell responses 
(Yao et al., 2013). 
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During CD4 determination, BLIMP1 is expressed in TReg and TH2 cells and is 
believed to commit CD4+ T-cells to these lineages via repression of effector molecules 
(Cimmino et al., 2008, Fazilleau et al., 2009, Johnston et al., 2009, Martins et al., 2008). 
In TReg  cells, BLIMP1 expression is believed to contribute to the immune-suppressive 
function of these cells. Mice deficient in T-cell-specific BLIMP1 expression develop 
colitis which is believed to be attributed to excessive IL-2 production (Kallies et al., 
2006, Martins et al., 2006). BLIMP1 expression is driven by IRF4 in TReg cells to induce 
immune-suppression is via induction of IL-10 resulting in suppression of TH1 and TH2 
immunity (Cretney et al., 2011, Huber and Lohoff, 2014). 
 In agreement with BCL6 data, deficiency of BLIMP1 in the CD4+ lineage caused 
these cells to preferentially differentiate into TFH cells (Johnston et al., 2009). 
Moreover, these cells also show an increase in proliferation in comparison to wild type 
CD4+ cells (Martins et al., 2006), suggesting BCL6 promotes, and BLIMP1 inhibits, 
proliferation in this lineage.  
Taken together studies have shown that BLIMP1 is critical for differentiation of 
both CD4+ and CD8+ T-cells and required to be under strict control by both IRF4 and 
BCL6. 
1.7.5 BLIMP1 in T-cell lymphoma 
Multiple studies have highlighted the PRDM1 gene as an important potential 
tumour-suppressor gene of T-cell lymphoma. Early investigations showed loss of 
PRDM1 expression through gene deletions in NK-cell neoplasms in comparison to 
normal NK cells (Iqbal et al., 2009, Karube et al., 2011). In one particular study (Karube 
et al., 2011), regions of 6q21 were frequently lost in NK lymphomas. But upon re-
expression of PRDM1 in these neoplasms, suppression of cell proliferation was 
achieved.  In addition, further studies have confirmed that 3% of primary ALK+ ALCL 
and 39% of primary ALK- ALCL contain BLIMP1 inactivations/deletions (Boi et al., 
2013). As a whole, these studies strongly implicate the role of PRDM1 as a tumour 
suppressor gene.  
BLIMPϭβ leǀels appeaƌ to Đoƌƌelate ǁith pooƌeƌ suƌǀiǀal outĐoŵe iŶ PTCL. OŶe 
study (Zhao et al., 2008), shoǁed that BLIMPϭβ-positive patients had a significantly 
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loǁeƌ ƌate of suƌǀiǀal thaŶ BLIMPϭβ-negative patients. In addition to this, inhibition of 
BLIMPϭβ ǀia tƌeatŵeŶt ǁith ďoƌtezoŵiď, a pƌoteosoŵe iŶhiďitoƌ, ƌeduĐed RNA aŶd 
protein levels of IRF4 and c-MYC in the T-cell lymphoma cell line HUT78, suggesting 
BLIMPϭβ ŵaǇ iŶteƌaĐt ǁith these taƌget geŶes iŶ PTCL (Zhao et al., 2008). The authors 
believe that NF-κB upƌegulatioŶ leads to suďseƋueŶt BLIMPϭβ upƌegulatioŶ, ǁhiĐh iŶ 
turn, results in increased activity of c-MYC and IRF4 prompting lymphomagenesis. The 
authors do not prove whether the effect seen is caused by NF-κB upƌegulatioŶ aloŶe oƌ 
thƌough the effeĐt of BLIMPϭβ iŶĐƌease; hoǁeǀeƌ theǇ aƌgue that BLIMPϭβ ŵaǇ aĐt like 
its analogs, PRDM2 (Retinoblastoma protein-interacting zinc finger gene, RIZ) and 
PRDM3 (Myelodysplasia syndrome 1 protein-ecotropic virus integration site 1 protein 
homolog,  MDS1-EVI1), each of which contain truncated PR domains but are required 
for leukaemogenesis (Sasaki et al., 2002, Cuenco et al., 2000). The work demonstrates 
the contrasting contributions of the BLIMP1 isoforms to oncogenesis of lymphoma, 
however furtheƌ ǁoƌk is ƌeƋuiƌed to fullǇ uŶdeƌstaŶd the ƌole of BLIMPϭβ. 
ReĐeŶtlǇ, BLIMPϭα ǁas shoǁŶ to iŶhiďit the eǆpƌessioŶ of miR155 in ALK+ ALCL 
(Boi et al., 2013). The pro-tumour activity of miR155 in ALK- ALCL has recently been 
elucidated by another publication (Merkel et al., 2015). In this study, deficiency of 
miR155 in ALK- ALCL cell lines resulted in increased levels of cleaved caspase 3 as well 
as a reduction in proliferation (Merkel et al., 2015). Furthermore, the study 
demonstrated that, using ALK+ ALCL cell lines, miR155 expression was unaffected by 
Crizotinib, suggesting that, if miR155 is oncogenic in ALK+ ALCL, its expression is not 
mediated through ALK. Therefore, these data collectively suggest that BLIMPϭα ŵaǇ 
be lost in ALK+ ALCL as a mechanism of promoting miR155 expression. 
These data highlight the diversity of BLIMP1 between T-cell lymphomas, 
potentially highlighting it as both a tumour suppressor and an oncoprotein. 
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1.8 Aims 
 The interactions between BCL6, IRF4 and BLIMP1 are well characterised in B-
cell non-Hodgkin lymphoma and this understanding has led to novel therapeutic 
targets for these neoplasms. However, their roles and interactions in T-cell non-
Hodgkin lymphoma, or indeed in normal T-cells, are poorly understood. Evidence 
suggests analogous roles for BCL6, IRF4 and BLIMP1 between B-cells and T-cells (Crotty 
et al., 2010, De Silva et al., 2012, Johnston et al., 2009, Shapiro-Shelef et al., 2003), 
such as the mutual repression of BCL6 and BLIMP1 which may suggest potential 
common ground for treatment options. Conversely, subtle differences, such as the 
conflicting interactions of BCL6 and IRF4 between B and T-cells (Bollig et al., 2012, De 
Silva et al., 2012), may provide insight into the important variances that contribute to 
each disease. 
Collectively, the data described above highlights the BCL6-IRF4-BLIMP1 axis as 
an important aspect of PTCL which, as for B-cell lymphoma, could potentially be 
dysregulated. Indeed, the incorrect expression of any of these genes could be 
considered tumorigenic. Thus the central hypothesis to be tested is: ͞BCL6 and IRF4 
may promote, while BLIMP1 may repress, T-cell lymphoma development and/or 
maintenance and hence constitute a putative therapeutic taƌget͟. This will be explored 
in four parts: 
 Aim 1: To analyse the role of BCL6 in the survival and proliferation of PTCL 
 Aim 2: To analyse the role of IRF4 in the survival and proliferation of PTCL  
 Aim 3: To analyse the role of BLIMP1 as a tumour suppressor in PTCL 
 Aim 4: To evaluate the role of ALK in ALK+ ALCL in the regulation of BCL6, IRF4, 
and BLIMP1 
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2. Materials and Methods 
 
2.1 Mammalian cell culture 
2.1.1 Cell culture conditions 
Lymphoma cell lines were cultured in plastic 75cm2 flasks with a vent cap 
(Corning) at 37oC in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco) 
supplemented with L-glutamine and foetal calf serum (FCS) (Gibco) in a humidified 
atmosphere containing 5% CO2, HEK ϮϵϯT Đells ǁeƌe Đultuƌed iŶ DulďeĐĐo’s Modified 
Eagles Medium (DMEM) 6171 (Sigma) supplemented with 10% (v/v) foetal calf serum 
(Gibco), 4mM L-glutamine (Sigma), and 10mM Sodium Pyruvate (Sigma). The cell lines 
used are listed in table 2.1Table 2.1: List of cell lines used in this project. Suspension 
lymphoma cells were routinely sub-cultured every 2-3 days by transferring a fraction of 
culture to a new 75cm2 flask with fresh 37oC medium. Adherent HEK 293T cells were 
sub-cultured every 2-3 days by initially separating the cells from DMEM medium and 
Table 2.1: List of cell lines used in this project 
Mac1 and Mac2a cell lines derived from the same patient. ALK = Anaplastic lymphoma kinase, GCB = Germinal Centre B, 
ABC = Activated B-cell, DLBCL = Diffuse Large B-cell lymphoma, RPMI = Roswell Park Memorial Institute, DMEM = 
DulďeĐĐo’s Modified Eagles Mediuŵ, FC“ = Foetal Calf “eƌuŵ.  
Cell line Lymphoma type Media 
SUDHL1 ALK+ Anaplastic Large Cell Lymphoma RPMI-1640 + 10% FCS 
Karpas-299 ALK+ Anaplastic Large Cell Lymphoma RPMI-1640 + 10% FCS 
DEL ALK+ Anaplastic Large Cell Lymphoma RPMI-1640 + 10% FCS 
SUPM2 ALK+ Anaplastic Large Cell Lymphoma RPMI-1640 + 10% FCS 
SR786 ALK+ Anaplastic Large Cell Lymphoma RPMI-1640 + 10% FCS 
Mac1 ALK- Cutaneous Anaplastic Large Cell Lymphoma RPMI-1640 + 10% FCS 
Mac2a ALK- Cutaneous Anaplastic Large Cell Lymphoma RPMI-1640 + 10% FCS 
FEPD ALK- Anaplastic Large Cell Lymphoma RPMI-1640 + 10% FCS 
DL40 ALK- CD30+ Large T-cell Lymphoma RPMI-1640 + 10% FCS 
Karpas-384 ɶɷ T-cell Non-Hodgkin Lymphoma  RPMI-1640 + 10% FCS 
HDLM2 T-cell Hodgkin Lymphoma RPMI-1640 + 20% FCS 
SUDHL4 GCB Diffuse Large B-cell Lymphoma RPMI-1640 + 20% FCS 
Karpas-422 GCB Diffuse Large B-cell Lymphoma RPMI-1640 + 20% FCS 
Toledo GCB Diffuse Large B-cell Lymphoma RPMI-1640 + 10% FCS 
Pfeiffer GCB Diffuse Large B-cell Lymphoma RPMI-1640 + 10% FCS 
HLY-1 ABC Diffuse Large B-cell Lymphoma RPMI-1640 + 10% FCS 
H929 Multiple Myeloma RPMI-1640 + 10% FCS 
LP1 Multiple Myeloma RPMI-1640 + 10% FCS 
HEK 293T - DMEM + 10% FCS 
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washing briefly with 37oC phosphate buffer saline (PBS) (137mM Sodium Chloride, 
2.7mM Potassium Chloride, 10mM Disodium Phosphate, 1.8mM Monopotassium 
Phosphate). Cells were then treated with 1ml of 1X Trypsin-EDTA solution (Sigma) and 
incubated at 37oC for 1 minute to allow detachment of cells from the flask. Next, 
trypsin-EDTA solution was neutralised using 9ml 37oC DMEM medium; cells were then 
transferred into a new 75cm2 flask with fresh DMEM medium. All cell lines used were 
validated through LGC Standards prior to use. 
2.1.2 Thawing of cryopreserved cells 
Cells, stored in freezing medium (section 2.1.4) in cryovials, were recovered 
from liquid nitrogen storage, thawed at 37oC and combined with 5ml of appropriate 
culture medium pre-warmed to 37oC. After brief centrifugation at 300g for 5 minutes 
to remove Dimethyl Sulfoxide (DMSO)-containing freezing medium, cells were 
resuspended in the appropriate medium and incubated at 37oC. 
2.1.3 Counting cells using a Haemocytometer and Trypan Blue exclusion 
A haemocytometer contains two chambers of four gridded areas of 1mm2 each 
of which containing sixteen individual 0.25cm2 squares. A coverslip is applied to the 
grid which is held 0.1mm above the grid allowing accurate determination of the total 
volume in each grid square.  To determine total number of cells, a sample is first 
combined in a 1:1 ratio with 0.4% Trypan Blue (Sigma) before being loaded into a 
single chamber and all non-blue cells which are encompassed inside the four 1mm2 
chambers are counted. The impermeable dye, Trypan Blue, cannot be taken up by 
living cells with intact membranes however dead cells will be stained blue by invasion 
of the dye and hence constitute a simple method of determining cell viability. Total 
viable cell number is calculated using the following formula:  
2.1.4 Freezing cells 
For cryopreservation, exponentially growing cells were counted using Trypan 
Blue exclusion (section 2.1.3) and 5x106 cells were collected and centrifuged at 300g 
for 5 minutes. Supernatant was removed and cells were resuspended in 1ml standard 
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Figure 2.2: Structure of Crizotinib (PF-2341066) taken from http://www.selleckchem.com 
Figure 2.1: Structure of 79-6 inhibitor taken from Cerchietti et. al (2010) 
Figure 2.3: Structure of Lenalidomide taken from http://pubchem.ncbi.nlm.nih.gov 
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culture medium + 10% DMSO. DMSO is used as a cryopreservation agent. Cells were 
then transferred to cryovials (1ml/cryovial) and stored at -80oC, in a freezing container, 
for 24 hours before transferring to liquid nitrogen maintained at -196oC. 
2.1.5 Mycoplasma testing 
All cell lines were routinely screened for mycoplasma infections by combining 
aspirates of cell culture medium with a mycoplasma detection reagent using the 
MǇĐoAleƌt MǇĐoplasŵa DeteĐtioŶ Kit ;LoŶzaͿ aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s 
protocol. The kit measures the activity of mycoplasma enzymes which can be detected 
colourmetrically using a FLUOStar Omega Plate Reader (BMG Labtech). Cells were 
routinely screened for mycoplasma on a 6-week basis. 
2.2 Drugs/Inhibitors 
2.2.1 BCL6 inhibitor, 79-6 
 The BCL6 inhibitor, 79-6, was designed to target the BTB/POZ domain of BCL6 
and prevent the interaction of BCL6 with co-repressors such as NCoR, BCoR, and 
HDACs (Cerchietti et al., 2010a). 79-6 was ordered from Merck Millipore, 50mg, 
product code: 197345. The drug was initially reconstituted in DMSO to a concentration 
of 100mM. Further dilutions were performed in DMSO and stored at -20oC. The 
chemical structure of 79-6 is shown in figure 2.1.  
2.2.2 ALK inhibitor, Crizotinib 
 Crizotinib is a dual c-MET and ALK inhibitor originally designed as a c-MET 
inhibitor. The drug was designed to target the ATP-binding site of c-MET thereby 
preventing the phosphorylating activity of the kinase (Cui et al., 2011). Crizotinib was 
ordered from SelleckChem, 5mg, product code: S1068. The drug was reconstituted in 
DMSO to a concentration of 40mM and subsequently diluted to working stocks in the 
μM ƌaŶge usiŶg steƌile ǁateƌ aŶd stoƌed at -20oC. The chemical structure of Crizotinib 
is shown in figure 2.2. Recently the drug has been approved for use for use in ALK+ 
non-small cell lung carcinoma (NSCLC) due to its ability to also bind ALK with high 
avidity and prevent the phosphorylating activity of ALK (Gerber and Minna, 2010). 
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2.2.3 Lenalidomide 
 Lenalidomide is a thalidomide analogue which has been utilised across multiple 
cancers. The drug works by targeting and inhibiting Cereblon, an E3 ubiquitin ligase, 
resulting in both direct anti-tumour and immunomodulatory effects (Breitkreutz et al., 
2008, Gandhi et al., 2014). Lenalidomide was ordered from SelleckChem, 50mg, 
product code: S1029. The drug was reconstituted to a concentration of 200mM in 
DMSO. Chemical structure can be found in figure 2.3.  
2.3 Resazurin viable cell assay 
2.3.1 Principle 
 Resazurin is a blue dye which can be metabolised by mitochondrial enzymes to 
the pink fluorescent dye, Resorufin and hence used as a measure of metabolically 
active cells. Resorufin can be detected by absorbance at 570nm or by fluorescence at 
585nm when excited at 570nm. The fluorescence produced is proportional to the 
metabolic activity of the population and therefore to the number of metabolically 
active cells in a given population but the assay cannot readily distinguish cytostatic or 
cytotoxic effects of a treatment. 
2.3.2 Method 
 Resazurin sodium salt was ordered from Sigma, 5g, product code: R7017. Upon 
arrival, Resazurin was reconstituted in sterile water (Gibco) to a final concentration of 
100µg/ml and stored in 1ml aliquots at -20oC in the dark. In order to perform the 
assay, cells were first subjected to growth curve analysis to ascertain the correct 
seeding density required for up to 4 days growth at 37oC, 5% CO2 (see chapter 3, 
section 3.2.9). Briefly, cells were counted by Trypan Blue exclusion (see section 2.1.3) 
before centrifuging at 300g for 5 minutes. Supernatant medium was then aspirated off 
and cells were then reconstituted in fresh medium to 1x106 cells/ml. This culture was 
then serially diluted to achieve a range of concentrations for analysis (see chapter 3, 
section 3.2.9). 100µl of each concentration of cells was then plated out, in triplicate, in 
a 96-well plate (COSTAR). Wells were surrounded with 100µl PBS to avoid evaporation. 
A control well containing medium-only was added to all plates to serve as a blank, the 
plate was then incubated at 37oC, 5% CO2, for 96 hours. After incubation, 11µl of 
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100µg/ml Resazurin reagent was added to each well, in the dark, and incubated at 
37oC, 5% CO2, for a further 2 hours. After, fluorescence was detected using a FLUOStar 
Omega Plate Reader (BMG Labtech). Fluorescence was recorded at 590nm, data was 
normalised with respect to medium-only control well. For drug experiments, cells were 
counted by Trypan Blue exclusion (see section 2.1.3) before centrifuging  at 300g for 5 
minutes, supernatant was aspirated off and cells were reconstituted in fresh medium 
to double the final concentration required as determined by growth curve analysis (see 
chapter 3, section 3.2.9). 50µl of cell culture was then plated out, in triplicate, in a 96-
well plate. To this 50µl of appropriate drug, at double the final concentration required, 
was added accordingly to the wells. Control wells containing either medium-only 
(blank) or cells and medium only (zero) were added and all wells were surrounded with 
100µl PBS. Cells were then incubated at 37oC, 5% CO2 for 72-120 hours according to 
experimental parameters. Resazurin reagent was added and measured as previously 
described. To analyse data, raw fluorescent values were calculated as a proportion of 
the zero control well. Values were plotted and respective IC50 values determined using 
cell viability curves on GraphPad Prism 6.0 software. 
2.4 siRNA knockdown 
2.4.1 Principle 
Naturally occurring short-interfering RNA (siRNA) is a double-stranded length of 
RNA, typically between 21 and 25 nucleotides, derived from double-stranded RNA 
(dsRNA), that utilises the RNA interference (RNAi) pathway to prevent translation of 
specific RNA sequences (Agrawal et al., 2003). Double-stranded RNA is cleaved by an 
RNase III nuclease, Dicer, creating an siRNA duplex with a two ϯ’ nucleotide overhang 
on each strand. This duplex is then processed through the cellular RNAi machinery into 
single-stranded RNA (ssRNA) complementary to the target mRNA. The ssRNA combines 
with RNA-induced silencing complex (RISC) proteins, directing these to complementary 
mRNA sequences and where they effect post-transcriptional silencing either by mRNA 
degradation or by translational inhibition. Translational inhibition is favoured if 
sequence similarity is not perfect (Pratt and MacRae, 2009). Experimentally, synthetic 
siRNAs (usually 19-25 nucleotides in length) mimicking Dicer products are delivered to 
cells to artificially silence target transcripts. Typically, multiple siRNAs to the same 
target are used in combination to reduce the non-specific effects that a single siRNA 
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may exhibit, a single siRNA may knockdown other vital targets within a cell if too 
abundant.  
2.4.2 Method 
 Sequences of siRNAs can be found in table 2.2. Lyophilised siRNA 
oligonucleotides (GE Dharmacon) were reconstituted using 1X siRNA Buffer (GE 
Dharmacon) to a final concentration of 20µM, divided into 5µl aliquots, and stored at -
20oC. To transfect suspension lines with siRNA, cells were first counted using Trypan 
Blue exclusion (section 2.1.3), 2x106 cells were then centrifuged at 300g for 5 minutes 
and medium was removed. Cell pellet was then resuspended in 200µl fresh 37oC 
medium (final concentration 5x106 cells/ml) and  loaded into a 4mm Electroporation 
Cuvette (Peqlab) before the adding 5µl of 20µM appropriate siRNA to achieve a final 
concentration of 500nM. Cells were then electroporated using the EPI2500 Pulse 
Generator (Fischer Scientific) according to voltages found in table 2.2. Optimal voltages 
were determined for each individual siRNA to achieve a voltage which resulting in 
sufficient knockdown with the least toxic effects (see chapter 3, section 3.2.2). Cells 
were electroporated for 10ms at appropriate voltages before standing at room  
  
Table 2.2: siRNA sequences and voltages for electroporation 
   Voltage 
 Construct Target SeƋueŶce ;5’-ϯ’Ϳ SUDHL1 Karpas-299 SUDHL4 
B
C
L6
 S
M
A
R
T
P
o
o
l 
si
R
N
A
 
BCL6-001 CCUUAAUCGUCUCCGGAGU 260V 280V 340V 
BCL6-002 GUAUAUACCCGUACAACGU 260V 280V 340V 
BCL6-003 GUUAUAACUACUCCGGAGA 260V 280V 340V 
BCL6-004 CAUCAAGCCUCCUCGUGAA 260V 280V 340V 
IR
F
4
 s
iR
N
A
 
p
o
o
l 
IRF4-001 CCCGACGGGCTCTATGCGAAA 260V 280V 340V 
IRF4-002 CAGGCCGTTTCTCATACTACA 260V 280V 340V 
 Dharmacon Non-silencing siRNA #2 Sequence not provided 260V 280V 340V 
 
89 
 
temperature  for 15 minutes. Cells were then diluted to an appropriate concentration 
using fresh 37oC medium and transferred to a 6-well plate (CORNING) for culture at 
37oC, 5% CO2. 
2.5 Lentiviral-mediated transduction 
2.5.1 Principle of shRNA 
Lentiviral short-hairpin RNA (shRNA) knockdown is a mechanism of RNAi that 
can be used to inducibly or stably knockdown targets. Unlike siRNA, shRNA is 
introduced into a cell via a vector which can integrate into the genome. The inducible 
shRNA vector used in this project, pTRIPZ (figure 2.4), is designed to utilise the 
endogenous micro-RNA 30 (miR-30) pathway by incorporating a 22 nucleotide dsRNA 
and a 19 nucleotide loop from miR-30 to the shRNA. This addition allows the shRNA to 
be recognised as a primary miR-30 transcript and allows processing by Drosha in the 
nucleus to a pre-shRNA. After processing, pre-shRNA is exported out of the nucleus by 
Figure 2.4: Vector map of pTRIPZ taken from Thermo Scientific Technical Manual 
TRIPZ is a doxycycline-inducible vector driving the shRNA of choice and red fluorescent protein (RFP) from a 
doxycycline responsive cytomegalovirus promoter (TRE). The vector also contains an Internal Ribosome Entry Site 
(IRES) sequence which facilitates translation initiation from the within mRNA sequences. In addition, the vector 
contains bacterial antibiotic resistance genes for ampicillin (AmpR) and Zeomycin (Zeo) as well as the mammalian 
antibiotic resistance gene for puromycin (PuroR). Expression of puromycin resistance gene is constitutive and 
independent of doxycycline induction, driven by a Ubiquitin C (UBC) promoter, whilst expression of AmpR and Zeo 
is driven by the University of California (pUC) promoter. To alloǁ iŶtegƌatioŶ iŶto the host geŶoŵe, ϱ’ LoŶg 
Terminal Repeat (LTR) and Self-inactivating LTR (sinLTR) regions are present. Additional plasmid components 
include: Central Polypurine Tract (cPPT) required for translocation of vector to the nucleus of non-dividing cells, 
Woodchuck Posttranscriptional Regulatory Element (WPRE) element which facilitates translational stability of 
transcripts, Reverse tetracycline transactivator (rtTA3) required for efficient induction via doxycycline, and Psi 
packaging sequence (ΨͿ ǁhiĐh faĐilitates paĐkagiŶg of the ǀeĐtoƌ. To iŶduĐe the plasŵid, doǆǇĐǇĐliŶe ďiŶds the 
rtTA3 element resulting in activation of the element. This then allows rtTA3 to bind the TRE promoter resulting in 
activation of transcription. 
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Exportin 5 before associating with Dicer resulting in the removal of the stem loop. At 
this point, the shRNA sequence is processing in the same manner as siRNA (see section 
2.4.1) (Boden et al., 2004).  
The shRNA system is more desirable over siRNA knockdown as the system 
utilises the endogenous micro RNA processing machinery that is used by the cell to 
produce functional micro-RNAs (Rao et al., 2009). However, high levels of shRNA may 
elicit an anti-viral response causing the activation of the innate immune system 
resulting in degradation of cellular mRNAs (Bumcrot et al., 2006). 
 
 
Figure 2.5: Vectoƌ ŵaps of packagiŶg plasŵids pMDϮ.G aŶd pCMV ΔRϴ.ϵϭ, and expression vector pSIEW 
Packaging vectors are used during transfection of cells: AͿ pMDϮ.G aŶd BͿ pCMV ΔRϴ.ϵϭ. The vectors contain 
the viral genes pol, env, and gag that together create a lentivirus as well as the tat gene to enhance 
transcription driven from a Cytomegalovirus (CMV) promoter. Viral genes are distributed between two vectors 
to prevent the formation of self-replicating lentivirus. C) Vector map for pSIEW. SIEW vector constitutively 
expresses a coding sequence of interest (CDS) and Green Fluorescent Protein (EGFP) from the Spleen Focus 
Forming Virus (SFFV) promoter. The vector also contains an Internal Ribosome Entry Site (IRES) sequence which 
facilitates translation initiation from within mRNA sequences. All vectors contain an ampicillin resistance gene 
(AmprͿ. “IEW ƌesistaŶĐe geŶe is dƌiǀeŶ ďǇ a “Pϲ pƌoŵoteƌ. To alloǁ iŶtegƌatioŶ iŶto the host geŶoŵe, ϱ’ aŶd ϯ’ 
Long Terminal Repeat (LTR) regions are present in the SIEW vector. Other elements in the SIEW vector include: 
Rev Response Element (RRE) and cPPT element both of which facilitate RNA translation, and the Woodchuck 
Posttracriptional Regulatory Element (WPRE) required for enhancing expression from the vector.  
A) B) 
C) 
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2.5.2 Principle of overexpression 
In addition to TRIPZ, the pSIEW expression vector was utilised in this project 
(figure 2.5C). The expression vector allows constitutive transcription of a coding 
sequence resulting in significant production of target mRNA sequences. Expression 
constructs are used for multiple purposes such as: assessing the effect of ectopic 
expression of potential tumour suppressor genes on the survival of cells, or to produce 
peptides and antibodies. 
Foƌ fuŶĐtioŶal studies, ƌeiŶtƌoduĐed ŵRNA seƋueŶĐes tǇpiĐallǇ laĐk ϱ’ 
Untranslated Region (UTRͿ aŶd ϯ’UTR eleŵeŶts; this ĐaŶ alloǁ siŵultaŶeous 
knockdown of endogenous target (by targeting shRNA to UTR sequences) whilst 
expressing sequence of choice. This method is particularly useful for assessing the 
effect of mutated gene sequences on cellular function. 
2.5.3 Principle of lentivirus generation  
One method of introducing viral vectors is lentiviral transduction whereby a 
lentivirus is engineered to deliver shRNA directly into the host genome. To produce 
functional lentivirus for transduction, transfer vectors must be packaged. Our 
packaging protocol involves transfecting HEK 293T cells with the transfer vector and 
two packaging vectors, using the calcium phosphate method (Kwon and Firestein, 
2013). Simultaneous expression of the viral pol, env, and gag genes, together with the 
transfer vector, allows intracellular formation of intact viral particle, which is released 
into the culture medium (figure 2.6). 
Cells of interest can be transduced with lentivirus to stably introduce a 
construct into the genome. It is important to achieve a balance between the level of 
expression of construct and the number of integrations, as the greater the number of 
integrations, the greater the chance of non-specific disruption of gene functions via 
integration of vector into the gene.  
 
 
92 
 
  
Figure 2.6 Formation of a lentivirus particle 
Lentiviruses require three core components to create a functional infectious particle: a reverse 
transcriptase/integrase (encoded by the pol gene), envelope proteins (encoded by the env gene), and capsid 
proteins (encoded by the gag gene). After appropriate vectors, pCMV and pMD2.G, are transfected into HEK 
293T cells transcription of the pol, env, and gag genes occurs from the vectors. The Pol integrase and transfer 
vector (pTRIPZ or pSIEW) are encapsulated by envelope proteins. Meanwhile, gag capsid protein coats the cell 
membrane. Finally, encapsulated transfer vector combines with gag-bound cellular membrane and is 
exocytosed producing a functional packaged lentivirus.  
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2.5.4 Method 
2.5.4.1 Culturing of lentiviral vector bacteria 
 All bacterial cultures were grown in Lysogeny Broth (LB) (10g Bacterial 
Tryptone, 10g Sodium Chloride, 5g Yeast Extract, 1L sterile water) containing 1µg/ml 
ampicillin at 37oC, with shaking, in autoclaved, foil-covered conical flasks unless stated 
otherwise. Cultures were split 1:500 with fresh LB for 16 hour incubations for general 
culturing. All bacteria work was conducted around a blue Bunsen burner flame. 
2.5.4.2 Bacterial culturing of lentiviral vectors 
 Glycerol stocks of TRIPZ vector-containing bacteria were acquired from GE 
Thermo Scientific, sequences and references are found in table 2.3. pSIEW glycerol 
stocks were kindly donated by Dr. Paul Sinclair. Upon arrival, all glycerol stocks were 
stored at -80oC. To produce further stocks, a scraping of the current glycerol stock was 
taken using a sterile needle and mixed in 3ml of 1µg/ml ampicillin LB and incubated at 
37oC for 8 hours with shaking in a sterile 20ml universal tube (Thermo Scientific) to 
produce a pre-culture. After 8 hours, up to 100µl of culture was pipetted onto an LB-
1.5% agar plate (4g Bacto Agar (BD Biosciences, product code: 214010), 250ml LB) and 
spread evenly using a sterile spreader. LB-agar plates were then incubated at 37oC 
overnight. After incubation, individual colonies were selected for pre-culture. Briefly, 
using a p200 tip, individual colonies were lifted from agar plate and mixed with 3ml 
fresh 1µg/ml ampicillin LB in separate 20ml universal tubes. Cultures were then 
incubated at 37oC for 8 hours with shaking. After incubation, 1ml of each culture was 
centrifuged at 7,000g for 3 minutes whilst the remaining culture was stored at 4oC. 
Bacterial DNA was then isolated from centrifuged bacteria using a QIAprep Spin 
Miniprep kit (produĐt Đode: ϮϳϭϬϲͿ aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s pƌotoĐol. PƌeseŶĐe 
Target Reference Target Sequence (5'-3') 
BCL6 
V3THS_333939 TGACTGATGTTGTCATTGT 
V3THS_404721 AGGTGAACCATGTCAGCAA 
V2THS_132926 CAAAGGATACTGTAACACT 
IRF4 
V3THS_377531 CCAGCAGGTTCACAACTAC 
V3THS_377532 GGGGCTACGATTTACCAGA 
Non-silencing control RHS4743 Not supplied 
 
Table 2.3: shRNA sequences for TRIPZ vectors 
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of plasmid was confirmed through use of restriction endonuclease digests and agarose 
gel electrophoresis. After confirmation, 200µl of plasmid-containing cultures were 
recovered from 4oC storage and mixed with 3ml fresh 1µg/ml ampicillin LB, in a 
universal tube, before incubating at 37oC with shaking for 8 hours. Cultures were then 
transferred to conical flasks and mixed with 150ml of fresh 1µg/ml ampicillin LB before 
incubating at 37oC for with shaking for 16 hours. To produce glycerol stocks, 500µl of 
bacterial culture was then combined with 500µl of 80% autoclaved glycerol (diluted 
with sterile water) and transferred to a cryovial. Samples were then stored at -80oC. 
The remaining culture was utilised for large-scale isolation of bacterial vector. Cultures 
were divided evenly into 50ml falcon tubes (CORNING) and centrifuged at 3,000g for 
15 minutes. LB supernatant was then removed and plasmid DNA isolated from 
bacterial pellet using the Endofree Plasmid Maxi Kit (Qiagen) according to the 
ŵaŶufaĐtuƌeƌ’s pƌotoĐol. All plasŵids ǁeƌe ƌeĐoŶstituted iŶ ϭϬϬµl TE Buffeƌ ;ϭϬŵM 
Tris.Cl, pH 8.0, 1mM EDTA) and stored at -20oC. PlasmidDNA was quantified using a 
NanoDrop ND-1000UV spectrophometer 128 (NanoDrop Technologies). Vector maps 
can be found in figures 2.4 and 2.5. 
2.5.4.3 Transfection of HEK 293T cells 
2x105 HEK 293T cells were suspended in 10ml DMEM medium in 100mm 
culture dishes (COSTAR) prior to transfection and incubated at 37oC, 5% CO2 for 24 
hours. Next, for each individual transfection plate; 5µg of pMD2.G vector, 15µg pCMV 
ΔRϴ.ϵϭ ǀeĐtoƌ, aŶd ϮϬµg transfer vector (TRIPZ or SIEW) were combined with 2.5µM 
HEPES in sterile water, pH 7.3 (Sigma, product code: H3375) at room temperature to a 
final volume of 250µl in a 1.5ml tube. To this, 250µl 0.5M Calcium Chloride solution to 
a final concentration of 0.25M and 500µl 2XHeBS solution (560mM NaCl, 100mM 
HEPES, 3mM Na2HPO4, pH 7.0) was added to the vector mixture and incubated at 
room temperature for 30 minutes to form calcium phosphate precipitates. After 
incubation, the transfection solution was added directly to HEK 293T plates and 
incubated at 37oC, 5% CO2 for 24 hours.  Next, medium was aspirated off the plates 
and cells were washed in PBS before applying fresh medium. Cells were incubated at 
37oC, 5% CO2 for 72 hours to allow formation of lentiviral particles. Finally, supernatant 
was harvested and centrifuged at 86,000g for 120 minutes at 4oC to concentrate virus. 
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Concentrated virus was resuspended in RPMI+10% FCS media and stored at -80oC in 
ϱϬμl aliƋuots. All vectors were packaged using this technique. 
2.5.4.4 Transduction of suspension cell lines 
 Prior to transduction, cells were counted using Trypan Blue Exclusion (section 
2.1.3). 5x105 cells were then centrifuged at 300g for 5 minutes, and resuspended in 
5ml of fresh medium in a universal tube. To this, 5µl of 8mg/ml polybrene (Merck 
Millipore, product code: TR-1003-G, stored at -20oC) was added to achieve a final 
concentration of 8µg/ml. 500µl of culture was then immediately plated in a 48-well 
plate (COSTAR) and surrounding wells filled with 500µl PBS to avoid evaporation. Cells 
were then treated with appropriate concentrations of viral particles, sealed using 
Parafilm, and transduced by centrifuging at 900g for 50 minutes at 34oC. After 
spinfection, Parafilm was removed, and cells were cultured as normal at 37oC, 5% CO2.  
2.5.4.5 Induction and selection of transduced suspension cell lines 
 To induce TRIPZ-transduced cells, doxycycline was required. Doxycycline was 
acquired from Sigma, product code: D9891-1G, resuspended in sterile water and 
stored at -20oC in 1ml aliquots. Transduced cells were treated with doxycycline to a 
final concentration of 2µg/ml and incubated at 37oC for 72 hours. Red Fluorescent 
Protein (RFP) levels for TRIPZ vectors, and Green Fluorescent Protein (GFP) levels for 
SIEW vectors, were detected using a FACSCalibur (BD Biosciences) (see section 2.8.2.2). 
For each cell line, optimal puromycin (Santa Cruz Biotechnology, product code: CAS 58-
58-2, stored at -20oC) concentration for selection was determined by incubation of 
cells for 72 hours with a range of puromycin concentrations followed by assessment by 
Resazurin. Briefly, 100µl of non-transduced cells were seeded in a 96-well plate at 
1x105 cells/ml and treated with 1µl puromycin to a final concentration of either 
0µg/ml, 0.5µg/ml, 1µg/ml, 2µg/ml, or 4µg/ml. Wells were then surrounded with 100µl 
PBS and cells were incubated at 37oC. After 72 hours, cells survival was assessed by 
Resazurin (section 2.3). The concentration of puromycin which killed all cells after 72 
hours was selected for each cell line. Concentrations of puromycin used were: 4µg/ml 
for SUDHL1, 2µg/ml for Karpas-299 and DEL, and 1µg/ml for SUDHL4. Puromycin was 
acquired from Santa Cruz Biotechnology, product code: sc-108071A, resuspended in 
sterile water and stored in 100µl aliquots at -20oC. Volumes of virus that produced 
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approximately 30% RFP/GFP-positivity as determined by flow-cytometry (the Poisson 
distribution dictates that a 30% transduction efficiency denotes a high probability of a 
single integration per cell across the culture) were selected using puromycin.  
2.6 Protein analysis 
2.6.1 Protein extraction 
5x106 cells were centrifuged at 300g for 5 minutes at 4oC and washed twice in 
cold PBS. Cell pellets were then lysed in Radioimmunoprecipitation buffer (RIPA) lysis 
buffer (50mM Tris, 150mM NaCl, 1% Sodium Deoxycholate, 1% Triton X-100, 0.1% SDS) 
(Harlow and Lane, 2006) supplemented with protease and phosphatase inhibitors 
(1mM Aminoethyl benzenesulfonyl hydrochloride, 800nM Aprotinin, 50µM Bestatin, 
15µM E-64, 5µM EDTA, 20µM Leupeptin, 10µM Pepstatin A) and incubated on ice for 
30 minutes. Following incubation, samples were subjected to sonication using a 
Soniprep 150 Plus Sonicator (Measuring and Scientific Equipment) for 10 seconds at an 
amplitude of 5.0. Finally, lysate was centrifuged at 16,000g for 15 minutes at 4oC and 
supernatant collected. Lysate was stored in RIPA buffer at -20oC. 
2.6.2 Protein quantification 
 Protein was quantified using the Pierce Bicinchoninic Acid (BCA) Assay and 
FLUOStar Omega microplate reader (BMG-Labtech) aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s 
protocol. The BCA assay measures the reduction of Cu2+ ions to Cu+ ions by proteins 
which then reacts with BCA to produce a purple colouring which can be detected at an 
absorbance of 562nm (Tuszynski and Murphy, 1990). By plotting a standard curve of 
known protein concentration, unknown protein concentrations can be determined by 
their absorbance. 
2.6.3 SDS-PAGE  
2.6.3.1 Principle 
 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) is a 
process by which proteins can be separated on a gel according to their molecular 
weight. Protein separation is achieved by conferring a negative charge to proteins by 
combining proteiŶ saŵple ǁith a loadiŶg ďuffeƌ, tǇpiĐallǇ ĐoŶtaiŶiŶg “D“ aŶd β-
mercaptoethanol, and boiling the protein sample. When loaded into a gel and a 
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current applied, charged protein will be repelled from the anode and migrate through 
the gel. Once separated, proteins are transferred to membrane by the same electrical 
stimulus. Proteins of interest are visualised by using primary antibodies against the 
denatured form of that protein. Once bound, a secondary antibody is applied with a 
conjugated horseradish peroxidase (HRP)-tagged epitope attached. The addition of 
Electrochemiluminescence (ECL) results in the metabolism of HRP resulting in the 
emission of light, therefore allowing antibody-bound proteins to be detected using an 
X-Ray film. 
2.6.3.2 Method 
Reagents used for SDS-PAGE are found in table 2.4. SDS-PAGE was performed 
using a 1.5mm 8% acrylamide gel due to the range of protein sizes detected (~140-
50kDa in size) (table 2.4). 20µg of total protein lysate was combined with 5µl of 4X 
sample loading buffer (1ml 4X SDS sample buffer table 2.4, ϱ% β-mercaptoethanol, 
0.04% Bromophenol Blue) and combined with RIPA buffer to a final volume of 20µl in a 
clean 1.5ml tube. Sample was then denatured by heating to 100oC for 5 minutes 
before centrifuging at full speed for 10 seconds. Gels were then assembled into a Mini-
PROTEAN® 3 system tank (Bio-Rad) and filled with 500ml 1X Running Buffer (100ml 
10X Running Buffer (table 2.4), 900ml deionised water). Protein samples were then 
pipetted into wells of gel; 15µl of SpectraTM Multicolour Broad Range Protein Ladder 
Standards (Thermo Scientific) was also loaded adjacent to protein samples. After, gel 
tank was filled with remaining 500ml 1X Running Buffer. Electrophoresis was then 
performed at a constant 120V for 90 minutes.  
Western blot analysis was performed by transferring proteins from SDS-PAGE 
gel to an Immobilon-P PVDF membrane (Millipore) at 100V for 1 hour using the Mini 
Trans-Blot System (Bio-Rad). Briefly, PVDF membrane was activated by incubating in 
methanol for 5 minutes at room temperature, before equilibrating in 1X Transfer 
buffer (200ml 5X Transfer Buffer (table 2.4), 200ml Methanol, 600ml deionised water) 
for 5 minutes at room temperature. After, gel and PVDF membrane were placed 
together and flanked by two sponges and two transfer buffer-soaked filter papers.  
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Product Reagent Ingredients Storage 
Volume 
required 
A
cr
y
la
m
id
e
 G
e
l 
8% 
Resolving 
Gel 
Protogel: 30% acrylamide, 0.8% bisacrylamide 
(Gene Flow, product code: A2-0072) Room temperature 2.7ml 
4X Resolving Gel Buffer: 1.5M Tris-HCl, 0.4% 
SDS, pH 8.8 (Gene Flow, product code: B9-
0012) Room temperature 2.6ml 
N, N, N', N'- Tetramethylenediamine (TEMED) 
(Sigma, product code:T9281-25ml) Room temperature 10µl 
Ammonium Persulphate (APS) (Sigma, product 
code: A3678-25g) 
Powder: Room temperature    
Liquid: combine 500mg with 
5ml of sterile water, aliquot 
into 100µl and store at -20C 30µl 
Sterile Water (Gibco, product code:10977-049) Room temperature 4.7ml 
6% 
Stacking 
Gel 
Protogel Room temperature 1ml 
Protogel Stacking Buffer: 0.5M Tris-HCl, 0.4% 
SDS, pH 6.8 (Gene flow, product code: B9-
0014)  Room temperature 1.25ml 
TEMED Room temperature 10µl 
APS 
Powder: Room temperature    
Liquid: combine 500mg with 
5ml of sterile water, aliquot 
into 100µl and store at -20C 50µl 
Sterile Water Room temperature 2.75ml 
 
4X SDS 
Sample 
buffer 
(50ml) 
250mM Tris pH 6.8 Room temperature 12.5ml 
 40% Glycerol Room temperature 20ml 
 8% SDS Room temperature 4g 
 
Sterile Water Room temperature 
Add until 
40ml total 
volume, pH to 
6.8, then top 
up to 50ml 
with sterile 
water 
 
10X 
Running 
Buffer 
25mM Tris Room temperature 60g 
 192mM Glycine Room temperature 288g 
 0.1% SDS Room temperature 20g 
 Sterile Water Room temperature 
Add until total 
volume 2L 
 
5X 
Transfer 
Buffer 
25mM Tris Room temperature 4g 
 192mM Glycine Room temperature 14.4g 
 0.0075% SDS Room temperature 750mg 
 Sterile Water Room temperature 
Add until total 
volume 2L 
 
10X TBS 
pH 7.6 
20mM Tris Room temperature 48.4g 
 150mM Sodium Chloride Room temperature 175.32g 
 Sterile Water Room temperature 
Add until total 
volume 1.6L, 
pH to 7.6 with 
HCl, then add 
until total 
volume is 2L 
 
Table 2.4: Recipes for commonly used western blot reagents 
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Transfer membranes were blocked in 1XTBS (100ml 10X TBS (table 2.4), 900ml 
deionised water)-0.1% Tween+5% milk for 1 hour at room temperature. Membranes 
were then incubated with primary antibody, diluted in 1XTBS-0.1% Tween-5% milk 
overnight. After incubation, membranes were subjected to 2x10 minute washes in 
1XTBS-0.1% Tween before incubating with the appropriate secondary antibody, diluted 
in 1XTBS-0.1% Tween-5% milk for 1 hour at room temperature. All antibodies used are 
found in table 2.5.  
To detect protein, membranes were subjected to 4x10 minute washes in 
1XTBS-0.1% Tween before addition of 1ml ECL detection reagent (GE Healthcare, 
product code: RPN2209) per membrane and incubation at room temperature for 1 
minute. Membranes were then wrapped in Saran Wrap and affixed to an X-Ray film 
cassette. Amersham Hyperfilm (GE Healthcare, product code: 28-9068-37) was then 
exposed to the membrane, in a dark room, and developed using an automated 
developer. 
To strip membranes for future antibody probing, membranes were incubated in 
a glass container with 20ml stripping buffer (2.5ml 0.5M Tris pH 6.8, 2ml 20% SDS, 
140μl Ϯ-β-mercaptoethanol, 15.4ml sterile H2O) in a 60oC shaking water bath for 30 
minutes. Membranes were then subjected to 4x10 minute 1XTBS-0.1% Tween washes, 
at room temperature, before blocking in 1XTBS-0.1% Tween-5% milk for 1 hour at 
room temperature. After which, membranes were ready for fresh primary antibody. 
 
Antibody Clone ID Company Dilution 
BCL6 SP155 Spring Biosciences 1/1,000 
IRF4 EP5699 Epitomics 1/10,000 
BLIMP1 C14A4 Cell Signalling 1/1,000 
c-MYC Y69 Abcam 1/1,000 
α-tubulin DM1A Sigma 1/10,000 
Polyclonal Goat Anti-Rabbit, HRP tagged P0448 Dako 1/10,000 
Polyclonal Goat Anti-Mouse, HRP tagged P044701 Dako 1/10,000 
 
Table 2.5: List of antibodies used for western blot analysis 
All membranes were incubated with primary antibodies overnight at 4oC and secondary antibodies were 
incubated for 1 hour at room temperature. 
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2.7 Gene expression analysis by Quantitative-PCR (qPCR) 
2.7.1 Principle 
Quantitative Reverse Transcription PCR (qRT-PCR) is a method used to quantify 
relative RNA levels between samples through use of a DNA-binding fluorescent dye. 
For qRT-PCR to assess mRNA transcript level, RNA is first extracted from cells and 
reverse transcribed to produce cDNA. The cDNA is combined with the fluorescent 
SYBR® Green compound which, when bound to nucleic acids, emits a green fluorescent 
light which can be detected 520nm. Therefore, absolute and relative cDNA levels 
between samples can be calculated by measurement of fluorescence intensity at 
520nm. To produce fluorescent signal strong enough to detect, forty rounds of PCR are 
undertaken with target-specific primers. Each successive PCR product is bound by 
SYBR® Green and hence doubles the original level of fluorescing compounds, qPCR 
machines can detect the intensity of fluorescence after each cycle of PCR and can 
quantify DNA levels by measuring the number of cycles required to achieve a certain 
threshold (Cycle Threshold – Ct) of fluorescence intensity. Relative expression of one 
product compared to another can then be calculated using the 2ΔΔCt method (Livak and 
Schmittgen, 2001):  
 
2.7.2 RNA extraction and cDNA synthesis 
2x106 cells were harvested for RNA extraction by centrifuging cell cultures at 
300g for 5 minutes in a 20ml universal tube. RNA was extracted from cell lines using 
the EZ-RNA (Biological Industries, product code: K1-0120) extraction kit, following the 
manufactuƌeƌ’s pƌotoĐol, aŶd eluted iŶ RNase-free water (Gibco). RNA was stored at -
80oC. The concentration of each sample was determined using a NanoDrop ND-1000 
UV spectrophometer 128 (NanoDrop Technologies). Reverse transcription was 
performed with 500ng of RNA using the RevertAidTM H Minus First Strand cDNA 
Synthesis kit (Fermentas International Inc., product code: K1632), using a random 
hexamer primer and reverse transcriptase provided in the kit, according to the 
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ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs. Briefly, the reverse transcription was performed with the 
following parameters: 25oC for 10 minutes, 42oC for 60 minutes, 70oC for 5 minutes. 
Samples were then stored at -20oC until required.  
2.7.3 SYBR® Green qPCR 
Relative gene expression assays were performed on a 384-well plate using the 
7900HT Sequence Detection System (Applied Biosystems) with the SYBR® Green Assay 
kit (Invitrogen).  Expression of target genes was analysed using primers in Table 2.5. 
Primers were designed using PrimerQuest software (Integrated DNA 
Technologies) to the following criteria: a GC content of 50%, a melting temperature of 
60-65oC, and an amplified sequence that spans an intron-exon boundary of 
approximately 200 bases. The specificity of each primer was determined using a 
melting curve analysis to ensure no primer dimers were formed. Lyophilised primer 
oligonucleotides were synthesised by Sigma and reconstituted in sterile water (Gibco) 
to a final concentration of 100µM. Primers were then stored at -20oC. Each qPCR well 
contained: 5µl Platinum SYBR® Green (Invitrogen), 0.4µl of 2.5µM forward primer (final 
concentration 100nM), 0.4µl of 2.5µM reverse primer (final concentration 100nM), 
3.2µl nuclease-free H2O, 1µl cDNA. Each sample was plated in triplicate for each 
primer set and every primer set contained a null-template control well to confirm 
absence of contamination. Plate was then sealed with a MicroAmp film lid (Life 
technologies, product code: 4309849). The plate was then centrifuged at 1,000g for 1 
minute prior to PCR cycling. 
Target Forward (5'-3') Reverse (5'-3') 
BCL6 CAAGACCGTCCATACCGGTG GCCCCACAGATGTTGCAAC 
IRF4 AGGATTGTTCCTGAGGGAGCCAAA ACCAATGTCCCATGACGTTTGGAC 
BLIMPϭα TCCAGCACTGTGAGGTTTCA TCAAACTCAGCCTCTGTCCA 
BLIMPϭβ GTACTCTGTGGTGGGTTAATCG ACACAAATGTTCATTTAAGGAGCTG 
c-MYC GTCTCCACACATCAGCACAACT GTTCGCCTCTTGACATTCTCCT 
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 
RPL13A TGAGTGAAAGGGAGCCAGAAG CAGACCTGGCATTCATGTGGCTTT 
p21 CCTCATCCCGTGTTCTCCTTT GTACCACCCAGCGGACAAGT 
TP53 CCCTTCCCAGAAAACCTACC AATCAACCCACAGCTGCAC 
ATR TCTCTGCAGGGTTTGTGGCTGTTT AAGTGCTTCACCCATGCTCCCTAT 
B2M GCCGTGTGAACCATGTGACT GCTTACATGTCTCGATCC 
HPRT CGTCTTGCTCGAGATGTGAT GCACACAGAGGGCTACAATGTG 
 Table 2.5: Primers used for quantitative PCR analysis 
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The following cycling parameters were used: 95oC for 2 minutes followed by 40 
cycles of 95oC for 15 seconds (melting) and 60oC for 1 minute (annealing/extension). 
Data was analysed using Applied Biosystems Sequence Detection System v2.3. Relative 
gene expression was calculated for each sample using the 2-ΔΔCt method (Livak and 
Schmittgen, 2001). The results were normalised to either RPL13A or GAPDH 
expression. RPL13A was chosen for 79-6 experiments (see chapter 3, section 3.2.10) 
for consistency with previously published literature. However, both RPL13A and 
GAPDH expression did not vary with 79-6 inhibitor treatments in this study. 
2.8 Flow cytometry 
2.8.1 Principles of flow cytometry 
 Flow cytometry is a laser-based technique used to detect fluorescent particles 
on or within individual cells in a stream passing through a detection apparatus. Cells 
can be fixed to prevent the degradation and lysis of cells during preparation. Cells can 
be chemically fixed by two means: with a cross-linking reagent such as formaldehyde 
or with a denaturing solution such as ethanol (Warnes, 2014). Cross-linking reagents 
bind to intracellular components and cause intramolecular and intermolecular bonds 
to foƌŵ ƌesultiŶg iŶ a ͞stasis͟ of Đellulaƌ ĐoŵpoŶeŶts. DeŶatuƌiŶg solutioŶs ƌeplace the 
intracellular fluids and cause denaturation of protein tertiary structures (Warnes, 
2014). Fixed cells are then treated with either fluorescent antibodies to specific cell 
surface or intracellular proteins or a fluorescent dye for analysis. Cells are passed 
through a flow cytometer and fluorescence data is collected as illustrated in figure 2.7. 
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Figure 2.7: Principles of a flow cytometer 
Cells are aspirated into the flow cytometer and combined with an isotonic fluid which helps align and force 
the cells into a single stream. The cells then pass through an excitation laser of known wavelength (typically 
488nm) which, upon contact with the cell, is split into two directions. Light scattered by cells at an angle <10o 
are detected by a forward scatter detector; this is generally regarded as a measure of the size of a cell. The 
remaining light is scattered 90o in relation to the original source and passes through a number of dichroic 
filters to separate out the various wavelengths. The first wavelength filtered is 488nm which is detected by a 
side scatter detector; this is generally regarded as a measure of cellular granularity. Further filters are 
applied separating wavelengths of 515-545nm (FL-1), 564-606nm (FL-2), >650nm (FL-3) which are detected 
by various fluorescent detectors. Other fluorescent detectors are available for specialist flow cytometers. 
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To analyse multiple fluorescent channels at once, a process known as 
compensation must be undertaken. This process involves the removal of emission 
spectrum from one fluorochrome from a detector designed to measure emission from 
a different fluorochrome to accurately conduct multicolour analysis. Compensation is 
necessary when the physical emission spectra of two fluorochromes overlap (figure 
2.8).  
 Lymphoma cell lines: SUDHL1, DEL, Karpas-299, and SUDHL4 underwent 
compensation before any experiments were conducted. The FL1 fluorescent channel 
was compensated using GFP-expressing cells, the FL2 channel was compensated using 
RFP-expressing cells, and the FL3 channel was compensated using 7-aminoactinomycin 
D staining (7-AAD). 
2.8.2 Method 
2.8.2.1 Propidium Iodide staining for cell cycle analysis 
 Propidium Iodide (PI) is a dye which binds cellular DNA and RNA which can be 
used to visualise cell cycle profiles. To stain, 1x106 cells were harvested by centrifuging 
at 300g for 5 minutes, supernatant removed and resuspended in 1ml PBS before 
centrifuging at 300g for 5 minutes. After, PBS supernatant was removed and cells were 
immediately fixed with 500µl 4oC 70% ethanol in a 1.5ml tube for 30 minutes on ice. At 
this stage, fixed cells could be stored at 4oC until required. Next, cells were washed 
Figure 2.8: Compensation of fluorescent channels 
A) Emission spectra for two fluorochromes. The emission spectrum of fluorochrome A overlaps the emission 
spectrum of fluorochrome B. B) Compensation subtracts the fluorescence observed from fluorochrome A to 
accurately measure fluorochrome B. C) Example of uncompensated and compensated plots for an FL1 
fluorochrome observed during the compensation process. Each quadrant defines a population. The bottom-left 
quadrant is defined by non-stained cells, the top-left quadrant is an FL2-positive population, bottom-right 
population is a FL1-positive population, and top-right is an FL1 and FL2-positive population. Uncompensated FL1 
fluorescence is detected by the FL2 detector, compensation removes aberrant FL2 readings. 
A) B) C) 
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twice in PBS (400g for 5 minutes), supernatant removed, and resuspended in 50µl of 
100µg/ml RNase (Sigma, product code: R6513-10MG) and transferred to a Polystyrene 
Falcon Round Bottom Tube (CORNING, product code: 352054). The addition of RNase 
causes the degradation of RNA within a sample so that only DNA is stained. Next, 
200µl of ϱϬμg/ml PI (Sigma, product code: 81845-25mg) was added to each sample 
and incubated at room temperature, in the dark, for 30 minutes. PI-stained cellular 
DNA content was analysed using the FACSCalibur flow cytometer (BD Biosciences). A 
total of 10,000 events were analysed. Cell cycle data was collected using CellQuest 
software (BD Biosciences, England) and analysed using Cyflogic software (CyFlo, 
Finland). RNase was resuspended in sterile water (Gibco) and stored at 4oC. 
2.8.2.2 Detection of GFP and RFP transduced cells 
 5x105 cells containing pSIEW or induced pTRIPZ vectors were harvested by 
centrifuging at 300g for 5 minutes, washed once in PBS (300g for 5 minutes), PBS was 
then removed and cells were fixed for 30 minutes on ice with 500µl Cytofix/Cytoperm 
solution (BD Biosciences, product code: 554722). Cells were then centrifuged at 300g 
for 5 minutes, supernatant removed, then washed once with 500µl Perm/Wash Buffer 
(BD Biosciences, product code: 554723) (300g for 5 minutes) and resuspended in 500µl 
Figure 2.9: RFP-gating strategy 
A) Gating strategy for all RFP-tracking experiments. Live cell population defined by left panel, RFP trace for non-
transduced cells defined in the right panel. Subsequent RFP expression is assessed from live cell population only. 
B) Example traces of RFP expression in a mixture of Parental cells and Non-silencing shRNA TRIPZ-transduced cells 
induced with 0.5µg/ml doxycycline for 72 hours. RFP-positive cells are defined as expressing RFP at greater-than-
or-equal-to 1 log greater than the highest expressing RFP-negative population to prevent any overlap of the two 
populations.  
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Perm/Wash Buffer before transferring to a Polystyrene Round Bottom Tube 
(CORNING). Data was collected using the FACSCalibur flow cytometer (BD Biosciences) 
with CellQuest software (BD Biosciences, England). A total of 10,000 events were 
collected. RFP-positive cell populations are defined as in figure 2.9. GFP-positive 
populations are defined separately for each experiment. Data was analysed using 
Cyflogic software (Cyflo, Finland). 
2.8.2.3 BrdU/7-AAD staining for cell cycle analysis 
 Bromodeoxyuridine (BrdU) is a thymidine analogue which can be incorporated 
into newly synthesised DNA (Lehner et al., 2011). 7-AAD is a DNA-stain. Together, the 
two molecules allow accurate identification of the cell cycle phase of cells within a 
sample. BrdU-positive cells represent those undergoing replication (S-phase) whilst 7-
AAD staining produces two populations, based on fluorescent intensity, of G1/G0 and 
G2/M stage cells. By allowing the incorporation of BrdU into cellular DNA and treating 
with a fluorescent antibody against BrdU before staining with 7-AAD these populations 
can be measured. 
 Cells to be analysed were treated with 10µl of 1mM BrdU per 1ml of culture 
and incubated for 30 minutes at 37oC, 5% CO2 before being harvested by centrifuging 
at 300g for 5 minutes, at least 5x105 cells were harvested. The supernatant was then 
removed, and the cell pellet was fixed with 500µl Cytofix/Cytoperm solution (BD 
Biosciences) for 30 minutes on ice. Cells were then treated using the FITC BrdU/7-AAD 
assay kit (BD Biosciences, product code: 559619Ϳ aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s 
protocol. Data was collected using the FACSCalibur flow cytometer (BD Biosciences) 
using CellQuest software (BD Biosciences, England). A total of 10,000 events, 
determined to be RFP-positive and high expressors by FL-2 gating, were analysed. High 
expressing RFP-positive cells were defined as shown in figure 2.9. Data was analysed 
using Cyflogic software (CyFlo, Finland). 
2.8.2.4 Active caspase-3 staining for apoptosis analysis 
Caspase-3 is a procaspase protein which is cleaved to an active caspase-3 
protein to initiate apoptosis (McIlwain et al., 2013). FITC-labelled anti active caspase-3 
fluorescent antibodies can be used as an indicator of apoptosis in cells. The level of 
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FITC fluorescence is directly proportional to the levels of active caspase-3 present in 
cells and is hence an indicator of apoptosis.  
Cells to be analysed were first harvested by centrifuging at 300g for 5 minutes 
(5x105 cells). Supernatant was then removed and cells were washed once in PBS (300g 
for 5 minutes). PBS was then removed and the cell pellet was then fixed in 
Cytofix/Cytoperm solution (BD Biosciences) for 30 minutes on ice. The cells were then 
centrifuged at 300g for 5 minutes and washed twice in Perm/Wash Buffer (BD 
Biosciences) (300g for 5 minutes) before resuspending cell pellet in in 25µl FITC active 
caspase-3 antibody (BD Biosciences – product code: 550480, diluted 1:5 in Perm/Wash 
Buffer) for 30 minutes at room temperature. 500µl of Perm/Wash Buffer was then 
added to the cells and transferred to Polystyrene Round Bottom Tubes (CORNING). 
Data was collected using the FACSCalibur flow cytometer (BD Biosciences) and 
CellQuest software (BD Biosciences, England). A total of 10,000 events were collected. 
Data was analysed using Cyflogic software (CyFlo, Finland). 
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3. The role of BCL6 in the maintenance of T-cell lymphoma 
3.1 Introduction 
 BCL6 is a transcriptional repressor which plays vital roles in both B- and T-cell 
development through regulation of lymphocyte proliferation and differentiation 
(Mendez et al., 2008, Pasqualucci et al., 2003, Saito et al., 2007). Importantly, BCL6 
demonstrates B-cell specific mutual inhibition of IRF4 and BLIMP1 and T-cell-specific 
mutual inhibition of BLIMP1 but is activated by IRF4 in T-cells (figure 3.1). BCL6 has 
been implicated as a driver of many B-cell lymphomas, however its role in T-cells is not 
well established. Overexpression of the protein has been detected in many T-cell 
malignancies suggesting a potential role in lymphomagenesis (de Leval et al., 2007, 
Duy et al., 2011, Kerl et al., 2001). Furthermore, in ALK+ ALCL, evidence suggests that 
BCL6 expression is driven by the NPM-ALK translocation (Chiarle et al., 2005, Zamo et 
al., 2002). 
 Research into BCL6 inhibition has yielded several peptides and drug 
compounds, all of which exploit BCL6s unique BTB/POZ domain. Indeed, treatment of 
BCL6-dependent cell lines with the peptides RI-BPI or Apt48, or the molecular inhibitor, 
79-6, result in anti-tumour effects (Cerchietti et al., 2010a, Cerchietti et al., 2009, 
Chattopadhyay et al., 2006). 
Figure 3.1: Interaction of BCL6 with IRF4 and BLIMP1 in B-cells vs. T-cells 
A) In B-cells, BCL6 exhibits mutual inhibition with BLIMP1 and IRF4 B) In T-cell differentiation, BCL6 retains this 
mutual inhibition activity with BLIMP1, however interactions with IRF4 differ. BCL6 expression, and subsequent 
T
FH
 cell differentiation is abrogated in Irf4
-/-
 mice demonstrating a positive interaction of IRF4 on BCL6 (Lohoff et. 
Al, 2002). However, the effect of BCL6 upon IRF4 expression is not known to date. 
A) B) 
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The aim of this chapter is to investigate BCL6 as a potential oncoprotein in T-
cell lymphoma by exploring the effect of BCL6 deficiency on proliferation, cell cycle, 
and induction of apoptosis of T-cell lymphoma cell lines. The chapter then investigates 
the effect of targeting BCL6 therapeutically using 79-6, as well as the determining the 
effect of BCL6 deficiency on expression of downstream targets IRF4 and BLIMP1. 
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3.2 Results 
3.2.1 Characterisation of lymphoma cell lines 
 To understand the heterogeneous nature of peripheral T-cell lymphoma in the 
context of the BCL6-IRF4-BLIMP1 transcription factor axis, western blotting for BCL6, 
IRF4, BLIMP1, and c-MYC protein levels were evaluated using whole-cell extracts from 
exponentially growing lymphoma cell lines. Expression of c-MYC was assessed to 
investigate if c-MYC protein levels correlated with IRF4 protein levels. Cells were 
cultured as normal at 37oC for 24 hours before lysing with RIPA buffer.  
The majority of cell lines included in this PTCL panel are ALCL due to availability. 
HDLM2 was also included due to the similar histological features the cell line exhibits 
to an ALK- ALCL. H929 and LP1 were included as positive controls for expressed IRF4, 
BLIMP1, and c-MYC whilst SUDHL4, HLY-1, and Karpas-422 were included as positive 
controls for expressed BCL6.  
As shown in figure 3.2, ALCL cell lines exhibited heterogeneous expression of 
BCL6 and BLIMP1 whilst IRF4 levels were expression at similar levels to MM cell lines in 
all PTCL cell lines apart from SUDHL1.  
BCL6 protein was expressed to similar levels to those found in the ABC-DLBCL 
cell line, HLY-1, but less than GCB-DLBCL cell lines SUDHL4 and Karpas-422 (figure 
3.2B), and is present in all ALK+ ALCL cell lines but variable across the remaining cell 
lines. This result is consistent with published gene expression profiling data 
demonstrating high expression of BCL6 in ALK+ ALCL compared to ALK- ALCLs (Lamant 
et al., 2007). 
IRF4 protein expression was generally consistent across all T-cell lines with 
levels reaching those found in MM cell lines (figure 3.2A). The low IRF4 protein 
detected in SUDHL1 (figure 3.2A) was deemed anomalous as protein expression levels 
were higher in all subsequent western blots for this cell line (figure 3.2B). 
Levels of c-MYC protein also appeared consistent with MM cell lines in all PTCL 
cell lines apart from Karpas-384. BLIMP1 protein expression was variable across T-cell 
lines with only SR786 and DL40 reaching levels similar to MM cell lines (figure 3.2A). 
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In addition, expression of BCL6 and BLIMP1 appear reciprocal in SUDHL1, 
Karpas-299, DEL, SUPM2, Mac1, Mac2a, and DL40 whereby BCL6 is high and BLIMP1 is 
low or vice versa. ALK- ALCL cell lines Mac1 and Mac2a are derived from the same 
patient, Mac1 is a presentation cell line whilst Mac2a is a relapse cell line. 
Interestingly, Mac2a gains expression of BCL6 and subsequently loses expression of 
BLIMPϭα upoŶ ƌelapse. BCL6 protein levels in SUDHL1, Karpas-299, SUPM2, and Mac2a 
are comparable to that of the ABC-DLBCL cell line HLY-1 (figure 3.2B). 
  
 
  
Figure 3.2: Expression of BCL6, IRF4, BLIMP1, and c-MYC in lymphoma cell lines 
A) Expression of transcription factors in peripheral T-cell lymphoma, Hodgkin lymphoma, and 
ŵultiple ŵǇeloŵa Đell liŶes. The BLIMPϭ aŶtiďodǇ deteĐts ďoth isofoƌŵs of BLIMPϭ: BLIMPϭα aŶd 
BLIMPϭβ ;uppeƌ aŶd loǁeƌ ŵoleĐulaƌ ǁeight ďaŶds ƌespeĐtiǀelǇͿ. The ideŶtitǇ of the thiƌd 
intermediate, band is unknown, possibly a truncated form of BLIMP1α. B) Expression of BCL6 and 
IRF4 by western blot of ALCL cell lines compared to DLBCL cell lines. Equal loading assessed by 
ďlottiŶg foƌ α-tubulin. ALK = Anaplastic Lymphoma Kinase, ALCL = Anaplastic large cell lymphoma, 
NHL = Non-Hodgkin lymphoma, MM = Multiple Myeloma, DLBCL = Diffuse large B-cell Lymphoma 
A) B) 
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3.2.2 Knockdown of BCL6 using siRNA 
 To investigate if BCL6 might regulate proliferation and/or survival of ALCL cell 
lines, siRNA-mediated knockdown was undertaken in the ALCL cell line, SUDHL1, and a 
control GCB-DLBCL cell line, SUDHL4. Optimal siRNA voltage was previously 
determined by members of the lymphoma group for SUDHL1, but this was not 
available for SUDHL4. To evaluate optimal voltage, 2x106 SUDHL4 cells were 
electroporated at either 280V, 300V, 320V, or 340V for 10ms with either a pool of 4 
BCL6 siRNAs or a non-silencing siRNA, incubated at room temperature for 15 minutes 
before seeding out at 5x105 cells/ml in 6-well plates and incubating at 37oC. After 24 
hours, cells were counted by Trypan Blue exclusion and protein extracts were collected 
and assessed by western blotting. Figure 3.3A shows the greatest level of BCL6 
knockdown occurs with 320V and 340V electroporation. However, treatment of cells at 
voltages above 300 volts was toxic (figure 3.3B). Therefore, to compensate for toxicity, 
all subsequent BCL6 siRNA knockdown experiments were performed with 4x106 cells 
and electroporated at 320V for SUDHL4.  
 
  
Figure 3.3: Optimisation of siRNA voltage in SUDHL4 
Cells were electroporated and seeded at 5x105 cells/ml. After 24 hours, protein lysates were collected. A) 
Level of BCL6 knockdown at electroporation voltages for 10ms. B) Total number of live cells as determined by 
Trypan blue exclusion. Results are representative of 2 independent experiments. 
A) B) 
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Figure 3.4: Individual siRNAs vs. BCL6 siRNA pool 
Knockdown of BCL6 in SUDHL1 cells electroporated at 260V for 10ms with 500nM of each siRNA. Protein collected 
24 hours post-transfection. 
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Figure 3.5: Counts of BCL6 knockdown lymphoma cells 
Data expressed as live cells remaining after BCL6 siRNA knockdown normalised to those treated with non-
silencing siRNA. Data represents the mean +/- standard error of the mean, of 3 independent experiments. 
Significance calculated using a paired students t-test, * p<0.05, ns = not significant. 
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In addition to determining the optimum voltages for electroporation, the 
knockdown efficiency of 500nM of each of the individual siRNAs that constitute the 
siRNA pool was compared to 500nM of the siRNA pool in SUDHL1 cells (figure 3.4). No 
individual siRNA produced a greater knockdown than the siRNA pool so the siRNA pool 
was used in all BCL6 siRNA knockdown experiments. 
3.2.3 BCL6 knockdown results in a modest reduction of proliferation/survival of 
lymphoma cell lines 
 In order to investigate if BCL6 knockdown affected the proliferation/survival of 
lymphoma cell lines, SUDHL1, Karpas-299, and SUDHL4 cells were electroporated with 
500nM of BCL6 siRNA or non-silencing siRNA and viable cells were counted every 24 
hours for 3 days. All cell lines showed some degree of decrease in their 
proliferation/survival after BCL6 knockdown (figure 3.5). SUDHL4, a GCB-DLBCL 
dependent upon BCL6 expression, showed the greatest decrease in cell number with 
knockdown (24 hours p=0.9297, 48 hours p=0.047, 72 hours p=0.7212) (figure 3.5) 
whilst SUDHL1 showed a limited effect (24 hours p=0.0451, 48 hours p=0.136, 72 hours 
p=0.0144) and Karpas-299 exhibited a trend but was not found to be significant (24 
hours p=0.1083, 48 hours p=0.2535, 72 hours p=0.6065) (figure 3.5).  
3.2.4 BCL6 siRNA knockdown has cell line-specific effects on IRF4 and BLIMP1 
expression 
 In order to investigate if BCL6 knockdown affected IRF4 and BLIMP1 expression 
in lymphoma cell lines, protein and RNA were collected every 24 hours for 3 days post-
electroporation and assessed by qRT-PCR and western blot. Successful knockdown was 
achieved in all cell lines tested (figure 3.6A); the greatest knockdown being recorded at 
24 hours across all cell lines. RNA levels of BCL6 were significantly reduced in SUDHL1 
at all timepoints (24 hours p=0.0155, 48 hours p=0.0095, 72 hours p=0.0201) and at 24 
hours in Karpas-299 but returned to basal levels after 48 hours (24 hours p=0.0002, 48 
hours p=0.9142, 72 hours p=0.3802) (figure 3.6B). In addition, BCL6 protein levels were 
decreased in these cell lines after 24 hours but increased slowly over the course of 72 
hours (figure 3.6A). Knockdown of BCL6 had no effect on IRF4 or BLIMP1 protein levels 
in either SUDHL1 or Karpas-299 (figure 3.6A). However, BCL6 knockdown resulted in an 
initial increase in IRF4 and BLIMP1 mRNA in SUDHL1 cells at 24 hours (IRF4 p=0.0365, 
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BLIMP1 p=0.0174) which gradually recovered to basal levels with increased BCL6 
protein levels over time (IRF4: 48 hours p=0.1265, 72 hours p=0.2496, BLIMP1: 48 
hours p=0.0833, 72 hours p=0.7529) (figure 3.6B). This effect was not seen in Karpas-
299 in either IRF4 (24 hours p=0.5334, 48 hours p=0.4399, 72 hours p=0.3263) or 
BLIMP1 (24 hours p=0.7556, 48 hours p=0.4694, 72 hours p=0.3397) (figure 3.6B). 
 
 
Figure 3.6: Effect of BCL6 knockdown on the BCL6-IRF4-BLIMP1 transcription factor axis 
A) Timecourse western blot of lymphoma cell lines treated with non-silencing or BCL6 siRNA and assessed after 
the indicated time points. Data representative of 3 independent experiments.. B) Relative mRNA levels in ALCL 
cell lines SUDHL1 and Karpas-299, Data represents the mean +/- standard error of the mean, of 3 independent 
experiments. 
A) 
B) 
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3.2.5 Doxycycline treatment of SUDHL1 cells results in reduced IRF4 expression 
Considering the subtle proliferation/survival phenotype caused by the siRNA 
knockdown of BCL6, shRNA knockdown was pursued to investigate if stable, 
prolonged, knockdown of BCL6 would produce a more marked effect. Initially, non-
transduced cells were treated with increasing concentrations of doxycycline to 
ascertain the highest concentration of doxycycline that could be used to induce 
lentiviral constructs with the least adverse effects on the transcription factors. 
Previously published data has demonstrated that high levels of doxycycline (5µg/ml) 
can induce changes in key signalling pathways and result in reduced proliferation of 
cell lines (Ahler et al., 2013, Pulvino et al., 2015). Therefore, cells were maintained in 
various concentrations of doxycycline for 1 week before protein levels of BCL6, IRF4, 
A) 
B) 
Figure 3.7: Knockdown of BCL6 using shRNA and effect of doxycycline on IRF4 protein levels 
A) Effect of culturing cells in increasing concentrations of doxycycline for 7 days on IRF4 protein levels in 
lymphoma cell lines. Dox=doxycycline. B) Representative western blots of shRNA-transduced cells treated 
with 0.5µg/ml doxycycline (SUDHL1) or 2μg/ml doxycycline (Karpas-299, DEL, SUDHL4) for 72 hours in 
SUDHL1, Karpas-299, DEL, and SUDHL4. Data representative of 3 independent experiments.  
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and BLIMP1 were assessed. BCL6 and BLIMP1 was unaffected by doxycycline however, 
IRF4 exhibited a dose-dependent suppression in SUDHL1 cells (figure 3.7A). The 
remaining cell lines, Karpas-299 and DEL, were unaffected by doxycycline (figure 3.7A). 
As a result, Karpas-299 and DEL were treated with 2µg/ml doxycycline to ensure 
maximum induction of vector, as defined in the TRIPZ manual, whilst SUDHL1 was 
treated with 0.5µg/ml doxycycline to minimise non-specific effects for all experiments.  
3.2.6 BCL6 shRNA knockdown results in reduced proliferation/survival of ALK+ ALCL 
cell lines 
 To ensure that both BCL6 shRNAs achieved BCL6 knockdown, cells were 
transduced with BCL6 shRNA or non-silencing shRNA constructs, selected in puromycin 
foƌ ϭ ǁeek ;ϰμg/ŵl puromycin – “UDHLϭ, Ϯμg/ŵl puƌoŵǇĐiŶ – DEL and Karpas-299, 
ϭμg/ŵl puƌoŵǇĐiŶ – SUDHL4), and induced with doxycycline. After 72 hours, western 
blotting showed marked decrease in BCL6 levels upon induction of BCL6 shRNA in all 
cell lines with both constructs (figure 3.7B). Knockdown was more prominent in 
SUDHL1 and DEL and less in Karpas-299 and SUDHL4 (figure 3.7B). Consistent with this, 
knockdown of BCL6 mRNA was greater in SUDHL1 and DEL than Karpas-299 (figures 
3.11 and 3.12). 
To evaluate the role of BCL6 on the proliferation of cell lines, transduced cell lines 
were induced for 72 hours with doxycycline to induce shRNA knockdown and RFP 
expression, before combining in a 50:50 ratio with non-transduced cells and cultured 
in doxycycline-containing medium; the time of mixing is indicated as day 0 in all 
experiments. RFP levels were then tracked by flow cytometry for 2 weeks post-mixing. 
2 of 3 cell lines containing BCL6 shRNA exhibited a reduction in RFP levels after 14 days 
(figure 3.8A). SUDHL4 DLBCL cells were also used as a positive control for BCL6 
sensitivity. BCL6 shRNA RFP-positive cells, which are indicative of BCL6 knockdown 
cells, were significantly reduced at day 14, in proportion with non-silencing shRNA 
cells, 2 days post-mixing (shRNA 1 p=0.00001, shRNA 2 p = 0.001) (figure 3.8A). Karpas-
299 showed the greatest effect on RFP-positivity with both BCL6 shRNAs, reducing 
RFP-positive populations 2 days after mixing (figure 3.8A). Both BCL6 shRNAs 
populations resulted in significantly reduced RFP populations in relation to non-
silencing shRNA populations by day 14 (shRNA 1 p=0.004, shRNA 2 p=0.001). BCL6 
shRNA populations in SUDHL1 were significantly reduced at day 14 with both shRNAs 
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compared to non-silencing shRNA populations (shRNA 1 p= 0.043, shRNA 2 p=0.0001) 
but only showed a reduction from day 11 (figure 3.8A). DEL exhibited the lowest effect 
on growth, day 14 was the only time point to have both BCL6 shRNAs significantly 
reduce RFP levels compared to control shRNA (shRNA 1 p=0.044, shRNA 2 p=0.003) 
(figure 3.8A). Despite the significant effect, DEL was deemed insensitive as only shRNA 
2 caused RFP populations to drop below 100% (figure 3.8A). In a parallel experiment, 
SUDHL1-transduced cells were also induced with 0.5µg/ml doxycycline and counted 
every 2-3 days, by Trypan Blue exclusion, for 14 days. In this experiment, BCL6 
knockdown with shRNA 1 cells also caused a significant reduction in the number of 
living cells in the SUDHL1 cell line compared to non-silencing shRNA cells, after 14 
days, by counting (p=0.011) (figure 3.8B). However, SUDHL1 BCL6 shRNA 2 cells failed 
to achieve a significant difference in cell number (p=0.165) (figure 3.8B). 
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Figure 3.8: BCL6 knockdown results in reduced growth rates of ALK+ ALCL cell lines 
A) RFP-tracking experiments in lymphoma cell lines, cells were mixed in a 50:50 ratio transduced to non-
transduced cells at day 0 and treated with doxycycline. Cells were maintained in doxycycline for the duration 
of the experiment of the experiment. Data is equal to 3 independent replicates; error bars indicate standard 
error of the mean. B) Total cell numbers in SUDHL1 relative to parental cells after 14 days in culture, data is 
equal to 4 independent replicates; error bars indicate standard error of the mean. Significance calculated 
using a paired students t-test, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
A) B) 
122 
 
3.2.7 BCL6 shRNA knockdown results in small increases in G2/M populations 
 To investigate whether BCL6 knockdown affected the cell cycle of ALCL cell 
lines, samples were taken for BrdU/7-AAD staining at days 2 and 4 of the RFP-tracking 
experiments shown in figure 3.8A. RFP-positive populations of SUDHL1, Karpas-299, 
and DEL harbouring BCL6 shRNA showed varying effects (figure 3.9). All shRNA 
constructs across all cell lines increased S-phase and decreased G1/G0 between RFP-
negative and RFP-positive populations (figure 3.9B). Despite this effect, there was a 
variable effect on the G2/M populations across the cell lines. SUDHL1 showed a small 
but significant increase in the proportion of G2/M populations with BCL6 knockdown 
after 2 days in culture (shRNA 1 p=0.049, shRNA 2 p=0.005) whilst non-silencing shRNA 
decreased G2/M populations (p=0.06) (figure 3.9B). This effect is more pronounced 
after 4 days in culture (shRNA 1 p=0.021, shRNA 2 p=0.005, non-silencing shRNA 
p=0.134) (figure 3.9B). BCL6 knockdown also increased the G2/M population in Karpas-
299 to a lower degree than SUDHL1. Whilst both shRNAs significantly increase G2/M 
populations at day 4 (shRNA 1 p=0.033, shRNA 2 p=0.01, non-silencing shRNA p=0.118) 
the effect is minimal (figure 3.9B). At day 2, shRNA 1 fails to significantly increase 
G2/M populations (p=0.367) whilst shRNA 2 increases slightly (p=0.039) and control 
shRNA decreases (p=0.036) (figure 3.9A). DEL failed to significantly alter G2/M 
populations at day 2 with BCL6 knockdown (shRNA 1 p=0.258, shRNA 2 p=0.904, non-
silencing shRNA p=0.118). In addition, after 4 days in culture, G2/M populations across 
all shRNA-positive cells are statistically not significant to shRNA-negative counterparts 
in DEL, however non-silencing shRNA significantly decreased G2/M populations (shRNA 
1 p=0.228, shRNA 2 p=0.07, non-silencing shRNA p=0.012) (figure 3.9B). Generally, 
SUDHL1 and Karpas-299 ALCL cell lines demonstrate an increase in G2/M populations 
following BCL6 shRNA induction by day 4. 
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To assess apoptosis, samples were also taken at days 2 and 4 in culture, stained 
with active caspase-3 antibody, and assessed by flow cytometry (figure 3.10A). Most 
cell lines failed to significantly induce apoptosis with either BCL6 shRNA compared to 
non-silencing shRNA, apart from shRNA 1 in SUDHL1 and DEL at day (SUDHL1: shRNA 1 
day 2 p=0.0162, day 4 p=0.0071, shRNA 2 day 2 p=0.359, day 4 p=0.2179, Karpas-299: 
shRNA 1 day 2 p=0.3107, day 4 p=0.1394, shRNA 2 day 2 p=0.3409, day 4 p=0.2903, 
DEL: shRNA 1 day 2 p=0.0385, day 4 p=0.4975, shRNA 2 day 2 p=0.0699, day 4 
p=0.7019) (figure 3.10B).  
3.2.8 BCL6 shRNA knockdown affects transcription of IRF4 and c-MYC transcripts 
 To assess the effect of BCL6 knockdown upon expression of BCL6, IRF4, BLIMP1, 
and c-MYC, shRNA-transduced cells were treated with doxycycline for two weeks and 
lysed for RNA and protein analysis after 3, 10, and 17 days treatment. SUDHL1 cells 
achieved significant BCL6 knockdown at both the RNA and protein level across a two-
week period (shRNA 1: day 3 p<0.0001, day 10 p=0.2576, day 17 p=0.01559, shRNA 2: 
day 3 p<0.0001, day 10 p<0.0001, day 17 p=0.0156) (figure 3.11). IRF4 transcripts in 
SUDHL1 showed a subtle, but not significant, increase upon BCL6 knockdown at day 3 
(shRNA 1: p=0.0161, shRNA 2: p=0.1536) (figure 3.11A), however this effect was lost by 
day 10 (shRNA 1: day 10 p=0.0959, day 17 p=0.7647, shRNA 2: day 10 p=0.2669, day 17 
p=0.4742) (figure 3.11B-C). No other significant changes to either the RNA or protein 
levels of the transcription factors were observed in SUDHL1 cells (figure 3.11). A similar 
trend was observed in Karpas-299 as in SUDHL1; BCL6 mRNA was significantly reduced 
(shRNA 1 p<0.0001, shRNA 2 p<0.0001) which resulted in marginal increases in IRF4 
transcript levels (shRNA 1 p=0.0453, shRNA 2 p=0.1939) but not protein levels after 72 
hours induction (figure 3.12A). No other significant changes in transcription factor RNA 
or protein were observed in Karpas-299 (figure 3.12A). In DEL, BCL6 knockdown caused 
a significant reduction in BCL6 mRNA levels (shRNA 1 p<0.0001, shRNA 2 p<0.0001) 
resulting in a marginal, but not significant, increase in c-MYC transcript levels only 
(shRNA 1 p=0.0644, shRNA 2 p=0.1848), this was not observed at the protein level 
(figure 3.12B) and had no effect on the remaining transcription factors (figure 
3.12B).3.2.9 Growth curves of cell lines for drug treatments 
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 To evaluate the seeding density required for effective assessment of drug 
potency for cell survival assays, cells were seeded in 96-well plates at varying 
concentrations and allowed to grow for 72 hours before assessing with Resazurin. 
After 4 days of growth, it was decided that the seeding concentration of 1x105 cells/ml 
was sufficient for all cell lines as the fluorescent signal had not plateaued across all cell 
lines at this concentration (figure 3.13). 
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Figure 3.12: The effect of BCL6 shRNA knockdown on the expression of BCL6, IRF4, and BLIMP1 in SUDHL1 
Transcript and protein levels of transcription factors after induction of shRNA and maintenance of culture with 
0.5µg/ml doxycycline-containing medium at A) Day 3, B) Day 10, C) Day 17. Data is derived from 4 independent 
replicates; error bars indicate standard error of the mean. Significance calculated using a paired students t-test, 
* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 3.13: The effect of BCL6 shRNA knockdown on the expression of BCL6, IRF4, and BLIMP1 in Karpas-299 and 
DEL 
Transcript and protein levels of transcription factors after induction of shRNA and maintenance of culture with 
2µg/ml doxycycline-containing medium at Day 0 in A) Karpas-299 and B) DEL. Data is derived from 4 independent 
replicates; error bars indicate standard error of the mean. Significance calculated using a paired students t-test, * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 3.13: Growth curve of lymphoma cell lines with Resazurin 
Raw fluorescent values of cells treated with Resazurin for 2 hours at each day. Results are derived from 3 
independent replicates; error bars indicate standard error of the mean. 
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3.2.10 ALCL cell lines are sensitive to 79-6 inhibitor 
 To further investigate the role of BCL6 in ALCL and to assess the possibility of 
pharmacological inhibition of BCL6 in these cells, cells were treated with increasing 
concentrations of 79-6 and assessed for proliferation/survival by a Resazurin assay. All 
cell lines, except from Karpas-422, were found to be sensitive to 79-6 treatment (figure 
3.14). Based upon previously published data, a cell line which exhibits an IC50 of below 
ϵϯϲµM is deeŵed ͞BCLϲ-depeŶdeŶt͟ ǁhilst aŶ ICϱϬ aďoǀe ϭϱŵM iŶdiĐates a ͞BCLϲ-
iŶdepeŶdeŶt͟ Đell liŶe (Cerchietti et al., 2010a). In agreement with this study, the IC50 
value of the B-cell control line, SUDHL4, was 490.3µM indicating sensitivity to 79-6. In 
addition, all T-cell lines were found to be sensitive with a range of IC50s between 
268.6µM and 583.0µM ;figuƌe ϯ.ϭϰAͿ. Hoǁeǀeƌ, the pƌeǀiouslǇ estaďlished ͞BCLϲ-
iŶdepeŶdeŶt͟ Đell liŶe, Toledo, deŵoŶstƌated aŶ ICϱϬ of ϳϮϭ.ϳµM. Fuƌtheƌŵoƌe, a Đell 
line demonstrated to be insensitive to RI-BPI, Pfeiffer (Cerchietti et al., 2009), also 
exhibited an IC50 of 375.2µM. As Karpas-422, another cell line insensitive to RI-BPI 
(Cerchietti et al., 2009), did not reach an IC50 we sought to investigate this further. It 
was hypothesised that the apparent insensitivity may be caused by death occurring in 
the vehicle control due to the high concentration of DMSO required. Therefore cells 
were treated with increasing concentrations of DMSO for 72 hours and assessed by 
Resazurin analysis. It was revealed that Karpas-422 was sensitive to the vehicle DMSO 
concentration (1%) and exhibited 66% death after 72 hours (figure 3.14B) whilst other 
cell lines were not as sensitive. T-cell lymphoma cell lines were more resistant to 
DMSO than B-cell lymphoma cell lines (figure 3.14B).  
3.2.11 79-6 induces apoptosis in all lymphoma cell lines 
 To overcome the toxicity of cell lines to DMSO, cell lines were treated with 
either an IC50 of 79-6, as determined by Resazurin analysis in figure 3.14A (an average 
of the IC50 values of SUDHL4, SUDHL1, and Karpas-299 was used for Karpas-422) or 
the respective concentration of DMSO vehicle. Cells were treated for 24 hours and 
assessed for the presence of cleaved caspase-3 by flow cytometry. SUDHL1, Karpas-
299, SUDHL4, and Karpas-422 showed significant increases in the level of apoptosis 
after 24 hours 79-6 treatment compared to vehicle controls (figure 3.15).  
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A) 
B) 
Figure 3.14: Resazurin profiles of 79-6 and DMSO treated cell lines 
A) Growth inhibition curves of all lymphoma cell lines after 72 hours treatment with varying concentrations of 79-6. 
Cell lines previously reported to be insensitive to inhibition of BCL6 are: Toledo, Pfeiffer, and Karpas-422 B) Growth 
inhibition curves of lymphoma cell lines titrated with increasing concentrations of DMSO after 72 hours. All data is 
derived from 3 independent replicates, error bars indicate standard error of the mean. 
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Figure 3.15: Levels of apoptosis in lymphoma cell lines with 79-6 treatment 
A) Representative flow trace depicting gating method for defining apoptotic-populations, live cell population is 
gated as shown in the left panel, subsequent unstained cells are depicted in the middle pane, active caspase-3 
stained cells are depicted in the right panel. B) Levels of apoptosis after 24 hours treatment with indicated 
drug concentration. Positive control for all samples is cells treated with 100µM staurosporine for 24 hours. 
Data is derived from 3 independent replicates, error bars indicate standard error of the mean. * p<0.05, ** 
p<0.01. 
A) 
B) 
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Both T-cell lines exhibited high apoptosis whilst the B-cell control, SUDHL4, exhibited 
the lowest apoptotic induction (figure 3.15). 
3.2.12 79-6 fails to induce changes in B-cell targets in T-cell lymphoma cell lines 
 As no cell lines were found to be insensitive to 79-6 we hypothesised that the 
drug may not be working through BCL6.  Therefore, mirroring a previously established 
experiment (Cerchietti et al., 2010a), to elucidate if BCL6 is targeted by 79-6, cells were 
subjected to 50µM 79-6 or vehicle for 8 hours and assessed for changes in expression 
of a panel of B-cell BCL6 target genes. This panel was chosen as a T-cell panel of BCL6 
targets was not yet established. 79-6 failed to produce significant changes in all BCL6 
targets tested in the T-cell lines SUDHL1 and Karpas-299 (figure 3.16). 79-6 treatment 
resulted in a slight reduction of BCL6 expression in SUDHL1 which was not 
reproducible in Karpas-299 (figure 3.16). As expected, SUDHL4 exhibited moderate 
increases in gene expression of BCL6, IRF4, ATR, MYC, P21, and TP53 with 79-6 
treatment, as BCL6 negatively regulates these genes, but unexpectedly 79-6 decreased 
BLIMP1 expression. Changes exhibited in IRF4, BLIMP1, and ATR were the only genes 
significantly altered compared to vehicle control (BCL6 p=0.2289, IRF4 p=0.0301, 
BLIMP1 p=0.037, ATR p=0.0156, c-MYC p=0.1057, p21 p=0.1376, TP53 p=0.23).
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Figure 3.16: Expression of BCL6 target genes after 8 hours with 79-6 treatment 
Relative mRNA abundance across lymphoma cell lines after treatment with 79-6 compared with 0.05% DMSO 
vehicle control. HPRT and B2M are included as control genes. Data is derived from 3 independent replicates; 
error bars indicate standard error of the mean. 
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3.3 Discussion 
The data presented in this chapter shows that BCL6 may play a role in the 
proliferation and or survival of some ALCL cell lines. In addition, the data suggests a 
role of BCL6 for correct cell cycle progression and therefore is a potential therapeutic 
target for ALCL.  
Whilst initially siRNA-mediated knockdown systems were employed for BCL6, 
this project moved to shRNA-mediated knockdown systems to overcome the 
drawbacks of siRNAs. Although siRNA provided a rapid BCL6 knockdown, the delivery 
of the siRNA induces cellular stress via electroporation. In addition, siRNA knockdown 
experiments suggested that loss of BCL6 did not cause a rapid deterioration of 
proliferation/survival (figure 3.5); therefore the shRNA knockdown system was 
employed to provide a stable knockdown. Knockdowns using shRNA are a useful tool 
as they allow persistent knockdown of a target in the presence of doxycycline allowing 
greater control over experimental parameters. 
In agreement with published data (Ying et al., 2013), BCL6 knockdown reduced 
growth of lymphoma cell lines suggesting an important role for BCL6 in proliferation. 
Indeed, BCL6 knockdown resulted in a 50% decrease in shRNA-positive cells in the 
GCB-DLBCL cell line, SUDHL4 (figure 3.8A); a direct agreement with published data 
demonstrating a 30-70% reduction in shRNA-positive cells after two weeks (Ying et al., 
2013). Whilst T-cell lymphoma cell lines exhibited a range of sensitivities to BCL6 
knockdown, Karpas-299 reduced shRNA-positive populations at a similar rate to 
SUDHL4 indicating the importance of BCL6 in this cell line (figure 3.8A). However, 
SUDHL1 and DEL exhibited a delayed or less-marked response (figure 3.8A) despite 
marked BCL6 knockdown. Whilst DEL exhibited a small reduction in shRNA-positive 
populations in only 1 of 2 shRNAs, there was no evidence of apoptosis induction or 
changes in cell cycle (figures 3.9B and 3.10B); therefore it is plausible to conclude that 
DEL may be largely insensitive to BCL6 knockdown. The delayed response of RFP-
reduction in SUDHL1 could be due to an important downstream BCL6 target, rather 
than the effect of BCL6 itself, that is important for proliferation. To evaluate this 
hypothesis, ChIP-Seq in combination with a Gene Expression Array would reveal any 
potentially important BCL6 targets. However, in SUDHL1 4 days post-combination, cells 
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harbouring BCL6 knockdown resulted in increased G2/M populations compared to 
RFP-negative cells suggesting an immediate effect of BCL6 knockdown also (figure 
3.9B). BCL6 knockdown may therefore cause an effect on cellular growth initially but 
compensate this effect by upregulation of one or more pathways to promote survival. 
For example, SUDHL1 has been demonstrated to exhibit high expression of CDK6 and 
c-MYC (Nagel et al., 2008, Raetz et al., 2002), molecules demonstrated to be important 
in cell survival and cell cycle progression which may compensate for BCL6 inhibition 
(Scheicher et al., 2015, Weilemann et al., 2015). BCL6 has previously been 
demonstrated to be important in cell cycle progression in DLBCL cell lines, knockdown 
of BCL6 results in accumulation of cells in G1/G0 populations (Ying et al., 2013). In 
SUDHL1 cells, accumulation of cells in G2/M was observed with BCL6 knockdown 
(figure 3.9B) suggesting BCL6 may regulate the cell cycle in T-cells at a different stage 
to B-cells. 
It has been reported that doxycycline can affect the metabolism and growth of 
a number of cell lines (Ahler et al., 2013, Pulvino et al., 2015). In one of these studies, 
exposure of cells to 1µg/ml doxycycline for 96 hours resulted in increased expression 
of metabolic pathway genes and increased production of lactate causing a reduction in 
the growth rate of cell lines (Ahler et al., 2013). Interestingly, in the work presented 
here a certain threshold of doxycycline was required to significantly down regulate 
IRF4 expression in SUDHL1 (figure 3.7A) suggesting doxycycline also affects pathways 
other than the metabolic pathway. Interestingly, knockdown of BCL6 at higher 
concentrations of doxycycline (2µg/ml) resulted in a greater effect on proliferation 
than at 0.5µg/ml in SUDHL1 suggesting BCL6 deficiency may synergise cells to stressful 
environments, such as the effects of doxycycline, however this data was not illustrated 
due to the confounding effect of reduction of IRF4 with doxycycline (figure 3.7A). In 
addition, BCL6 has been shown to repress the glycolytic pathway in CD8+ mouse T-cells 
(Leavy, 2014, Man and Kallies, 2014, Oestreich et al., 2014) which could indicate a 
potential synergistic mechanism of action.  
In order to address the issue of off-target doxycycline effects, a non-inducible 
knockdown system could be employed to eliminate the presence of doxycycline. The 
drawbacks of non-inducible systems include the inability to control unwanted effects 
from genomic integration as well as the inability to control induction of the shRNA. 
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Both inducible and non-inducible lentiviral knockdown systems rely on transducing 
different cells with a separate control virus which may give rise to specific growth bias 
if viral integrations differ between control and target shRNA cells. The benefit of the 
inducible system over the non-inducible system, however, is the ability to control for 
integration bias by comparing growth rates of transduced, non-induced cells against 
transduced, induced cells. In addition, inducible systems allow the evaluation of short-
term knockdown effects, without adaptation of cells to knockdown, as well as allowing 
expansion of transduced cells harbouring shRNA which would be toxic if active. 
Therefore, a robust investigation of BCL6 knockdown would employ both inducible and 
non-inducible systems to alleviate the issues with both techniques. However, shRNA 
knockdown systems can induce immune responses giving rise to aberrant results. A 
technique has been recently developed which allows the deletion of genomic regions 
through exploitation of the CRISPR-Cas9 system employed by bacteria (Shalem et al., 
2014). This technique would allow complete removal of BCL6 DNA from the cell line 
genome eliminating any BCL6-mediated effects. This technique is only viable however, 
if BCL6 is not vital for cellular survival as knockout of BCL6 may cause rapid death. This 
could be overcome by introducing a BCL6 coding sequence under the control of a 
tetracycline promoter, whereby presence of tetracycline switches off transcription of 
the expression cassette (Baron and Bujard, 2000). 
All cell cycle profiles also exhibited increases in S-phase with induction of 
shRNA (figure 3.9A). This may indicate changes in transcriptional activity brought 
about by doxycycline by induction of the glycolytic pathway in these cells (Ahler et al., 
2013). Alternatively, increased S-phase may be an artefact of inefficient flow 
cytometry compensation and be a result of detecting RFP expression in the FITC 
channel. 
This work has demonstrated sensitivity to the BCL6 inhibitor, 79-6, across 
multiple lymphoma subtypes. All cell lines are sensitive to 79-6 treatment suggesting 
that, if 79-6 is targeting BCL6, BCL6 constitutes a putative therapeutic target. The 
sensitivity of cell lines to 79-6 does not appear to correlate with expression of BCL6. 
Out of the T-cell lines, Karpas-299 expresses the most BCL6 protein whilst DEL 
expresses the least (figure 3.2). However, despite this, the IC50s recorded for each are 
very similar. It is reasonable, therefore, to conclude that levels of BCL6 protein do not 
138 
 
determine sensitivity to this inhibitor. For example, SUDHL4 and Karpas-422 express 
the most BCL6 protein across the panel of cell lines (figure 3.2B). These cell lines are 
GCB-DLBCL which naturally express high quantities of BCL6 as their cell of origin is a GC 
B-cell (Basso and Dalla-Favera, 2010). However, despite this, SUDHL4 is considered 
BCLϲ ͞depeŶdeŶt͟ ǁhilst Kaƌpas-ϰϮϮ is defiŶed as a BCLϲ ͞ƌesistaŶt͟ Đell liŶe ǁheŶ 
treated with RI-BPI (Cerchietti et al., 2010a, Cerchietti et al., 2009). Another problem 
arises with 79-6 however: those cell lines previously defined to be insensitive to RI-BPI, 
Karpas-422 and Pfeiffer, as well as Toledo, defined as requiring >15mM of 79-6 to 
achieve a 50% response (Cerchietti et al., 2010a, Cerchietti et al., 2009), were found to 
be sensitive in this study. Whilst Toledo exhibited the highest IC50 of all cells tested 
(721µM) which may be indicative of resistance, Pfeiffer exhibited a lower resistance 
(375µM) (figure 3.14A). Initially, Karpas-422 displayed pseudo-insensitivity by 
Resazurin analysis (figure 3.14A) however this was found to be caused by the high 
concentrations of DMSO required to solubilise a 1mM dose of 79-6 for cell lines (figure 
3.13B). Further investigation revealing the sensitivity of Karpas-422 to 79-6 (figure 
3.14) prompts the notion that 79-6 may not solely target BCL6. It is reasonable to 
believe that 79-6 works, at least in part, through BCL6 as B-cell targets of BCL6 were 
found to be upregulated by 79-6 treatment in SUDHL4 (figure 3.16). This is in 
agreement with previously published data which demonstrates that these targets were 
found to be greatly upregulated with 79-6 treatment (Cerchietti et al., 2010a). In the T-
cell lines however, it appears that 79-6 does not induce the expression of P53, P21, c-
MYC, IRF4, or BLIMP1 (figure 3.16).  
The high concentration of 79-6 required to elicit a growth inhibition response 
discordance with published data cast doubts upon the specificity of the drug. It is 
generally accepted that anticancer drugs should be efficacious within the nanomolar 
region where possible as higher concentrations of drug lead to higher non-specific 
effects (Wong et al., 2012). The lack of 79-6 specificity for BCL6 may originate due to 
the design process utilised. Briefly, 79-6 was designed using computer aided drug 
design to screen for compounds which associated with the same residues of the lateral 
groove of BCL6 as SMRT. Next, compounds were selected based upon efficacy and 
binding conformation. Finally, selected compounds were further refined evaluating 
which compounds alleviated BCL6-mediated repression of a luciferase construct 
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through use of a GAL4 DNA binding domain-BCL6BTB construct with a GAL4 luciferase 
reporter construct (Cerchietti et al., 2010a). This assay yielded the compound 79-6 
which was confirmed by X-ray crystallography to bind the lateral groove of BCL6. The 
authors test for the specificity of 79-6 by repeating the same luciferase reporter 
construct assay with GAL4 DNA binding domains fused to other BTB-containing 
proteins such as kaiso, hypermethylated in cancer 1, and promyelocytic zinc finger, 
demonstrating no discernible effect on luciferase levels. However, the authors do not 
test any other types of proteins for 79-6 binding. To fully elucidate if 79-6 targeted 
BCL6, the same luciferase reporter coupled assay could be utilised in this project to 
investigate if the BTB domains repressive activity on luciferase could be relieved with 
79-6 treatment. Critically however, further biochemical investigations into the binding 
of 79-6 with a diverse range of proteins should be investigated to ascertain any 
potential non-specific binding. 
In agreement with the 79-6 data, BCL6 shRNA knockdown could not 
significantly upregulate mRNA or protein expression of IRF4, BLIMP1, or c-MYC (figures 
3.11A and figure 3.12A). This is in direct contrast to what is known about normal T-cell 
phǇsiologǇ, BCLϲ aŶd BLIMPϭ aŶtagoŶise oŶe aŶotheƌ’s fuŶĐtioŶ aŶd, iŶ addition, 
directly bind and repress each other in T-cells (Cimmino et al., 2008, Johnston et al., 
2009). It is possible that BCL6 has a mutated promoter site in ALCL cells that prevents 
the binding of BLIMP1 as well as BCL6 itself, as seen in DLBCL (Pasqualucci et al., 2003). 
This could, potentially, result in constitutive BCL6 expression which could overcome 
inhibitor efficiency through overexpression of the protein. Alternatively, as BLIMP1 is 
commonly mutated in ALCL it may be mutated or deleted to prevent the repressive 
effects of BCL6 on PRDM1 transcriptional activity (Boi et al., 2013). In contrast to 
shRNA knockdown data, siRNA-mediated knockdown of BCL6 caused a modest 
increase in the RNA levels of IRF4 and BLIMP1 in SUDHL1, but not in Karpas-299 (figure 
3.6B), which was lost after 72 hours. Therefore, it is possible that BCL6 exerts 
repressive activity on IRF4 and BLIMP1 initially but is then lost, as the earliest time 
point assessed for shRNA-mediated knockdown is 72 hours post-induction (figure 3.11 
and figure 3.12) and therefore the cells may have compensated for BCL6 knockdown 
by this point. However, it should be noted that BCL6 targets are not the same between 
cells. A recent study showed that only 50% of BCL6 target genes are common between 
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breast cancer and B-cell lymphoma cancers (Walker et al., 2014). Interestingly, BCL6 is 
still required for the survival of these cell lines; however, BCL6 did not affect BLIMP1 
transcription activity (Walker et al., 2014). A recent study into targets of BCL6 in TFH 
cells has also demonstrated that BCL6 represses a number of targets involved in T-cell 
differentiation, signalling, and migration, including: STAT4, IFNGR1, GIMAP1, RORA and 
GATA3 (Hatzi et al., 2015). As well, BCL6 activity varies between B and T-cell lineages 
suggesting BCL6 will have vastly different targets. For example, an inactivating 
mutation introduced into Bcl6 into early B-cells in Bcl6-/- mice results in complete 
abrogation of GC and reduced TFH cell formation (Huang et al., 2013b). Conversely, 
introduction of the mutated Bcl6 into early T-cells results in normal TFH cell production 
suggesting a different transcriptional programme between cell lineages (Huang et al., 
2013b). Future work should therefore focus on investigation of the transcriptional 
control of known BCL6 T-cell target genes within T-cell lymphoma. 
Further work could focus on investigating BCL6 as a therapeutic target in T-cell 
lymphoma. 79-6 is a weak and non-specific inhibitor of BCL6 as, in this project, all cells 
were killed by the drug irrespective of reported dependency on BCL6 (figures 3.14 and 
3.15). RI-BPI however is a well-established BCL6 inhibitor proven to be very specific to 
BCL6 targeting (Cerchietti et al., 2010a, Cerchietti et al., 2010b, Walker et al., 2014). 
The primary drawbacks of RI-BPI as a therapeutic intervention are the inability for oral 
delivery, as well as the complexity and expense of synthesis of the peptide. 
The data presented suggests, that BCL6 is required for effective growth of at 
least some T-cell lymphoma cell lines. Indeed loss of BCL6 in normal murine CD8+ T-
cells is detrimental to the growth of these cells (Ichii et al., 2002). One possible 
mechanism of action which has been highlighted by this data is the repression of the 
glycolytic pathway. The anaerobic metabolism pathway is less efficient than aerobic 
respiration but it allows the production of Adenine-Triphosphate (ATP) without oxygen 
which may be beneficial for solid tumour cells in a hypoxic microenvironment. This 
could result in a rapid proliferation rate of tumour cells in harsher environments aiding 
metastasis (Hanahan and Weinberg, 2000). Indeed, it has been demonstrated across 
multiple malignancies that upregulation of PI3K can result in loss of glycolysis-
dependence, and more aggressive tumours (Kalaany and Sabatini, 2009). BCL6 may act 
in this way and inhibition may not produce a rapid response on its own; however if 
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BCL6 promotes anaerobic respiration it has the potential to synergise cells to 
treatments which may exploit anaerobic respiration. 
Future work may focus on expanding the panel of cell lines, or development of 
murine xenograft models, to incorporate types of PTCL other than ALCL to assess the 
role of BCL6 in these lymphomas. In particular, AITL characteristically has high BCL6 
expression and may be BCL6 dependent (Yuan et al., 2005). Of most importance, PTCL 
cell lines should be treated with RI-BPI to ascertain if cells are reliant upon BCL6 
through comparison with established BCL6-dependent cell lines. In addition, work 
should focus on combination therapy of BCL6 inhibition with current CHOP drugs and 
c-MYC inhibitors to investigate if BCL6 inhibition synergises cells to these treatments. 
Furthermore, exploiting the RD2 domain of BCL6 could prove important. This domain 
has recently been demonstrated to be required for HDAC recruitment and 
transcriptional inhibition of some genes and its actions may represent a means by 
which cells might resist the effects of BTB domain inhibition (Bereshchenko et al., 
2002, Fujita et al., 2004, Huang et al., 2014). A method of overcoming may be to rely 
on the RD2 domain to exert inhibitory actions on target genes. To improve BCL6 
knockdown experiments, utilisation of CRISPR-mediated knockout could be 
undertaken to evaluate if complete removal of BCL6 is fatal to cellular 
proliferation/survival. Finally, ChIP-Seq and Gene Expression Arrays of PTCL cell lines 
could be utilised to find novel T-cell targets of BCL6 to determine if any are important 
for PTCL survival. 
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4. IRF4 in the maintenance of T-cell lymphoma 
4.1 Introduction 
IRF4 is a transcription factor required for the differentiation, metabolism, and 
survival of B- and T-cells through transcriptional regulation of BCL6 and BLIMP1, 
amongst other targets (Yao et al., 2013, Bruhn et al., 2012, Mobini et al., 2009, Kwon 
et al., 2009). Whilst it is known that IRF4 promotes the activity of both BCL6 and 
BLIMP1 in T-cells, the reciprocal interactions are not as well established in T-cells as in 
B-cells (figure 4.1). Several pieces of evidence indicate that IRF4 may play a role in 
driving T-cell malignancies, including the identified role of IRF4 in HTLV-I transformed 
ATL (Wang et al., 2011a), the occurrence of IRF4 translocations in T-cell lymphoma, 
and the high expression of IRF4 exhibited across certain T-cell lymphomas subsets 
(Feldman et al., 2011, Feldman et al., 2009, Kwon et al., 2009). 
Therapeutic targeting of IRF4 is potentially difficult and no direct inhibitors 
exist. However a link between the immunomodulatory drug, Lenalidomide, and IRF4 
expression has been elucidated. Specifically, IRF4 expression correlates with 
Lenalidomide sensitivity in ABC-DLBCL and treatment with the drug leads to 
downregulation of IRF4 (Zhang et al., 2013). The drug has been used successfully for 
Figure 4.1: Interaction of IRF4 with BCL6 and BLIMP1 in B-cells vs. T-cells 
A) In B-cells, IRF4 has a mutual inhibition of BCL6 whilst promoting BLIMP1 expression B) In T-cell differentiation, 
IRF4 interactions are less well characterised. IRF4 facilitates both BCL6 and BLIMP1 activities during T-cell 
development (Bollig et al., 2012, Honma et al., 2008). BCL6 expression, and subsequent T
FH
 cell differentiation is 
abrogated in Irf4
-/-
 mice demonstrating a positive interaction of IRF4 on BCL6 (Lohoff et al., 2002). IRF4 also 
forms complexes with BATF to facilitate chromatin remodelling, this complex can then associate with STAT3 to 
promoter expression of BLIMP1 (Li et al., 2012). The effect of BCL6 and BLIMP1 upon IRF4 expression is not 
known to date. 
A) B) 
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IRF4-driven malignancies such as CLL and MM (Herman et al., 2011, Li et al., 2011) and 
thus may be useful for T-cell lymphomas. 
The aim of this chapter is therefore to investigate IRF4 as a potential 
oncoprotein in T-cell lymphoma. The chapter investigates the effect of IRF4 deficiency 
on proliferation, cell cycle, and induction of apoptosis of T-cell lymphoma cell lines. 
The chapter then examines the effect of targeting IRF4 therapeutically using 
Lenalidomide, as well as the determining the effect of IRF4 on expression of 
downstream targets BCL6, BLIMP1, and c-MYC. 
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4.2 Results 
4.2.1 IRF4 siRNA knockdown results in a slight reduction in proliferation/survival of 
SUDHL1 
 In order to investigate the effect IRF4 siRNA knockdown had upon the 
proliferation/survival of ALK+ ALCL cell lines, SUDHL1 and Karpas-299 were 
electroporated with 500nM IRF4 siRNA or non-silencing siRNA and counted by Trypan 
Blue exclusion every 24 hours for 3 days. SUDHL1 exhibited a slight decrease in the 
total number of cells at every time point (figure 4.2). Despite the trend observed in this 
cell line, no result was found to be significant (24 hours p=0.055, 48 hours p=0.061, 72 
hours p=0.137). Karpas-299 was unaffected by siRNA knockdown at all timepoints (24 
hours p=0.964, 48 hours p=0.564, 72 hours p=0.309). 
4.2.2 IRF4 siRNA knockdown has minimal, cell line-specific effects on BCL6 and 
BLIMP1 expression 
 RNA and protein was collected from SUDHL1 and Karpas-299 cells every 24 
hours for 3 days post-electroporation and assessed by qPCR and western blot. 
Successful knockdown of RNA and protein was achieved in both cell lines (figure 4.3) 
with the greatest knockdown being recorded at 24 hours in both cell lines (SUDHL1: 24 
hours p=0.0236, 48 hours p=0.0238, 72 hours p=0.041, Karpas-299: 24 hours p<0.0001, 
48 hours p=0.0385, 72 hours p=0.175). Knockdown of IRF4 in SUDHL1 resulted in 
increased expression of BCL6 protein at 24 hours which was not observed at 48 and 72 
hours (figure 4.3A). No effect on BLIMP1 protein expression was observed in SUDHL1. 
In contrast, Karpas-299 exhibited a reduction in BCL6 protein expression with IRF4 
knockdown (figure 4.3A), whilst no detectable effect was observed on BLIMP1 protein  
  
Figure 4.2: Counts of IRF4 knockdown lymphoma cells 
Counts show total live cells treated with 500nM IRF4 siRNA normalised to non-silencing siRNA counts. Error bars 
indicate standard error of the mean, data is representative of three independent replicates. No counts were found 
to be significantly altered by a paired t-test. 
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Figure 4.3: Effect of IRF4 knockdown on the BCL6-IRF4-BLIMP1 transcription factor axis 
A) Timecourse western blot of SUDHL1 and Karpas-299 treated with non-silencing or IRF4 siRNA and assessed after the 
indicated time points. Results are representative of 3 independent experiments. Protein bands depicted for BLIMP1 in 
Karpas-299 are believed to be due to non-specific binding of the antibody. B) Relative mRNA levels in ALCL cell lines SUDHL1 
and Karpas-299, n=3 error bars indicate standard error of the mean. Significance calculated using a paired students t-test, * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, ns = not significant. 
A) 
B) 
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levels. Despite the effect IRF4 knockdown had upon BCL6 protein levels, at the mRNA 
level, IRF4 knockdown in SUDHL1 resulted in slightly decreased BCL6 levels at 48 hours 
only which were not found to be significant (figure 4.3B) (24 hours p=0.5621, 48 hours 
p=0.1958, 72 hours p=0.637). BLIMP1 mRNA levels were increased by IRF4 knockdown 
at 24 and 72 hours in SUDHL1 but were not found to be significant (24 hours 
p=0.01701, 48 hours p=0.0675, 72 hours p=0.2391) (figure 4.3B). Karpas-299 showed 
no significant effect on mRNA expression of BCL6 or BLIMP1 at any time point (figure 
4.3B). However, there is a general trend of decreased BCL6 expression (24 hours 
p=0.3974, 48 hours p=0.2713, 72 hours p=0.3994), consistent with protein expression 
data, and a modest increase in BLIMP1 mRNA levels with IRF4 knockdown (24 hours 
p=0.2075, 48 hours p=0.8181, 72 hours p=0.7441) in these cells (figure 4.3B). Overall, 
there are small and inconsistent changes in BCL6 and BLIMP1 mRNA across both cell 
lines as well as between mRNA and protein levels. 
 
4.2.3 IRF4 shRNA knockdown results in reduced proliferation/survival of ALK+ ALCL 
cell lines 
 Considering the subtle proliferation/survival phenotype and inconsistent 
changes in mRNA/protein levels caused by the siRNA knockdown of IRF4, shRNA 
knockdown was pursued to investigate if stable, prolonged, knockdown of IRF4 would 
produce a more marked effect. To ensure the IRF4 shRNAs could knockdown IRF4, 
SUDHL1, Karpas-299, and DEL cells were transduced with IRF4 shRNA or non-silencing 
shRNA constructs, selected with puromycin for 1 week, and induced with 
concentrations of doxycycline defined previously (see chapter 3, section 3.2.5). After 
72 hours, protein levels showed a marked decrease in IRF4 levels with induction of 
IRF4 shRNAs in SUDHL1 and Karpas-299 but not in DEL (figure 4.4A). Due to the poor 
knockdown exhibited by DEL in shRNA 1 (figure 4.4A) and the inability to maintain 
knockdown levels using shRNA 2 (figure 4.9), the cell line was defined as a negative 
control for all experiments.  
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To evaluate the role of IRF4 on proliferation/survival of cell lines, transduced 
cell lines were combined in a 50:50 ratio with non-transduced cells and treated with 
doxycycline to induce shRNA knockdown and RFP expression. RFP levels were tracked 
by flow cytometry for 2 weeks post-mixing. IRF4 shRNA expression induced a reduction 
in RFP levels after 14 days in two out of three cell lines (figure 4.4B). At day 14, RFP-
positive cells, indicative of IRF4 knockdown cells, were significantly reduced in SUDHL1 
and Karpas-299 in proportion to non-silencing shRNA control (SUDHL1: shRNA 1 
p=0.001, shRNA 2 p=0.045, Karpas-299: shRNA 1 p=0.01, shRNA 2 p=0.012). 
Conversely, RFP-positive cells in DEL did not significantly alter in proportion to non-
silencing counterparts (shRNA 1 p=0.21, shRNA 2 p=0.759). 
Consistent with these data, IRF4 knockdown in both SUDHL1 and Karpas-299 
showed a significant reduction in the number of living cells by Trypan Blue exclusion 
with both shRNAs compared to non-silencing shRNA control (SUDHL1: shRNA 1 
p=0.009, shRNA 2 p=0.005, Karpas-299: shRNA 1 p=0.034, shRNA 2 p=0.006). 
Conversely, both IRF4 shRNAs expressed in DEL had no effect on live cell count 
compared to non-silencing shRNA control (shRNA 1 p=0.675, shRNA 2 p=0.104) (figure 
4.4C). 
4.2.4 IRF4 shRNA knockdown results in a minor increase in G2/M populations 
 To evaluate if IRF4 knockdown resulted in decreased proliferative activity by 
altering cell cycle kinetics, flow cytometric cell cycle analysis was undertaken (figure 
4.5A). Samples were collected at days 2 and 4 of the RFP-tracking experiment shown in 
figure 4.5A. At day 2, RFP-positive populations of SUDHL1 showed a small increase in 
G2/M populations in only the IRF4 shRNA 1 culture (p=0.043) whilst no significant 
effect was observed on the G2/M population fraction across the remaining shRNAs 
(figure 4.5B) (shRNA 2 p=0.133, non-silencing shRNA p=0.455).  However, after 4 days 
in culture, both IRF4 shRNAs significantly increased G2/M populations in SUDHL1 
which was not found in non-silencing shRNA cells (figure 4.5B) (shRNA 1 p=0.001, 
shRNA 2 p=0.017, non-silencing shRNA p=0.069). Karpas-299 showed no significant 
effect on G2/M populations with IRF4 knockdown after 2 days in culture, although 
non-silencing shRNA treated cells did exhibit a significant small reduction in G2/M 
populations which was not found in IRF4 knockdown cells (figure 4.5B) (shRNA 1  
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p=0.248, shRNA 2 p=0.903, non-silencing shRNA p=0.026). After 4 days in culture, 
Karpas-299 exhibited very slight (albeit significant) increases in G2/M populations with 
IRF4 shRNA compared to non-silencing shRNA (figure 4.5B) (shRNA 1 p=0.003, shRNA 2 
p=0.014, non-silencing shRNA p=0.488). By day 2, IRF4 knockdown in DEL resulted in a 
minor (but significant) increase in G2/M populations using IRF4 shRNA 1 (p=0.009) but 
not IRF4 shRNA 2 (p=0.064) or non-silencing shRNA (p=0.086) (figure 4.5B). 
However, as seen with Karpas-299, non-silencing shRNA slightly decreased the 
G2/M population fraction which was not observed in IRF4 shRNA-treated 
counterparts. At day 4, IRF4 shRNA 1 treatment failed to increase G2/M populations 
(p=0.071) whilst IRF4 shRNA 2 increased a miniscule but significant increase in G2/M 
populations, (p=0.006) (figure 4.5B). These data demonstrate that cell lines sensitive to 
IRF4 knockdown, particularly SUDHL1, exhibit small increases in G2/M populations 
after 4 days culture in a competitive tracking experiment. Karpas-299 demonstrates a 
similar effect on cell cycle but to a much lower magnitude. 
 To assess apoptosis, samples were also taken at days 2 and 4 in culture, stained 
with active caspase-3 antibody, and assessed by flow cytometry (figure 4.6A). All cell 
lines harbouring IRF4 knockdown, apart from SUDHL1 IRF4 shRNA 1 and 2 at day 4 
(shRNA 1 p=0.0185, shRNA 2 p=0.0039), failed to reproducibly increase levels of 
apoptosis compared to non-silencing shRNA control (SUDHL1: day 2 shRNA 1 
p=0.8204, shRNA 2 p=0.2939, Karpas-299: day 2 shRNA 1 p=0.5227, shRNA 2 p=0.9109, 
day 4 shRNA 1 p=0.9277, shRNA 2 p=0.21335, DEL: day 2 shRNA 1 p=0.5992, shRNA 2 
p=0.247, day 4 shRNA 1 p=0.5415, shRNA 2 p=0.076) (figure 4.6B). Whilst induction of 
apoptosis was not significant at day 2 with SUDHL1 IRF4 shRNA 2 there is a consistent 
induction of apoptosis with this IRF4 shRNA. 
 
4.2.5 IRF4 promotes the expression of c-MYC with variable effects on BLIMP1 
expression in Karpas-299 
 To assess the effect of IRF4 knockdown on expression of BCL6, IRF4, BLIMP1, 
and c-MYC, shRNA-transduced cells were cultured with doxycycline-containing 
medium for two weeks and lysed for RNA and protein analysis after 3, 10, and 17 days. 
SUDHL1 demonstrated significant IRF4 knockdown at both the RNA and protein level 
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across all days (both shRNAs and all days p<0.0001) whilst Karpas-299 demonstrated 
significant knockdown on days 3 and 10 at the RNA level (day 3: shRNA 1 p<0.0001, 
shRNA 2 p<0.001, day 10: shRNA 1 p<0.0001, shRNA 2 p=0.0067, day 17: shRNA 1 
p=0.2472, shRNA 2 p=0.6676) and across all days at the protein level (figures 4.7 and 
4.8) whilst DEL only achieved significant knockdown at the RNA level on days 3 and 10 
(day 3: shRNA 1 p<0.0001, shRNA 2 p<0.0001, day 10: shRNA 1 p=0.0238, shRNA 2 
p=0.001, day 17: shRNA 1 p=0.33, shRNA 2 p=0.1679) (figure 4.9).  
155 
 
 
   
Figure 4.7: The effect of IRF4 shRNA knockdown on the expression of BCL6, IRF4, and BLIMP1 in SUDHL1 
Transcript and protein levels of transcription factors after induction of shRNA and maintenance of culture with 
0.5µg/ml doxycycline-containing medium at A) Day 3, B) Day 10, C) Day 17. Data is derived from 4 independent 
replicates, error bars indicate standard error of the mean. Significance calculated using a paired students t-test, 
* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 4.8: The effect of IRF4 shRNA knockdown on the expression of BCL6, IRF4, and BLIMP1 in Karpas-299 
Transcript and protein levels of transcription factors after induction of shRNA at A) Day 0 , B) Day 7, C) Day 14. Day 0 is 
iŶdiĐatiǀe of ϳϮ houƌs tƌeatŵeŶt ǁith Ϯμg/ŵl doǆǇĐǇĐliŶe. Data is eƋual to ϰ iŶdepeŶdeŶt ƌepliĐates, error bars indicate 
standard error of the mean. Significance calculated using a paired students t-test, * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001. 
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B) 
C) 
A) 
Figure 4.10: The effect of IRF4 shRNA knockdown on the expression of BCL6, IRF4, and BLIMP1 in DEL 
Transcript and protein levels of transcription factors after induction of shRNA at A) Day 0 , B) Day 7, C) Day 14. 
Day 0 is indicative of ϳϮ houƌs tƌeatŵeŶt ǁith Ϯμg/ŵl doǆǇĐǇĐliŶe. Data is eƋual to ϰ iŶdepeŶdeŶt ƌepliĐates, 
error bars indicate standard error of the mean. Significance calculated using a paired students t-test, * p<0.05, 
** p<0.01, *** p<0.001, **** p<0.0001. 
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IRF4 knockdown resulted in a significant increase in BLIMP1α transcript levels 
at all timepoints in SUDHL1 (day 3: shRNA 1 p=0.0002, shRNA 2 p=0.0003, day 10: 
shRNA 1 p=0.0034, shRNA 2 p=0.0465, day 17: shRNA 1 p=0.0091, shRNA 2 p=0.0022) 
with no effect on BCL6 (day 3: shRNA 1 p=0.0836, shRNA 2 p=0.779, day 10: shRNA 1 
p=0.3036, shRNA 2 p=0.1495, day 17: shRNA 1 p=0.5943, shRNA 2 p=0.0724), BLIMP1β 
(day 3: shRNA 1 p=0.3811, shRNA 2 p=0.0746, day 10: shRNA 1 p=0.3317, shRNA 2 
p=0.409, day 17: shRNA 1 p=0.9187, shRNA 2 p=0.5769), or c-MYC (day 3: shRNA 1 
p=0.1824, shRNA 2 p=0.438, day 10: shRNA 1 p=0.3317, shRNA 2 p=0.409, day 17: 
shRNA 1 p=0.5282, shRNA 2 p=0.052) transcripts across all timepoints in SUDHL1 ( 
(figure 4.7). Despite having no effect on BCL6 transcript levels, BCL6 protein levels 
were decreased with both IRF4 shRNAs as well as non-silencing shRNA-positive cells at 
day 3 only. No other transcription factors were affected (figure 4.7A). Parental cells 
showed a reduction in BCL6 protein levels compared to shRNA-positive cells, in 
SUDHL1, at days 10 and 17 (figure 4.7B and 4.7C). 
Contrary to SUDHL1, IRF4 knockdown in Karpas-299 at day 3 resulted in 
significantly decreased BLIMP1α (day 3: shRNA 1 p=0.0001, shRNA 2 p<0.0001, day 10: 
shRNA 1 p=0.2721, shRNA 2 p=0.2305, day 17: shRNA 1 p=0.9187, shRNA 2 p=0.5769), 
and BLIMP1β (day 3: shRNA 1 p=0.0001, shRNA 2 p=0.0001, day 10: shRNA 1 p=0.0654, 
shRNA 2 p=0.1446, day 17: shRNA 1 p=0.9055, shRNA 2 p=0.5809) as well as c-MYC 
mRNA at day 17 (day 3: shRNA 1 p=0.0539, shRNA 2 p=0.0945, day 10: shRNA 1 
p=0.1009, shRNA 2 p=0.3114, day 17: shRNA 1 p<0.0001, shRNA 2 p=0.0005), and a 
small, but significant decrease in BCL6 mRNA at day 3 with both shRNAs and day 17 
with shRNA 1 (day 3: shRNA 1 p<0.0001, shRNA 2 p<0.0001, day 10: shRNA 1: 
p=0.9298, shRNA 2: p=0.6796, day 17: shRNA 1 p=0.0284, shRNA 2 p=0.2157) (figure 
4.8A and 4.8B). BCL6 and c-MYC reduction was also observed at the protein level at 
these timepoints. At day 17, IRF4 mRNA levels were returning to basal levels whilst 
BLIMP1α and BLIMP1β were now unaffected by IRF4 knockdown (figure 4.8C). 
Reduction of BCL6 and c-MYC mRNA was still evident at the RNA and protein level after 
17 days (figure 4.8C). 
DEL exhibited knockdown of IRF4 at the RNA level across days 3 and 10 (figure 
4.9). However, protein knockdown was consistently unachievable at days 3 and 10 and 
was minimal by day 17 (figure 4.9C). Despite poor protein knockdown, loss of IRF4 
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resulted in decreased BCL6 protein levels at day 17 (figure 4.9C). In agreement with 
Karpas-299, IRF4 knockdown resulted in slightly decreased BLIMP1α (day 3: shRNA 1 
p=0.0003, shRNA 2 p=0.0002, day 10: shRNA 1 p=0.0475, shRNA 2 p=0.1357, day 17: 
shRNA 1 p=0.635, shRNA 2 p=0.1753), but not BLIMP1β (day 3: shRNA 1 p=0.3987, 
shRNA 2 p=0.841, day 10: shRNA 1 p=0.643, shRNA 2 p=0.7936, day 17: shRNA 1 
p=0.6636, shRNA 2 p-0.4968) RNA levels at days 3 and 10 (figure 4.9A and 4.9B). In 
addition, IRF4 knockdown caused a slight reduction in c-MYC transcript at day 3 (figure 
4.9A) which recovered by day 17 (figure 4.9C) (day 3: shRNA 1 p=0.0579, shRNA 2 
p=0.0471, day 10: shRNA 1 p=0.5556, shRNA 2 p=0.6534, day 17: shRNA 1 p=0.4778, 
shRNA 2 p=0.3224). Non-silencing shRNA cells treated with doxycycline decreased 
BCL6 protein levels at days 10 and 17 and BLIMP1 protein levels at day 10. 
In summary, IRF4 knockdown was achieved in SUDHL1 and Karpas-299 but not 
DEL. All cell lines exhibited small variable effects on the expression of BCL6, IRF4, 
BLIMP1, and c-MYC with IRF4 knockdown. Of note, IRF4 knockdown in SUDHL1 
resulted in an increase in only BLIMP1α mRNA but no effect on mRNA or protein of any 
other targets. Conversely, IRF4 knockdown in Karpas-299 resulted in a reduction of 
BLIMP1α mRNA and c-MYC mRNA and protein. 
 
4.2.6 PTCL cell lines are insensitive to Lenalidomide treatment 
 To evaluate if Lenalidomide, a Cereblon inhibitor previously determined to 
downregulate expression of IRF4 in MM cell lines, would be a viable therapeutic 
intervention to target IRF4-sensitive cell lines, cells were incubated with the drug for 
72 and 120 hours (figure 4.10). Myeloma cell lines and primary patient material have 
been previously demonstrated to be sensitive to Lenalidomide treatment below 10µM 
(Kronke et al., 2014, Rajkumar et al., 2005). Therefore, MM cell lines H929 and LP1 
were used as positive controls.  
Initial experiments focused on treatment of cells for 72 hours. However, most 
cells failed to achieve an IC50 at this timepoint (figure 4.10A). Therefore, cells were 
incubated for a longer timecourse (120 hours) and assessed for growth inhibition. 
Positive control cell lines were both partially sensitive to Lenalidomide treatment 
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following 120 hours treatment but neither reached an IC50 (figure 4.10B). The 
lymphoma cell line panel was insensitive to Lenalidomide after 120 hours apart from 
SUDHL1 and DL40 which showed a degree of sensitivity (figure 4.9B). SUDHL1 was the 
only cell line to achieve an IC50, at 5µM (figure 4.10B). 
4.2.7 ALK+ ALCL cell lines demonstrate increased sensitivity to JQ-1 with 
Lenalidomide treatment 
 To investigate if the putative IRF4-MYC interaction demonstrated by IRF4 
shRNA knockdown in Karpas-299 could be exploited therapeutically, cells were treated 
with a combination of a BRD4 inhibitor (c-MYC is a downstream target of BRD4), JQ-1, 
and Lenalidomide for 72 hours (figure 4.11). SUDHL1 and Karpas-299 did not reach an 
IC50 value with JQ-1 treatment alone, however, with the addition of Lenalidomide, 
SUDHL1 achieved an IC50 of 800nM and Karpas-299 achieved an IC50 of 3µM (figure 
4.11). FEPD and LP1 were found to be more sensitive to JQ-1 treatment than SUDHL1 
or Karpas-299 and demonstrated minor additive effects of the drug combination, 
differences between curves at the highest concentration of JQ-1 were found to be 
significant in SUDHL1 and LP1 (SUDHL1 p<0.0001, Karpas-299 p=0.0891, FEPD 
p=0.0591, LP1 p=0.0002) (figure 4.11).  
 
 
 
Figure 4.10: Resazurin profiles of Lenalidomide treated cells 
Growth inhibition curves of all cell lines treated with increasing concentrations of Lenalidomide for A) 72 
hours or B) 120 hours and assessed by Resazurin relative to 0.05% DMSO vehicle. Reported sensitive cells lines 
are: H929 and LP1. All data are derived from 3 independent replicates, error bars indicate standard error of 
the mean. 
A) B) 
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Figure 4.11: Resazurin profiles of Lenalidomide and JQ-1 in combination 
Growth inhibition curves of all cell lines treated with increasing concentrations of JQ-1 only or JQ-1+100µM 
Lenalidomide (Len) relative to vehicle after 72 hours. Vehicle for JQ1 only treatment was 0.05% DMSO, vehicle for 
JQ-1+100µM Len was 100µM Lenalidomide in 0.05% DMSO. All data are derived from to 3 independent replicates, 
error bars indicate standard error of the mean. Significance calculated using a paired students t-test, * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001. 
JQ-1 only 
JQ-1 + 100µM Len 
JQ-1 only 
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JQ-1 only 
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4.3 Discussion 
In this chapter, IRF4 has been established as important for the proliferation of 
ALK+ ALCL cell lines with one potential mechanism in some cell lines being a positive 
interaction between IRF4 and c-MYC. Furthermore, IRF4 has been demonstrated to 
promote G2/M progression, at least in SUDHL1 cells. In agreement with the data 
presented in this project, multiple groups have recently published data showing that 
IRF4 is required for ALK+ ALCL proliferation/survival (Weilemann et al., 2015, 
Boddicker et al., 2015). 
IRF4 has been demonstrated to be important for the proliferation/survival of 
ALK+ ALCL cell lines. SUDHL1 and Karpas-299 displayed significant reductions in cell 
numbers with IRF4 shRNA knockdown as well as reduction in RFP-positive populations 
in competitive assays (figure 4.4B and 4.4C). However, siRNA knockdown of IRF4 in 
Karpas-299 in this project demonstrated no effect on proliferation/survival by Trypan 
Blue exclusion (figure 4.4B). This is in contrast to published data which demonstrates a 
reduction in cellular proliferation of Karpas-299 with IRF4 knockdown using a 
Thymidine Incorporation assay (Boddicker et al., 2015). Whilst the exact nature of this 
discrepancy is not known, it could be due to the insufficient potency of knockdown 
achieved using siRNA in this project compared to Boddicker et al., or due to the 
differences in sensitivity of the assays. 
DEL did not display an effect on proliferation/survival upon IRF4 knockdown 
(figure 4.4), possible due to the poor levels of protein knockdown observed with IRF4 
shRNAs (figures 4.4A and 4.9). Indeed, IRF4 shRNA knockdown has been demonstrated 
to reduce the proliferation/survival of DEL in vitro (Weilemann et al., 2015), suggesting 
knockdown in this project was not sufficient to induce a phenotype. To counteract this, 
transduced DEL cells could be seeded out in a colony forming assay in semi-solid agar 
to produce shRNA clones with increased IRF4 knockdown. Multiple clones would be 
required to ensure that any phenotypes observed are not a result of the clone-specific 
shRNA integration sites. 
 IRF4 knockdown caused increased G2/M populations compared to non-
silencing counterparts in SUDHL1 and, to a lesser extent, in Karpas-299 (figure 4.5B) 
suggesting that IRF4 may exert its activity through promotion of cell cycle progression. 
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In agreement with this hypothesis, it has been previously reported that IRF4 is 
important for cell cycle progression in normal T-cell development and pre-B cells (Ma 
et al., 2008, Yao et al., 2013). Despite the effect IRF4 knockdown had upon cell cycle, 
knockdown of IRF4 did not consistently induce apoptosis between both IRF4 shRNAs 
(figure 4.6B). The induction of apoptosis caused by IRF4 shRNA 2 could be a true 
phenotype and additional to stalling of the cell cycle in G2/M. However, as there is no 
indication of any apoptosis induction in shRNA 1, a more plausible explanation could 
be that the phenotype is due to off-target effects of shRNA 2. To test this hypothesis, 
further IRF4 shRNA constructs should be employed in similar assays to assess if 
induction of apoptosis is true. Furthermore, a different method of detecting apoptosis 
could be undertaken using the current shRNAs, such as western blotting for cleaved 
PARP or caspase-3. This is because inefficient compensation can lead to a false-positive 
indication of apoptosis. 
 Thus these data currently suggest that IRF4 may play a more permissive role in 
the survival of ALCL cell lines, focusing primarily on rapid growth rate. In agreement 
with this, studies using Irf4-deficient murine CD8+ T-cells demonstrate these cells 
proliferate slower than wild-type counterparts in vitro but did not induce apoptosis 
(Raczkowski et al., 2013, Yao et al., 2013). However, a second independent study 
investigating deficiency of IRF4 in CD8+ T-cells, provided evidence to suggest that loss 
of IRF4 does not affect the proliferation of these cells (Man et al., 2013). IRF4 has 
previously been demonstrated to promote the expression of metabolism genes, 
FOXO1 and HIF1A and loss of IRF4 resulted in reduced oxygen consumption rate, 
decreased ATP production, and reduced glycolytic activity (Man et al., 2013). Thus, in 
ALK+ ALCL, IRF4 may promote metabolic pathways to facilitate faster proliferation. In 
agreement with this, an independent study has revealed that knockdown of IRF4 in 
ALK+ ALCL cell lines results in downregulation of a HIF1A gene signature (Weilemann et 
al., 2015). To investigate this effect, future work may focus on utilising gene expression 
arrays on IRF4 knockdown cells to identify putative IRF4 targets. Pathway analysis of 
these targets would elucidate if IRF4 is involved in the regulation of genes required for 
metabolic activity. 
During this project, it was revealed that IRF4 promotes the expression of c-MYC 
mRNA in Karpas-299 and possibly DEL but not SUDHL1 cells (figures 4.7, 4.8, and 4.9) 
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and also promoted the expression of c-MYC protein in Karpas-299 (figure 4.8). A 
positive feedback loop between IRF4 and c-MYC resulting in overexpression of both 
transcription factors has been identified as a mechanism underlying the 
proliferation/survival of MM (Dib et al., 2008). c-MYC is a well characterised 
oncoprotein which, amongst other roles, can drive rapid proliferation in part by 
regulating important cell cycle regulators such as cyclins and CDKs  (Dang et al., 2006, 
Eilers and Eisenman, 2008). A possible explanation for accumulation of G2/M 
populations in IRF4 knockdown cells could be reduced expression of these cell cycle 
regulators via downregulation of c-MYC in Karpas-299. In agreement with these data, 
others have recently demonstrated that knockdown of IRF4 in some ALK+ ALCL cell 
lines results in downregulation of c-MYC (Weilemann et al., 2015, Boddicker et al., 
2015). Furthermore, one study has revealed that IRF4 knockdown in some ALCL cell 
lines can be rescued with overexpression of c-MYC (Weilemann et al., 2015). However, 
SUDHL1 does not exhibit this interaction between IRF4 and c-MYC (figure 4.7) 
suggesting other mechanisms of IRF4 dependency may exist in this cell line.  
Whilst SUDHL1 expressed the lowest levels of IRF4 protein of all PTCL cell lines 
(see chapter 3, figure 3.2), it appears to rely on this expression for proliferation. 
SUDHL1 was sensitive to IRF4 knockdown and Lenalidomide treatment (figures 4.7 and 
4.10), a drug known to downregulate IRF4 expression (Zhang et al., 2013). However, all 
remaining ALCL cell lines were insensitive to Lenalidomide treatment (figure 4.10). 
There are several possible explanations for the disagreement between IRF4 
knockdown sensitivity and Lenalidomide treatment sensitivity in Karpas-299. For 
example, Lenalidomide downregulates multiple targets such as Ikaros, Aiolos, and 
phosphorylation of extracellular signal-regulated kinase (ERK), (Breitkreutz et al., 
2008, Gandhi et al., 2014). Therefore, differences in expression or activity of these in 
ALCL may alter the sensitivity to Lenalidomide.  In addition, Lenalidomide may require 
a longer incubation to induce an effect in a cell line dependent manner. Sensitivity to 
Lenalidomide may not be truly observed with the Resazurin assay however. The 
Resazurin assay is believed to exploit the chemical transfer of electrons from NADPH, 
FADH, and NADH during mitochondrial enzyme oxidation of these molecules (de Fries 
and Mitsuhashi, 1995). Therefore, the technique is not a direct measure of cellular 
survival but rather a measure of the metabolic activity of the cell culture as a whole. 
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Therefore, cells which arrest, but metabolise rapidly can be misconstrued as healthy 
dividing cells. A more robust method of assessing survival of these cells with 
Lenalidomide treatment would be to count cells directly by Trypan Blue exclusion or 
treat cells with Lenalidomide and assess survival via a clonogenic assay.  
 To investigate if IRF4 and c-MYC could be simultaneously targeted in ALCL as a 
therapeutic avenue, cell lines were treated with JQ-1, a BRD4 inhibitor demonstrated 
to potently repress c-MYC protein expression (Delmore et al., 2011). Combination of c-
MYC inhibition and IRF4 inhibition has recently been suggested as a potential 
therapeutic approach for PTCL (Weilemann et al., 2015, Boddicker et al., 2015). 
Treatment with both drugs demonstrated that, albeit to a minor extent, SUDHL1, MM 
cell lines, and Karpas-299, survived less than either treatment alone (figure 4.10 and 
4.11). These data suggest that dual targeting of the IRF4-BRD4 axis could be beneficial 
for some ALCL patients. To further investigate this avenue, direct c-MYC inhibitors 
should be employed in combination with Lenalidomide to elucidate if the effect of JQ-1 
and Lenalidomide treatment is c-MYC-dependent or due to another target of BRD4. In 
addition, analysis of IRF4 levels in ALK+ ALCL cell lines after JQ-1 treatment should be 
undertaken to elucidate whether inhibition of BRD4 directly impacts IRF4 expression. 
IRF4 shRNA knockdown resulted in an increase in BLIMP1α, but not BLIMP1β, 
transcripts in SUDHL1 (figure 4.7) and, in addition, siRNA knockdown of IRF4 resulted 
in increased expression of BLIMP1 (figure 4.3B). This is in direct contrast to Karpas-299 
and DEL which demonstrated a reduction of BLIMP1α and BLIMP1β with IRF4 shRNA 
knockdown (figure 4.8). These results may be indicative of different roles of IRF4 
across the cell lines. In agreement with Karpas-299 and DEL, in normal T-cell and B-cell 
physiology, IRF4 promotes the expression of BLIMP1 (Kwon et al., 2009, Li et al., 2012, 
Yao et al., 2013). However, in SUDHL1, IRF4 appears to directly repress BLIMP1α 
expression which could be a mechanism of downregulating the potential tumour 
suppressor gene expression. Karpas-299 and DEL displayed a minor reduction in the 
expression of BCL6 mRNA with IRF4 knockdown (figures 4.3B, 4.7-4.9) suggesting IRF4 
promoted the expression of BCL6 in these lines, consistent with normal T-cell 
physiology (Kwon et al., 2009, Lohoff et al., 2002). Therefore, IRF4 may promote the 
expression of BCL6 to maintain expression of a potential tumour promoter. 
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Future work for this study would utilise gene expression arrays in combination 
with ChIP-Seq analysis of PTCL cell lines to find novel IRF4 targets. Our results and 
those of Weilemann et al. suggest that while some ALCLs are addicted to IRF4 through 
interaction with c-MYC, others depend upon c-MYC-independent effects of IRF4. In this 
study IRF4 did not affect c-MYC expression in SUDHL1 cells (figure 4.7) and Weilemann 
et al. observed that c-MYC expression could only rescue IRF4 knockdown in 1 of 3 of 
their cell lines (Weilemann et al., 2015). Therefore, it would be beneficial to discover 
IRF4 targets other than c-MYC which contribute to ALCL survival as these may 
themselves present therapeutic targets.  
Further investigation into the binding partners of IRF4 should be conducted. In 
B-cells IRF4 binds PU.1 to effect its activity, but PU.1 is not expressed in T-cells (Brass 
et al., 1996, Escalante et al., 2002). As a result, IRF4 must bind with other targets to 
affect transcription. Immunoprecipitation assays would reveal if IRF4 bound to some 
known T-cell transcriptional partners, such as BATF (Li et al., 2012), FOXO1 or HIF1A 
(Man et al., 2013). ChIP-Seq would allow investigation into whether IRF4 shared 
binding sites with other novel partners in T-cell lymphoma. Of particular interest would 
be to investigate the role of BATF3 in IRF4-dependent ALK+ ALCL. BATF3 is a 
transcriptional repressor which can heterodimerise with JUN and is required for the 
correction differentiation of CD8+α deŶdƌitiĐ Đells (Peng et al., 2014). Recently, BATF3 
has been implicated as one of the key genes specifically expressed by ALK+ ALCL (Iqbal 
et al., 2014). Whilst direct interaction of IRF4 and BATF3 has not been demonstrated, it 
is known that IRF8 (a close relation of IRF4) can interact with BATF3 (Hildner et al., 
2008, Ise et al., 2011). Furthermore, IRF4 has demonstrated binding to BATF-JUN 
complexes during T-cell differentiation (Li et al., 2012). Therefore, it is plausible that a 
potential pro-tumour mechanism of action for IRF4 could be mediated through BATF3 
interaction. 
As IRF4 inhibitors are not currently available, it would be beneficial to explore 
downstream targets of IRF4 as a potential therapeutic avenue. Another aspect would 
be to investigate the use of c-MYC inhibitors on IRF4-dependent cell lines to exploit the 
c-MYC/IRF4 interaction observed in some ALCL cell lines. Further IRF4 knockdown 
experiments should be undertaken across different PTCL cell lines as well as primary 
patient cultures to investigate if IRF4 is required across PTCL cell lines as a whole and 
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whether IRF4 translates as a viable therapeutic target in patient samples. There is good 
rationale for IRF4 being a viable target as 91% of ALCL patient tumours have been 
previously demonstrated to be IRF4-positive by immunohistochemistry (Weilemann et 
al., 2015). Whilst gene expression arrays have already been utilised with IRF4 
knockdown in ALCL cell lines: Karpas-299, DEL, and FEPD (Weilemann et al., 2015), it 
may be of interest to investigate how IRF4 works in our cell lines. For example, 
published data indicates that IRF4 knockdown does not affect the growth of SUDHL1 
(Weilemann et al., 2015, Boddicker et al., 2015) which is a direct contrast to data 
presented in this report (figure 4.4A).  
Although shRNA-mediated knockdown was useful in this project for 
overcoming the rapid recovery of IRF4 levels in SUDHL1 with siRNA knockdown (figure 
4.3), the technique has some drawbacks. The lentiviral delivery system can be 
problematic as lentiviruses can typically integrate into preferential sites around the 
genome (Biffi et al., 2011). This is particularly problematic if the virus inserts a 
sequence into a specific locus causing deregulation of genes important for proliferation 
and survival and thus can produce spurious results. For example, BACH2 contains a 
preferential integration site for EBV in BL (Takakuwa et al., 2004). However, this 
problem was overcome in this project through use of a bulk-transduced population, 
instead of individual clones, which will harbour intercellular variances in integrations. 
Furthermore, shRNA-mediated knockdown relies upon the micro-RNA processing 
pathway to be functional in these cells. Dysregulation of micro-RNA pathways is well 
established in cancers, therefore, the processing of shRNA may be hindered (Melo and 
Esteller, 2011). Additionally, a drawback of both siRNA and shRNA is the induction of 
interferon responses in cells leading to activation of immune responses (Bridge et al., 
2003). A recent advancement has demonstrated the ability to knockout genes in 
human genomes via a CRISPR-mediated technique (Shalem et al., 2014). This may be a 
viable means of assessing the effect of complete loss of IRF4 on PTCL cell lines 
although a potential drawback in the technique is that if IRF4 is vital for these cell lines, 
then all cells will die rapidly. This issue can be overcome by combining knockout with 
an inducible expression vector containing IRF4 coding sequence to allow more control 
over experimental procedures. 
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5. The transcriptional repressor, BLIMP1, as a tumour suppressor in ALCL 
5.1 Introduction 
BLIMP1 is a transcriptional repressor encoded by the PRDM1 gene which is 
required for B- and T-cell differentiation through interaction with many targets, 
including BCL6 and IRF4 (Shapiro-Shelef and Calame, 2005). The relationship between 
BLIMP1 and BCL6/IRF4 remain conserved between B- and T-cells (figure 5.1). There are 
two maiŶ isofoƌŵs of BLIMPϭ, desigŶated BLIMPϭα aŶd BLIMPϭβ, although otheƌs 
haǀe ďeeŶ ƌepoƌted. BLIMPϭα has ďeeŶ deŵoŶstƌated to eǆhiďit gƌeateƌ ƌepƌessiǀe 
aĐtiǀitǇ thaŶ BLIMPϭβ (Gyory et al., 2003). BLIMP1 is well established as a tumour 
suppressor in B-cell malignancies and is commonly inactivated or deleted in ABC-DLBCL 
(Pasqualucci et al., 2006, Tam et al., 2006, Mandelbaum et al., 2010). In addition, 
deletions of PRDM1 were frequently found in NK-cell lymphomas and re-introduction 
of BLIMP1 into these neoplasms resulted in reduced cellular proliferation (Karube et 
al., 2011). 
The aim of this chapter is therefore to investigate the role of BLIMP1 as a 
tumour suppressor in T-cell lymphoma and to establish its interactions with BCL6 and 
IRF4. The chapter will investigate the effect overexpression of BLIMP1α oƌ BLIMPϭβ 
Figure 5.1: Interaction of BLIMP1 with IRF4 and BCL6 in B-cells vs. T-cells 
A) In B-cells, BLIMP1 exhibits mutual inhibition with BCL6 to allow formation of slow-proliferation plasma cells 
(Shapiro-Shelef et al., 2003). B) In T-cell differentiation, BLIMP1 and BCL6 repress one another to achieve 
differentiation of T
H
 cells. The effect of BLIMP1 on IRF4 expression is not known to date, however IRF4 can 
positively regulate expression of BLIMP1 via interaction with BATF and STAT3 (Li et al., 2012). 
A) B) 
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has upon the proliferation and survival of T-cell lines as well as the effect on expression 
of BCL6 and IRF4 mRNA and protein.  
5.2 Results 
5.2.1 BLIMP1 overexpression is achievable in ALK+ ALCL cell lines 
 To investigate the role of BLIMP1 in ALCL, we first needed a vector that could 
express both BLIMP1 isoforms to a detectable level. Endogenous BLIMP1 protein is 
difficult to detect due to the low levels of expression exhibited by PTCL cell lines. 
However, upon transduction of cells with pSIEW-BLIMP1α aŶd p“IEW-BLIMPϭβ 
vectors, protein was detectable after four days (figure 5.2A and B). SUDHL1 treated 
with 25µl of pSIEW-BLIMPϭα eǆhiďited loǁ ǀiaďilitǇ ǁhilst those tƌeated ǁith Ϯϱµl of 
pSIEW-BLIMPϭβ, oƌ ϭϱµl oƌ Ϯϱµl of p“IEW ǀiƌus, had ĐoŵpletelǇ died ďǇ ϰ daǇs. This 
was believed to be due to the multiple integrations of the viral vector into the host 
genome as all the populations were 100% GFP-positive. Karpas-299 was able to 
tolerate virus up to 25µl, however at 50µl of virus the cells spontaneously died (data 
not shown). There was not sufficient volume of surviving cells to assess protein levels 
in SUPM2 treated with pSIEW-BLIMPϭα aŶd p“IEW-BLIMPϭβ at aŶǇ ǀiƌus 
concentration; however protein could be extracted from cells treated with 5µl pSIEW 
virus. The cell death exhibited by SUPM2 was believed to be a spurious effect caused 
by poor culturing. Therefore, to determine the ideal viral titre, GFP traces were 
analysed to determine which virus volumes produced similar transduction efficiencies 
to those found in SUDHL1 for SUPM2 (figure 5.2C). 15µl of pSIEW-BLIMPϭα aŶd p“IEW-
BLIMPϭβ ǀiƌuses aŶd ϱµl of p“IN-SIEW virus for SUDHL1 and SUPM2 were selected 
based upon the transduction efficiency and non-specific cell death exhibited at these 
volumes. For Karpas-299, 25µl of all viruses was chosen for future transductions. 
5.2.2 BLIMP1 overexpression represses IRF4 and endogenous BLIMP1 in ALK+ ALCL 
 BLIMPϭα oǀeƌeǆpƌessioŶ ƌesulted iŶ sigŶifiĐaŶt iŶĐƌeases iŶ BLIMPϭα ŵRNA iŶ 
all cell lines (SUDHL1 p=0.0257, Karpas-299 p=0.0139, SUPM2 p=0.0002). 
OǀeƌeǆpƌessioŶ of ďoth BLIMPϭα aŶd BLIMPϭβ pƌoteiŶs ƌesulted iŶ a ŵaƌked deĐƌease 
in IRF4 transcript levels in SUDHL1 (BLIMP1α p<Ϭ.ϬϬϬϭ, BLIMPϭβ p<Ϭ.ϬϬϬϭͿ (figure 
5.3A). In addition, both constructs resulted in a depletion of detectable IRF4 protein 
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(figure 5.3D and F) in SUDHL1 and perhaps also in SUPM2. However, BCL6 expression 
was unaffected by either BLIMP1 isofoƌŵ ;BLIMPϭα p=Ϭ.ϭϮϰϭ, BLIMPϭβ p=Ϭ.ϭϵϵϵͿ. 
 Contrary to SUDHL1, SUPM2 and, to a lesser extent, Karpas-299 displayed a 
reduction in c-MYC ŵRNA leǀels ǁith eǆpƌessioŶ of BLIMPϭα (SUPM2 p=0.0197, 
Karpas-299 p=0.011), ďut Ŷot BLIMPϭβ (SUPM2 p=0.3645, Karpas-299 p=0.7801) 
B) A) 
C) 
Figure 5.2: Optimisation of pSIEW vector transduction in SUDHL1, SUPM2, and Karpas-299 
Cells were spinfected at 900g for 50 minutes with either 0µl, 5µl, 15ul, 25ul, or 50µl of virus and cultured as normal for 
4 days. All samples containing 50µl of pSIEW-BLIMP1α, pSIEW-BLIMP1β, or pSIEW died due to multiple integrations. A) 
Western blot after 4 days transduction in SUDHL1. There were no living cells in those treated with 25µl of SIEW-
BLIMP1β, or 15µl and 25µl of SIN-SIEW virus. B) Western blot after 4 days transduction in Karpas-299. C) Live cells were 
gated according to the gate applied on forward scatter/side scatter plots. Subsequent GFP-traces for SUPM2 and 
SUDHL1 are depicted by histograms after 4 days with % GFP-positivity table. 
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(figure 5.3B and 5.3C). However, in Karpas-299, expression of BLIMPϭα oƌ BLIMPϭβ 
resulted in no change of BCL6 or IRF4 mRNA or protein levels (BCL6 p=0.1473, IRF4 
p=0.3702) (figure 5.3B and 5.3E). 
 Whilst eŶdogeŶous BLIMPϭα Đould Ŷot ďe deteĐted ǁhilst eǆpƌessiŶg “IEW-
BLIMPϭα, usiŶg the pƌiŵeƌs iŶ this studǇ, eŶdogeŶous BLIMP1β could be analysed. 
Interestingly, in all cell lines, eǆpƌessioŶ of BLIMPϭα ;aŶd BLIMPϭβ iŶ “UDHLϭͿ Đaused 
reductions in BLIMP1β mRNA expression, significantly in SUDHL1 and SUPM2 (SUDHL1 
p=0.0003, Karpas-299 p=0.2342, SUPM2 p=0.0004) (figure 5.3A-C). In addition, the 
eǆpƌessioŶ of BLIMPϭβ had a sŵall Ŷegative effect on the expression of BLIMP1α in 2/3 
cell lines (SUDHL1 p=0.0003, Karpas-299 p=0.8823, SUPM2 p=0.0483).  
5.2.3 BLIMP1 overexpression reduces the proliferation/survival of ALK+ ALCL cell lines 
 To investigate the role of BLIMP1 as a tumour suppressor, cells were 
transduced with virus according to the volumes defined in section 5.2.1. Flow 
cytometric samples were then collected every 2-3 days over a 2 week period and GFP-
expression was assessed. GFP-expression was plotted against day 0 expression (48 
hours after transduction) (figure 5.4). Both SUDHL1 and SUPM2 showed significant 
reduction of GFP-positiǀe Đells oǀeƌ tiŵe folloǁiŶg BLIMPϭα oƌ BLIMPϭβ eǆpƌessioŶ 
compared to the pSIEW vector control (“UDHLϭ: BLIMPϭα p=Ϭ.ϬϬϭ, BLIMPϭβ p=Ϭ.ϬϬϯ, 
SUPM2: BLIMPϭα p=Ϭ.ϬϬϭ, BLIMPϭβ p=Ϭ.ϬϬϭͿ ;figuƌe ϱ.ϰB aŶd ϱ.ϰDͿ. BLIMPϭα-
eǆpƌessiŶg Đells lost GFP eǆpƌessioŶ fasteƌ thaŶ BLIMPϭβ-expressing counterparts. In 
Karpas-299 cells GFP-expression, however, remained stable throughout the 
experiment with both BLIMP1 constructs (figure 5.4C). In all cell lines, GFP expression 
tended to increase over time with the control vector. 
5.2.4 BLIMP1 overexpression induces cell death in ALK+ ALCL cell lines 
 To further evaluate the impact of BLIMP1 overexpression on sensitive cell lines, 
cells were stained with propidium iodide to assess cell cycle populations at days 0 and 
2 of GFP-tracking (48 and 96 hours after transduction, respectively) (figure 5.5A). Both 
sensitive cell lines, SUDHL1 and SUPM2, showed significant increases in sub-G1 
populations by day 2 compared to control vector with both pSIEW-BLIMPϭα ;“UDHLϭ 
p=0.002, SUPM2 p=0.011) and pSIEW-BLIMPϭβ ;“UDHLϭ p=Ϭ.Ϭϰϵ, “UPMϮ p=Ϭ.ϬϬϲͿ 
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(figure 5.5B and D). Karpas-299 cell cycle profiles remained unchanged by pSIEW-
BLIMPϭα aŶd p“IEW-BLIMPϭβ Đoŵpaƌed to p“IEW ĐoŶtƌol ;figuƌe ϱ.ϱCͿ. A sigŶifiĐaŶt 
increase in sub-Gϭ populatioŶs ǁas oďseƌǀed iŶ “UDHLϭ at daǇ Ϭ ǁith BLIMPϭβ 
eǆpƌessioŶ ďut Ŷot BLIMPϭα ;figuƌe 5.5B). SUPM2 and Karpas-299 cell cycle profiles 
were not significantly altered at day 0 (figure 5.5C and D). 
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Figuƌe 5.ϯ: OveƌexpƌessioŶ of BLIMPϭα aŶd BLIMPϭβ iŶ ALK+ ALCL cell liŶes 
Quantitative PCR graphs for A) SUDHL1, B) Karpas-Ϯϵϵ, aŶd CͿ “UPMϮ. OǀeƌeǆpƌessioŶ of BLIMPϭβ ĐaŶŶot ďe 
deteĐted ďǇ ƋPCR as the pƌiŵeƌs taƌget the oŶlǇ uŶiƋue ƌegioŶ of BLIMPϭβ, the ϱ’UTR, ǁhiĐh is Ŷot pƌeseŶt iŶ the 
SIEW-BLIMPϭβ ĐoŶstƌuĐt. Eƌƌoƌ ďaƌs aƌe derived from 3 independent experiments and represent standard error of 
the mean. Respective western blots for D) SUDHL1, E) Karpas-299, and F) SUPM2. Significance calculated using a 
paired students t-test, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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5.3 Discussion 
  
 BLIMP1 is well established as a tumour suppressor in NK T-cell malignancies 
(Iqbal et al., 2009, Karube et al., 2011) and, during the course of this project, was 
discovered to be a tumour suppressor in ALK+ ALCL by another independent group (Boi 
et al., 2013). IŶ agƌeeŵeŶt ǁith this puďlished data, oǀeƌeǆpƌessioŶ of BLIMPϭα 
resulted in reduced proliferation/survival of SUDHL1 and SUPM2 cells in culture 
(figures 5.4B and 5.4D), accompanied by induction of apoptosis as reflected by an 
increase in sub-G1 population by flow cytometry (figures 5.5B and 5.5D). Therefore, 
this data as a ǁhole suggests that BLIMPϭα aŶd BLIMPϭβ ŵaǇ ĐoŶstƌaiŶ the 
proliferation and survival of ALCL cells and that their transcriptional targets might be 
molecules which could be exploited for the treatment of ALK+ ALCL. 
 Overexpression experiments have revealed that BLIMP1 does not affect BCL6 
mRNA or protein expression across all three ALK+ ALCL cell lines (figure 5.3), 
suggesting that BLIMP1 has lost the ability to repress BCL6 in ALCL cells. BLIMP1 has 
previously been shown to directly inhibit BCL6 expression in normal CD4+ and CD8+ T-
cells (Cimmino et al., 2008). Loss of repressive activity of BLIMP1 on BCL6 could be 
indicative of a mutation/alteration in BCL6 that could alleviate repression. Indeed BCL6 
has been demonstrated to harbour mutations in its promoter region, in DLBCL, to 
prevent its own autoregulation or regulation by IRF4 (Pasqualucci et al., 2003, Saito et 
al., 2007).  
Hoǁeǀeƌ, oǀeƌeǆpƌessioŶ of BLIMPϭα aŶd BLIMPϭβ did ƌesult iŶ ƌepƌessioŶ of 
IRF4 mRNA and protein in SUDHL1 and SUPM2 (figure 5.3A and 5.3C). Little is known 
about the effect  of BLIMP1 upon IRF4 in normal T-cells, however, this data agrees with 
published data showing that BLIMP1 represses IRF4 expression in ALK+ ALCL (Boi et al., 
2013). IŶ additioŶ, oǀeƌeǆpƌessioŶ of BLIMPϭα ƌesulted iŶ suppƌessioŶ of c-MYC mRNA 
levels in SUPM2 and, to a lesser extent, in Karpas-299 (figure 5.3B and 5.3C). Whilst 
BLIMP1 has been demonstrated to directly repress c-MYC in plasma cells (Lin et al., 
1997), it is unknown whether the work presented in this report demonstrates a direct 
repressive effect of BLIMP1 or a secondary repressive effect via loss of IRF4 expression 
resulting in reduction of c-MYC (Weilemann et al., 2015). BLIMP1 ChIP could be used to 
determine if BLIMP1 binds c-MYC directly. 
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Both BLIMPϭα aŶd BLIMPϭβ eǆhiďit the saŵe leǀel of ƌepƌessioŶ of IRF4 mRNA 
;figuƌe ϱ.ϯA aŶd ϱ.ϯCͿ. Theƌefoƌe, ĐoŶtƌaƌǇ to oŶe hǇpothesis suggestiŶg that BLIMPϭβ 
ŵaǇ aĐt as a Đoŵpetitiǀe iŶhiďitoƌ of BLIMPϭα ďǇ ďiŶdiŶg BLIMPϭα sites aŶd eǆeƌtiŶg 
lesser repressive activity to targets (Zhao et al., 2008), this data suggests both isoforms 
aƌe aďle to ƌepƌess eǆpƌessioŶ eƋuallǇ. Hoǁeǀeƌ, BLIMPϭα ƌepƌoduĐiďlǇ ƌesulted iŶ a 
more rapid loss of GFP-positiǀe Đells Đoŵpaƌed to BLIMPϭβ iŶ ďoth “UDHLϭ aŶd 
SUPM2 (figure 5.4B aŶd ϱ.ϰDͿ suggestiŶg that BLIMPϭα ĐaŶ eǆeƌt gƌeateƌ tuŵouƌ 
suppƌessoƌ aĐtiǀitǇ thaŶ BLIMPϭβ. This effeĐt, hoǁeǀeƌ, ŵaǇ ďe due to the faĐt that 
BLIMPϭα appeaƌs to ďe eǆpƌessed to a higheƌ leǀel thaŶ BLIMPϭβ iŶ ďoth of these Đell 
lines (figures 5.3D and 5.3F). Repression of IRF4 by BLIMP1 may also reinforce the 
notion of IRF4 as a tumour promoting protein in ALCL. Contrary to SUDHL1 and 
SUPM2, overexpression of BLIMP1 did not affect expression of BCL6 or IRF4 in Karpas-
299 (figure 5.3B) which may be indicative of different transforming mechanisms 
ďetǁeeŶ the Đell liŶes. IŶ additioŶ to IRFϰ, BLIMPϭα has ďeeŶ deŵoŶstƌated to 
suppress miR155 in published data however this has not been demonstrated with 
BLIMPϭβ (Boi et al., 2013). miR155 is a known oncogene that, amongst other roles, 
upregulates p-STAT3 levels (Merkel et al., 2015). The oncogenic role of miR155 has 
been demonstrated in breast cancer (Czyzyk-Krzeska and Zhang, 2014) and more 
recently in ALK- ALCL (Merkel et al., 2015). The authors of the most recent paper 
conclude that miR155 is not required for ALK+ ALCL due to the low intrinsic levels of 
expression (Merkel et al., 2015). In addition, treatment of ALK+ ALCL cell lines with 
Crizotinib resulted in no changes in miR155 levels suggesting it was not regulated by 
ALK. These data as a whole, however, suggest that upregulation of miR155 may occur, 
at least in paƌt, thƌough ƌepƌessioŶ of BLIMPϭα iŶ ALK+ ALCL aŶd ŵaǇ ĐoŶstitute aŶ 
oncogenic target in ALK+ ALCL. 
Whilst all three ALK+ ALCL cell lines used in this chapter have been shown to 
exhibit BLIMP1 deletions by FISH (Boi et al., 2013), Karpas-299 is the only cell line to 
ĐoŵpletelǇ laĐk BLIMPϭα pƌoteiŶ eǆpƌessioŶ ;see Đhapteƌ 3, figure 3.2). Despite this, 
oǀeƌeǆpƌessioŶ of BLIMPϭα did Ŷot sloǁ the gƌoǁth of these Đells ;figuƌe ϱ.ϰCͿ, Ŷoƌ 
significantly induce apoptosis (figure 5.5C). The exact reason for this is unknown; 
however it is possible to speculate a combination of factors resulting in BLIMP1 
overexpression insensitivity. According to published data (Boi et al., 2013) and SNP 6.0 
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array data collected in our lab (data not shown), the BLIMP1 locus is deleted in Karpas-
299. However, the deletion does not appear to be the reason for loss of protein 
expression as mRNA levels of BLIMP1α observed in Karpas-299 are similar to those 
observed in SUDHL1 and SUPM2, both of which contain detectable BLIMP1 protein 
(see chapter 3, figure 3.2A). Therefore, BLIMP1 may be mutated to give rise to 
aberrant transcripts. This type of activity has been observed in DLBCL whereby BLIMP1 
has been demonstrated to harbour a wide spectra of mutations leading to truncated 
proteins, frameshift deletions, or nonsense mutations causing inactivation of one or 
more alleles of BLIMP1 (Pasqualucci et al., 2006). Furthermore, these cells lack BLIMP1 
protein expression whilst retaining BLIMP1 mRNA expression. 
 Alternatively, upregulation of proteasomal degradation pathways may be the 
Đause of BLIMPϭα pƌoteiŶ loss iŶ Kaƌpas-299. One publication demonstrates that 
BLIMP1 is degraded by Small Ubiquitin-like Molecule 1 (SUMO-1) in vitro by a process 
known as SUMOlyation (Shimshon et al., 2011). Therefore, a mechanism of 
overcoming BLIMP1 overexpression could be to upregulate proteasomal degradation 
pathwaǇs; ǁhilst this Đould eǆplaiŶ laĐk of eŶdogeŶous BLIMPϭα, it seeŵs uŶlikelǇ to 
be the cause of BLIMP1 overexpression insensitivity as BLIMP1 protein is detectable 
with overexpression vectors suggesting proteasomal degradation pathways have not 
targeted this protein (figure 5.3E). In addition, it could be hypothesised that mutations 
may be present in the BLIMP1 binding sites of critical BLIMP1 targets preventing the 
ďiŶdiŶg of BLIMPϭα oƌ BLIMPϭβ. Whilst this has Ŷot ďeeŶ deŵoŶstƌated ŶatuƌallǇ iŶ 
malignancies, mutations introduced to BLIMP1 target gene promoters in BL abrogated 
BLIMP1 repression (Cubedo et al., 2011).  In agreement with this hypothesis, loss of 
BCL6 inhibition by BLIMP1 is evident across all cell lines tested (figure 5.3), though the 
exact mechanism of this is unknown. It could be speculated that BLIMP1-mediated 
repression of BCL6 is overridden by constitutive STAT3 signalling driven by the NPM-
ALK translocation (Chiarle et al., 2008). Sequencing of the BCL6 locus in these cell lines 
could elucidate whether mutations of BLIMP1 binding sites are present, alternatively 
ChIP-“eƋ of BLIMPϭ Đould also ƌeǀeal if BLIMPϭα oƌ BLIMPϭβ still possess the aďilitǇ to 
bind the BCL6 locus.  
IŶteƌestiŶglǇ, oǀeƌeǆpƌessioŶ of eitheƌ BLIMPϭα oƌ BLIMPϭβ ƌesulted iŶ 
repression of endogenous BLIMP1β mRNA, whilst overexpressioŶ of BLIMPϭβ also 
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resulted in repression of endogenous BLIMP1α mRNA in SUDHL1 and SUPM2 cell lines 
(figure 5.3A and C). This repression may be an intrinsic method of compensating 
overexpression of BLIMP1. One mechanism may be through upregulation of B-cell 
lineage-specific activator protein (BSAC). BSAC has been demonstrated by ChIP to 
directly bind BLIMP1 and, when ectopically expressed, result in the repression of 
BLIMP1 expression (Mora-Lopez et al., 2007). Another important molecule may be 
BACH2 which has also been shown to bind and repress BLIMP1 expression in B-cells 
(Ochiai et al., 2006). Therefore, investigation into the levels of either BSAC or BACH2 
with BLIMP1 overexpression may validate a role for these proteins in these cell lines.  
These data have demonstrated that BLIMP1 is a bona fide tumour suppressor 
in ALK+ ALCL and may exert its activity via down regulation of multiple targets, such as 
IRF4 and c-MYC. Repeat experiments could focus on improving the control vector to 
ĐoŶtaiŶ a ŵutated, iŶaĐtiǀe ǀeƌsioŶ of BLIMPϭ α oƌ BLIMPϭβ to eŶsuƌe the effeĐt 
observed is specifically due to active BLIMP1. In addition, as propidium iodide staining 
does not distinguish between necrosis and apoptosis it may be necessary to prove that 
BLIMP1 induces apoptosis via an apoptosis assay. GFP expression is detected in the 
same fluorescent channel as the FITC caspase-3 flow cytometry assay employed during 
this project, which therefore would not be suitable in our experiments. However, 
collecting whole cell extracts of BLIMP1 overexpressing cells and probing for apoptotic 
proteins such as PARP, and caspase-3, would allow assessment of apoptosis induction. 
Futuƌe ǁoƌk ǁould foĐus oŶ eǆpƌessioŶ aƌƌaǇs foƌ BLIMPϭα aŶd BLIMPϭβ 
overexpression to identify genes regulated by BLIMP1 in these cell lines Of particular 
interest would be to utilise an array for the insensitive Karpas-299 and the sensitive 
SUDHL1 and SUPM2 to assess which genes are differentially regulated which could 
explain the different BLIMP1 sensitivities. 
This would allow further investigation into the pathways that are specifically 
important to survival of SUDHL1 and SUPM2. Work investigating BLIMP1 
overexpression in other subtypes of PTCL would be of use, particularly in AITL, 
characteristic for containing high BCL6 expression (Nurieva et al., 2009). It would also 
be of benefit to investigate if there are differences in gene expression targets between 
BLIMPϭα aŶd BLIMPϭβ aƌƌaǇs to fuƌtheƌ eluĐidate the iŶdiǀidual ƌole of eaĐh. These 
experiments would demonstrate if BLIMP1 is important for the survival of all PTCLs, or 
182 
 
just ALCL, as well as clarify whether loss of BCL6 antagonism is specific to ALCL 
subtypes or is common across all PTCL.  
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6. NPM-ALK in the regulation of the BCL6-IRF4-BLIMP1 Transcription 
Factor Axis 
6.1 Introduction 
ALK is a tyrosine kinase which is believed to be required for the development of 
the nervous system in embryos (Iwahara et al., 1997, Morris et al., 1994). ALK is the 
target of chromosomal translocation or mutations in several types of tumour. Whilst 
many translocation partners exist for ALK, the most common in ALCL is the 
t(2;5)(p23;q35) creating the NPM-ALK fusion tyrosine kinase. In ALK+ ALCL, ALK is 
therefore constitutively active resulting in constitutive activation of STAT3 which 
directs cell survival and proliferation (Khoury et al., 2003, Zamo et al., 2002, Amin et 
al., 2004). Importantly, STAT3 can induce expression of BCL6 and IRF4 demonstrating 
putative therapeutic targets (Walker et al., 2013, Kwon et al., 2009). 
ALK inhibitors have recently found utility for the treatment of ALK-rearranged 
non-small cell lung cancer and myofibroblastic tumours, and are in trials for ALCL 
(Butrynski et al., 2010, Gambacorti-Passerini et al., 2011, Kwak et al., 2010). Crizotinib 
is a dual ALK and c-Met inhibitor utilised in the treatment of these malignancies (Sahu 
et al., 2013). Crizotinib inhibits the phosphorylation, and subsequent activation, of ALK 
(Cui et al., 2011, Sahu et al., 2013). 
The aim of this chapter is therefore to evaluate the role of ALK in regulating the 
BCL6-IRF4-BLIMP1 transcription factor axis in ALK+ ALCL by examining the effect of ALK 
inhibition, using Crizotinib, on cell proliferation/survival and the effect this has upon 
the mRNA and protein levels of BCL6, IRF4, and BLIMP1 in ALK+ vs. ALK- ALCL cell lines. 
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6.2 Results 
6.2.1 ALK+ ALCL cell lines are selectively sensitive to Crizotinib 
 To assess the Đell liŶes’ seŶsitiǀitǇ to ALK iŶhiďitioŶ, ALCL Đell liŶes ǁeƌe tƌeated 
with Crizotinib for 72 hours and assessed by Resazurin assay. The ALK+ ALCL cell lines: 
SUDHL1, Karpas-299, and DEL were all sensitive to Crizotinib, reaching IC50s below 
1µM, whilst the ALK- ALCL cell line Mac1 was resistant and failed to reach an IC50 
(figure 6.1). 
6.2.2 Inhibition of ALK reveals two distinct effects on RNA levels of BCL6, IRF4, 
BLIMP1, and c-MYC 
To evaluate how ALK affected the BCL6-IRF4-BLIMP1 transcription factor axis, 
cells were treated with a low concentration of Crizotinib (50nM and 100nM) over a 24 
hour period and lysed for RNA and protein analysis. All cell lines exhibited a reduction 
in BCL6 mRNA and protein in a dose-dependent manner (SUDHL1: 50nM 4 hours 
p=0.001, 50nM 8 hours p=0.0022, 50nM 24 hours p<0.0001, 100nM 4 hours p=0.0005, 
100nM 8 hours p<0.0001, 100nM 24 hours p<0.0001, Karpas-299: 50nM 4 hours 
p=0.0071, 50nM 8 hours p=0.0073, 50nM 24 hours p=0.0017, 100nM 4 hours 
p<0.0001, 100nM 8 hours p=0.0007, 100nM 24 hours p<0.0001, DEL: 50nM 4 hours 
p=0.0027, 50nM 8 hours p=0.0015, 50nM 24 hours p<0.0001, 100nM 4 hours 
p=0.0014, 100nM 8 hours p=<0.0001, 100nM 24 hours p<0.0001) (figure 6.2).  
Figure 6.1: Survival curve of ALCL cell lines treated with Crizotinib 
Growth inhibition curve as assessed by Resazurin fluorescence. Data is derived from 3 independent replicates, 
error bars indicate standard error of the mean. 
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There were two distinct patterns observed across the cell lines with respect to 
IRF4, BLIMP1 and, c-MYC expression. SUDHL1 exhibited a reduction in IRF4 (50nM 4 
hours p=0.0148, 50nM 8 hours p=0.029, 50nM 24 hours p<0.0001, 100nM 4 hours 
p=0.005, 100nM 8 hours p<0.0001, 100nM 24 hours p<0.0001), BLIMP1α (50nM 4 
hours p=0.0002, 50nM 8 hours p=0.0013, 50nM 24 hours p=0.123, 100nM 4 hours 
p=0.0002, 100nM 8 hours p<0.0001, 100nM 24 hours p=0.0007), and BLIMP1β (50nM 
4 hours p<0.0001, 50nM 8 hours p<0.0001, 50nM 24 hours p<0.001, 100nM 4 hours 
p<0.0001, 100nM 8 hours p<0.0001, 100nM 24 hours p<0.0001) mRNA levels with ALK 
inhibition whilst expression of c-MYC was unaltered BLIMP1β (50nM 4 hours p=0.7069, 
50nM 8 hours p=0.1212, 50nM 24 hours p=0.1756, 100nM 4 hours p=0.6648, 100nM 8 
hours p=0.0.066, 100nM 24 hours p=0.7485)  (figure 6.2A). In agreement with this, 
IRF4 and BLIMP1 protein was reduced after 24 hours with Crizotinib treatment (figure 
6.2A).  
Karpas-299, and DEL to a minor degree, demonstrated initial reductions in IRF4 
mRNA levels at 4 hours with Crizotinib treatment (Karpas-299: 50nM p=0.0002, 100nM 
p=0.0002, DEL: 50nM p=0.3251, 100nM p=0.0837), however by 8 hours mRNA levels 
had returned to basal levels and at 24 hours mRNA was increased with Crizotinib 
treatment (Karpas-299: 50nM p=0.0015, 100nM p=0.003, DEL: 50nM p=0.1148, 100nM 
p=0.0476) (figure 6.2B and 6.2C). In addition, BLIMP1α and BLIMP1β levels were 
unaffected at 4 hours (Karpas-Ϯϵϵ: BLIMPϭα ϱϬŶM p=Ϭ.ϴϰϴϵ, BLIMPϭα ϭϬϬŶM 
p=0.172, BLIMPϭβ ϱϬŶM p=Ϭ.ϭϬϱϱ, BLIMPϭβ ϭϬϬŶM p=Ϭ.ϲϯϯϬ, DEL: BLIMPϭα ϱϬŶM 
p=Ϭ.ϴϭϵϴ, BLIMPϭα ϭϬϬŶM p=Ϭ.ϬϳϮ, BLIMPϭβ ϱϬŶM p=Ϭ.ϭϭϱϱ, BLIMPϭβ ϭϬϬŶM 
p=0.1572) but increased in a dose-dependent manner from 8 hours (Karpas-299: 8 
hours: BLIMPϭα ϱϬŶM p=Ϭ.ϬϬϮϮ, BLIMPϭα ϭϬϬŶM p=Ϭ.Ϭϯϯϭ, BLIMPϭβ ϱϬŶM 
p=Ϭ.ϬϮϴϬ, BLIMPϭβ ϭϬϬŶM p=Ϭ.Ϯϱϵϱ, Ϯϰ houƌs: BLIMPϭα ϱϬŶM p=Ϭ.ϬϬϮϰ, BLIMPϭα 
100nM p=0.0605, BLIMPϭβ ϱϬŶM p=Ϭ.ϬϬϮϰ, BLIMPϭβ ϭϬϬŶM p=Ϭ.Ϭϯϰϲ, DEL: ϴ houƌs: 
BLIMPϭα ϱϬŶM p=Ϭ.ϭϳϮ, BLIMPϭα ϭϬϬŶM p=Ϭ.ϬϬϴϯ, BLIMPϭβ ϱϬŶM p=Ϭ.Ϭϰϱϲ, 
BLIMPϭβ ϭϬϬŶM p=Ϭ.ϬϬϭϱ, Ϯϰ houƌs: BLIMPϭα ϱϬŶM p=Ϭ.ϬϮϮ, BLIMPϭα ϭϬϬŶM 
p=0.0071, BLIMPϭβ ϱϬŶM p=Ϭ.ϬϭϬ, BLIMPϭβ ϭϬϬŶM p=Ϭ.ϬϯϬϲͿ across both cell lines 
(figure 6.2B and 6.2C). 
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Figure 6.2: The effect of Crizotinib treatment on the expression of BCL6, IRF4, and BLIMP1 in ALK+ ALCL 
Transcript and protein levels of transcription factors after 4, 8, and 24 hours treatment with Crizotinib in A) 
SUDHL1, B) Karpas-299, and C) DEL. Data is derived from 3 independent replicates, error bars indicate 
standard error of the mean. 
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Expression of c-MYC was reduced in a dose-dependent manner across both cell 
lines (Karpas-299: 8 hours: 50nM p=0.0.0026, 100nM p=0.0004, 24 hours: 50nM 
p=0.4835, 100nM p=0.0007, DEL: 8 hours: 50nM p=0.0062, 100nM p<0.0001, 24 hours: 
ϱϬŶM p=Ϭ.Ϭϲϱϰ, BLIMPϭβ ϭϬϬŶM p=Ϭ.ϮϮϰϭͿ (figure 6.2B and 6.2C). Despite the effect 
at the RNA level, the protein levels of IRF4 and BLIMP1 were largely unaffected in 
either cell line (figure 6.2B and 6.2C). 
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6.3 Discussion 
In this chapter, all ALK+ ALCL cell lines were found to be selectively sensitive to 
the ALK inhibitor, Crizotinib, in agreement with published data and in keeping with 
development of Crizotinib as a clinical agent in ALK+ ALCL (Gambacorti-Passerini et al., 
2011, Redaelli et al., 2013). In addition, inhibition of ALK lead to changes in the 
transcription of BCL6, IRF4, BLIMP1, and c-MYC indicating that ALK regulates this axis in 
ALK+ ALCL. 
Crizotinib is a dual c-Met and ALK inhibitor (Sahu et al., 2013) and both c-Met 
and its ligand Hepatocyte Growth Factor have been detected by RT-PCR in ALCL cell 
lines. (Pons et al., 1998). It is therefore conceivable that the effects of Crizotinib on 
transcription factor expression in these experiments occurred through inhibition of c-
Met-dependent as well as ALK-dependent events. However, as the survival of ALK+ 
ALCLs was sensitive to Crizotinib but that of the ALK- ALCL cell line, Mac1, was not 
(figure 6.1), it is likely that the Crizotinib-sensitive pathway of interest in these cell 
lines was downstream of ALK rather than c-Met.  
Analysis of transcription factor levels after Crizotinib treatment yielded two 
patterns in the regulation of expression, summarised in figure 6.3. All cell lines treated 
with Crizotinib resulted in a downregulation of BCL6 mRNA and protein (figure 6.2) 
indicating that BCL6 expression is driven by NPM-ALK in ALK+ ALCLs. This is in 
agreement with previously published data which suggested that BCL6 expression is 
driven by STAT3, a direct target of ALK (Walker et al., 2013).  
Figure 6.3: Summary of the interactions of ALK across ALK+ ALCL cell lines 
Interaction network of ALK based upon data in this chapter in A) SUDHL1 B) Karpas-299 and DEL. 
AͿ BͿ 
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In contrast the effect on IRF4 mRNA expression was variable. IRF4 was 
downregulated at all timepoints in SUDHL1 but upregulated in Karpas-299 and DEL 
(figure 6.2), albeit after an initial downregulation in Karpas-299 and perhaps also DEL. 
NPM-ALK may thus drive expression of IRF4 but in some cell lines ALK inhibition could 
result in upregulation of IRF4 as either a result of secondary regulatory effects 
downstream from ALK signalling or as a reflex upregulation of IRF4 as a pro-survival 
mechanism against Crizotinib treatment. This type of mechanism has been observed in 
other systems whereby treatment of ALL or CML cells with the BCR-ABL kinase 
inhibitor, Imatinib, results in upregulation of BCL6 for survival (Duy et al., 2011). 
Importantly however, the changes in IRF4 mRNA levels seen were not recapitulated at 
the protein level (figure 6.2). Data published during the course of this project 
demonstrated that treatment of Karpas-299 cells with 150nM Crizotinib for 24 hours 
was sufficient to downregulate IRF4 protein expression (Weilemann et al., 2015). 
These contradictory data could be due to the use of different concentrations of 
Crizotinib, to differences in cell cultures conditions, or to differences between the cell 
lines used. 
Crizotinib regulation of expression of BLIMPϭα aŶd BLIMPϭβ also diffeƌs 
between cell lines. Whilst ALK inhibition appears to reduce the expression of both 
BLIMP1 isoforms in SUDHL1 (figure 6.2A), it promotes the expression of both isoforms 
in Karpas-299 and DEL (figure 6.2B and 6.2C). This discrepancy in regulation could be 
indicative of different fundamental interactions between the axis and BLIMP1. The 
expression of BLIMP1α and BLIMP1β mRNA is only increased after 8 hours treatment 
in Karpas-299 and DEL (figure 6.2B and 6.2C) suggesting that the BLIMP1 mRNA 
increase may be an indirect effect of ALK inhibition. Consistent with differences 
between cell lines, expression of c-MYC mRNA is reduced by ALK inhibition in Karpas-
299 and DEL but not in SUDHL1 (figure 6.2). This suggests that ALK directly drives the 
expression of c-MYC in Karpas-299 and DEL whilst c-MYC may be driven by a different 
effector in SUDHL1. 
The data presented in this chapter confirms that Crizotinib is a viable treatment 
for ALK+ ALCL. Furthermore, this data agrees with published data promoting the 
potential of utilising Crizotinib in a clinical setting. 
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It cannot be ruled out that c-Met may contribute to the effects seen and 
therefore future work could focus on using a different ALK inhibitor to assess if these 
results can be reproduced. In addition, STAT3 is a direct target of ALK (Zamo et al., 
2002), and therefore cells could be treated with a STAT3 inhibitor to evaluate if the 
effects observed with Crizotinib are repeated with STAT3 inhibition. Alternatively, 
knockdown of ALK and STAT3 could be utilised to assess if similar effects are observed. 
Further analysis of other ALK+ ALCL cell lines should be undertaken to assess if there is 
a common effect on the axis expression with ALK inhibition.  
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7. Conclusion and Discussion 
 
The biology of PTCLs is poorly understood and as a result, they are difficult to 
classify and treat effectively. There is no standard, effective treatment for PTCLs; 
generally patients are treated with non-targeted multi-agent chemotherapy regimens 
such as CHOP (Vose et al., 2008). Consequently, long-term survival for patients is poor 
and novel therapies targeting critical biological dependencies are required. The BCL6-
IRF4-BLIMP1 transcription factor axis plays a key role in the regulation of B-cell 
maturation and differentiation as well as that of CD4+ and CD8+ T-cells (Crotty et al., 
2010, Johnston et al., 2009, Rutishauser et al., 2009). Recently, the axis has been 
implicated in a number of lymphoid malignancies including DLBCL and some types of 
NK/T-cell lymphoma (Boi et al., 2013, Pasqualucci et al., 2006, Pasqualucci et al., 2003, 
Shaffer et al., 2009, Weilemann et al., 2015). This project has examined and identified 
the importance of BCL6 and IRF4 expression and BLIMP1 suppression to the 
maintenance of proliferation and survival in ALCL. 
Initial analysis of the expression of the transcription factor axis across PTCL cell 
lines revealed that ALK+ ALCL cell lines express more BCL6 than other PTCLs. A possible 
explanation for this is that BCL6 expression is driven by the NPM-ALK fusion tyrosine 
kinase present in ALK+ ALCLs. NPM-ALK is constitutively catalytically active ALK (Chiarle 
et al., 2005, Zamo et al., 2002) and has many targets, including STAT3, which it 
phosphorylates resulting in its activation (Chiarle et al., 2005, Zamo et al., 2002). 
Activated STAT3 has been demonstrated to drive the expression of many targets, 
including BCL6 and IRF4 (Walker et al., 2013, Zamo et al., 2002). In agreement with 
this, treatment of all ALK+ ALCL cell lines tested with Crizotinib resulted in decreased 
mRNA and protein expression of BCL6 and, at early timepoints, IRF4. Therefore, BCL6, 
and to an extent IRF4, are driven by constitutively active ALK in ALK+ ALCL. However, 
this does not explain the high expression of BCL6 protein exhibited in ALK- ALCL oƌ ɶɷ 
T-NHL cell lines. It could be speculated that BCL6 expression is a result of a STAT3 
mutation resulting in constitutively active STAT3. Indeed, activating mutations of 
STAT3 have been reported in ALK- ALCLs as ǁell as ɶɷ T-NHL which have been 
implicated in the maintenance of cellular proliferation (Crescenzo et al., 2015, Kucuk et 
al., 2015). 
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Recently it was demonstrated that downregulation of miR155 expression leads 
to reduction of p-STAT3 levels in ALK- ALCL (Merkel et al., 2015). This interaction is 
particularly important in the context of this study as p-STAT3 drives the expression of 
both BCL6 and IRF4 (Chiarle et al., 2008, Kwon et al., 2009, Walker et al., 2013, Zamo 
et al., 2002). However, Merkel et al. showed that the miR155 gene is highly methylated 
in SUPM2 cells and thus expressed at low levels (Merkel et al., 2015). It is therefore 
difficult to ascertain the exact role of miR155 in ALK+ ALCL currently but low level 
expression of miR155 in ALK+ ALCL may nevertheless be sufficient for it to exert pro-
tumour effects.  
High BCL6 expression could be a result of downregulation of antagonistic 
transcription factors, for example BLIMP1. In normal T-cell physiology, BLIMP1 and 
BCL6 are mutually antagonistic and determine cell fate via this mechanism (Cimmino 
et al., 2008, Johnston et al., 2009). Of the PTCL cell lines presented in chapter 3, 50% 
exhibit low or no expression of at least one BLIMP1 isoform at the protein level. 
Despite this, some cell lines contain mutual expression of BLIMP1 and BCL6 protein 
suggesting mutual inhibition may be lost. In agreement with this, knockdown of BCL6 
in this project did not cause any effect on the expression of BLIMP1 mRNA or protein 
in any of the cell lines tested whilst BLIMP1 overexpression failed to reduce the 
expression of BCL6 mRNA or protein in this project and previously published data (Boi 
et al., 2013). As the cell of origin of ALCL is unknown, it is difficult to ascertain the 
interaction between BCL6 and BLIMP1 in these lymphomas. It is plausible that BCL6 
and BLIMP1 targets differ between T-cell lymphoma and normal T-cell physiology. For 
example, BCL6 only shares 50% of its target genes between DLBCL and breast cancer 
(Walker et al., 2014), and, additionally in TFH cells, BCL6 targets effectors required for 
T-cell differentiation, migration, and signalling (Hatzi et al., 2015) suggesting that the 
BCL6 transcriptional programme varies according to cellular context. 
To investigate if a direct BCL6-BLIMP1 interaction is present, there are multiple 
experiments which could be undertaken. ChIP-Seq would demonstrate if the 
transcription factors bound to the promoters of the antagonist, or a luciferase reporter 
construct coupled to a BCL6/BLIMP1 promoter could be utilised to investigate if 
overexpression of BCL6/BLIMP1 caused repression of luciferase. 
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This project has demonstrated that BCL6 is required to sustain the proliferation 
of some ALK+ ALCL cell lines. Lentiviral-mediated knockdown of BCL6 caused reduced 
growth rates compared to controls but did not induce apoptosis. As knockdown of 
BCL6 caused increased G2/M population subsets in 2 of 3 cell lines, it is possible that 
BCL6 promotes cellular proliferation through the promotion of cell cycle progression. 
In agreement with this argument, previously published data demonstrates that 
knockdown of BCL6 in DLBCL causes G1 arrest and fails to induce apoptosis (Ying et al., 
2013). The mechanism of this effect was not investigated but it seems not to involve 
suppression of p21 as p21 expression was not altered by 79-6.  
Recently, it has been identified that BCL6 is important for the control of 
metabolism in CD4+ and CD8+ T-cells through repression of glycolytic pathway genes 
(Oestreich et al., 2014). In addition, deficiency of Bcl6 in murine CD8+ T-cells is 
detrimental to cellular growth (Ichii et al., 2002). Therefore, if ALCLs share traits with 
CD8+ T-cells it is possible that BCL6 is working through the same mechanism. The 
glycolytic pathway is important for normal cellular production of ATP from glucose and 
oxygen; however repression of this pathway promotes the anaerobic respiration 
pathway. Whilst less efficient, the anaerobic pathway allows production of ATP in the 
absence of oxygen which would be beneficial for cells in oxygen-starved environments, 
such as those yet to undergo angiogenesis (Hanahan and Weinberg, 2000). Indeed, 
there are documented cases of the generation of more aggressive tumours via the 
removal of glycolysis-dependence (Kalaany and Sabatini, 2009). 
The data in this project would suggest that loss of BCL6 activity does not induce 
apoptosis as BCL6 knockdown failed to induce apoptosis. However, treatment of all 
cell lines with 79-6 did induce apoptosis irrespective of their reported BCL6 
dependency. As a result, it appears that 79-6 might exert off-target effects to induce 
apoptosis as published data on 79-6 demonstrates that the drug does not induce death 
in more than 40% of Toledo or OCI-Ly4 cells at 15mM (Cerchietti et al., 2010a). 
However, in this project, treatment of Toledo with 1mM of 79-6 was enough to kill all 
cells by Resazurin analysis. 
 The dependency of ALCL cell lines on BCL6 could be clarified by examining 
known BCL6 targets. Although not well documented in T-cells at the time of the 
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experiment, BCL6 targets were available for B-cells. BCL6 directly targets and represses 
the expression of genes involved in repressing apoptosis, namely ATR and P53, to allow 
DNA recombination for CSR and SHM as well as the cell cycle progression gene, P21 to 
promote cell cycling (Cerchietti et al., 2010a). However, treatment of ALCL cell lines 
with 79-6 failed to induce expression of these targets in the T-cell lines whilst 
expression was induced in DLBCL control suggesting that the BCL6 targets are not 
common between B-cells and T-cells or that 79-6 does not inhibit BCL6 in ALCL lines. It 
is possible that 79-6 is inhibiting BCL6, in part, based upon the induction of BCL6 target 
genes within SUDHL4. In light of this data, 79-6 does not constitute a viable 
therapeutic option for patients due to the poor specificity of the drug. More recently 
however, BCL6 targets for TFH cells have been published (Hatzi et al., 2015). Therefore, 
this experiment should be repeated using T-cell-specific BCL6 targets: STAT4, IFNGR1, 
GIMAP1, RORA and GATA3.   
The transforming mechanism of IRF4 is still unknown in PTCL; whilst 
translocations of the gene exist in a small percentage of PTCLs (Feldman et al., 2009), 
the oncogenic role of the translocation has never been proven. However, a number of 
activating IRF4 mutations have been identified in ATL, MM, and CLL (Havelange et al., 
2011, Kataoka, 2014, Melchor et al., 2014). These mutations all cluster in the DNA-
binding domain of IRF4 suggesting altered function of this domain is important for 
transformation of malignant cells. It is possible that IRF4 mutations may exist across 
PTCLs and it is important to sequence IRF4 in these tumours to identify any potential 
activating mutations. As well as coding mutations, SNPs present in IRF4 intronic 
regions have also been demonstrated to contribute to constitutive IRF4 expression 
(Boddicker et al., 2015). To further investigate these mutations, knockdown of IRF4 in 
these cell lines could be performed in conjunction with rescue experiments with 
mutated sequences. Indeed, a more robust experiment would be to knockout IRF4, if 
the cells are viable, and introduce the mutated IRF4 and assess the effect on 
proliferation of these cells. 
IRF4 has been demonstrated to be vital for the proliferation/survival of some 
ALCL cell lines in this project and, during the course of this work, similar findings have 
been published by two other groups (Boddicker et al., 2015, Weilemann et al., 2015). 
These data suggest that IRF4 plays a role in ALCL similar to that of MM, and HTLV- and 
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EBV-transformed cells (Dib et al., 2008, Wang et al., 2011a, Xu et al., 2008, Shaffer et 
al., 2008). In addition, 2 of the 3 cell lines examined in this project also demonstrated 
reduced c-MYC expression with IRF4 knockdown, suggesting a potential positive 
interaction between the transcription factors as observed in MM (Shaffer et al., 2008). 
Furthermore, recent work demonstrated that c-MYC inhibition resulted in IRF4 
downregulation in ALCL, suggesting IRF4 is also driven by c-MYC in these cells 
(Boddicker et al., 2015). Regulation of c-MYC is critically important for any cancer. 
Translocations involving the gene are common across DLBCL and BL (Thieblemont and 
Briere, 2013) and are seen in rare cases of ALCL (Liang et al., 2013). In non-transformed 
cells, c-MYC is important for regulating both apoptosis and proliferation. However, 
overexpression of c-MYC can drive rapid proliferation and also cause deregulation of 
cell cycle regulators (Dang et al., 2006, Eilers and Eisenman, 2008). According to 
recently published data, treatment of ALK+ ALCL cell lines (Karpas-299, JB6) with 
150nM Crizotinib for 24 hours results in downregulation of both IRF4 and c-MYC 
protein expression (Weilemann et al., 2015). The authors conclude that c-MYC 
downregulation is an effect of IRF4 downregulation. This is in agreement with data for 
the cell lines presented in the project, Karpas-299 and DEL, as knockdown of IRF4 in 
these cell lines causes downregulation of c-MYC in these cell lines and, additionally, c-
MYC mRNA expression correlates with IRF4 mRNA expression with Crizotinib 
treatment. In addition, it has been established that IRF4 also promotes CD30 and NF-
κB eǆpƌessioŶ iŶ ALCL to dƌiǀe its oǁŶ eǆpƌessioŶ (Boddicker et al., 2015). Therefore, 
collectively these data suggest that IRF4 is a putative tumour-promoting protein that 
drives its own expression through multiple pathways.  
Interestingly, downregulation of IRF4 in this project lead to an increase in 
BLIMP1α mRNA levels in SUDHL1 but not Karpas-299 or DEL. This interaction is 
contrary to normal T-cell function whereby IRF4 facilitates BLIMP1 activity (Li et al., 
2012). However, this dysregulation may be expected in SUDHL1 as a mechanism of 
suppƌessiŶg the tuŵouƌ suppƌessoƌ aĐtiǀitǇ of BLIMPϭα. The data also deŵoŶstƌates 
that Karpas-299 and DEL retain the positive effect of IRF4 expression upon BLIMP1 and 
thus suggest a different mechanism of overcoming BLIMP1 tumour suppressor activity. 
Investigation into the inhibition of ALK lead to the observation that IRF4 mRNA 
is initially downregulated in all ALK+ ALCL cell lines examined demonstrating that IRF4 
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is driven by ALK signalling. However, IRF4 mRNA is then upregulated in 2 of the 3 cell 
lines which could be indicative of a potential compensatory mechanism for loss of ALK 
activity. This type of mechanism has been observed in BCR-ABL-positive ALL with 
Imatinib whereby treatment of cell lines with Imatinib lead to a sharp increase in the 
expression of BCL6. This effect was believed to be a compensatory mechanism for the 
loss of BCR-ABL to promote survival (Duy et al., 2011). 
Interestingly, knockdown of IRF4 also induced stalling in the G2/M stage of the 
cell cycle and failed to induce apoptosis in most of the cell lines tested. However, in 
contrast to BCL6, IRF4 has been demonstrated to be important for the promotion of 
glycolysis, ATP production, and increased oxygen consumption (Man et al., 2013). In 
agreement with this, knockout of IRF4 in T-cells revealed IRF4 binds HIF1A which is 
required for cellular homeostasis (Man et al., 2013, Yao et al., 2013). Furthermore, 
gene expression profiling of ALK+ ALCL cells revealed an enrichment of the HIF1A gene 
signature suggesting this is a vital pathway in ALCL (Iqbal et al., 2014). Therefore, it is 
plausible that BCL6 and IRF4 promote proliferation of ALCL cells by promoting different 
metabolic pathways. Indeed, it is possible that both transcription factors are important 
for maintenance of proliferation and therefore dual-inhibition of both could be a 
useful therapeutic approach. To investigate this, knockdown of both BCL6 and IRF4 
should be undertaken or, conversely, treatment of IRF4 knockdown cells with BCL6 
inhibitor, to assess if a combinatory effect could be exploited. Alternatively, direct 
inhibition of the metabolic pathways would elucidate whether the pathway can be 
exploited in these malignancies. The overlapping functions suggest that ALCLs may also 
benefit from treatment with drugs exploiting metabolic pathways. 
One unexplored aspect of the tumourigenic function of IRF4 in ALCLs is the 
identity of the transcription factors with which it cooperates. In B-cells, IRF4 typically 
binds PU.1 and SPIB to exert its activity (Basso and Dalla-Favera, 2012, Escalante et al., 
2002), however due to the low quantities of these binding proteins in T-cells, IRF4 
binds to other targets such as BATF and STAT3 to exert its effects (Kwon et al., 2009, Li 
et al., 2012, Murphy et al., 2013). It would be of interest to investigate the levels and 
functional dependencies of BATF, STAT3, PU.1, and SPIB in T-cell lymphomas to 
investigate whether these co-factors play any role in the survival of these cells in 
cooperation with IRF4. Indeed, published gene expression profiling of ALCLs 
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demonstrate a high BATF3 gene signature suggesting a potential role for BATF3 
specifically in ALCL (Iqbal et al., 2014). This could also be reinforced with ChIP-Seq to 
demonstrate whether IRF4 shares the same binding sites as any of these co-factors. 
This work would be of benefit as it would offer another therapeutic alternative to 
targeting IRF4, as no inhibitors of the protein currently exist. 
The data presented in chapter 5 demonstrated that overexpression of either 
BLIMP1 isoform is detrimental to the survival of 2 out of 3 of the ALCL cell lines. 
Therefore, it appears beneficial to cell line survival to reduce expression of BLIMP1 
ǁheƌeǀeƌ possiďle. Whilst oǀeƌeǆpƌessioŶ of eitheƌ BLIMPϭα oƌ BLIMPϭβ failed to 
induce changes in BCL6 expression, IRF4 expression was negatively regulated in 2 of 
the 3 cell lines by overexpression of either isoform. As BLIMP1 was defined as a 
tumour suppressor in these lymphomas, the data reinforces the concept of pro-
tumorigenic IRF4 functions. 
BLIMP1 may exert inhibitory effects on ALCL cells in several ways. For example, 
expression of BLIMP1 in the ALK+ ALCL cell line SUPM2 has been reported to result in 
downregulation of an oncogenic microRNA, miR155 (Boi et al., 2013). Therefore, one 
possible mechanism by which BLIMP1 could suppress lymphoma development is 
through inhibition of miR155 expression leading to downregulation of p-STAT3 and 
eventually BCL6 and IRF4, amongst other targets. However, BCL6 expression was not 
downregulated by BLIMP1 overexpression in any cell line in this study or in that of Boi 
et al. (Boi et al., 2013). Since BCL6 expression is mediated through NPM-ALK in all ALK+ 
ALCL cell lines tested, the repressive effect of BLIMP1 on BCL6 could be diminished by 
the constitutive expression of NPM-ALK. This effect may be confirmed in a previous 
studǇ ǁhiĐh deŵoŶstƌates that oǀeƌeǆpƌessioŶ of BLIMPϭα iŶ ALK+ ALCL did Ŷot Đause 
a detectable reduction in BCL6 mRNA levels by gene expression array (Boi et al., 2013). 
It is possible that critical BLIMP1 targets have been modified in some way 
within cell lines to prevent the binding of BLIMP1, or that BLIMP1 itself is mutated to 
render it dysfunctional. Whilst it has not been documented to date, mutations 
introduced into BLIMP1 targets in BL abrogate the binding of BLIMP1 to regulatory 
regions (Cubedo et al., 2011). It has previously been documented that PRDM1 can 
harbour frameshift deletions, truncations, and point mutations in DLBCL leading to the 
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inactivation of the BLIMP1 protein (Pasqualucci et al., 2006). To this possibility in ALCL 
lines, the PRDM1 gene of the cell lines would require sequencing. Sequencing of the 
PRDM1 locus may be interesting in Karpas-299 in particular as this line harbours a 
deletion of 6q21 (Boi et al., 2013) aŶd eǆpƌesses Ŷo deteĐtaďle leǀels of BLIMPϭα 
protein in this project but expresses large quantities of BLIMP1 mRNA (data not 
shown). Therefore, the data suggests either a mutation resulting in protein instability 
oƌ a deƌegulatioŶ of pƌoteiŶ degƌadatioŶ. IŶteƌestiŶglǇ, BLIMPϭα has ďeeŶ shoǁŶ to ďe 
degraded following SUMOlyation (Shimshon et al., 2011) so that hyperactivation of 
this pathway could result in increased degradation of BLIMP1 protein. Somewhat 
similarly, inactivation of the FBXO11 ubiquitin ligase protein in DLBCL leads to 
increased expression of BCL6 protein (Duan et al., 2012).  
This project has highlighted a potential differing mechanism of transformation 
between certain ALK+ ALCL cell lines, namely between SUDHL1 and Karpas-299/DEL. 
Regarding the transcription factor axis, SUDHL1 responds differently to drug 
treatments compared to Karpas-299 and DEL. For example, treatment of SUDHL1 with 
Crizotinib results in reduction of BCL6, IRF4, and BLIMP1 mRNA expression but not c-
MYC expression. However, treatment of Karpas-299 and DEL with Crizotinib results in 
reduction of all targets initially, with IRF4 and BLIMP1 mRNA expression increasing 
after 24 hours suggesting that ALK may have differing interactions in these cell lines. 
SUDHL1 was also the only ALK+ ALCL cell line to show sensitivity to Lenalidomide 
treatment reinforcing the hypothesis of differing transforming mechanisms between 
SUDHL1 and other ALK+ ALCLs. In addition, loss of IRF4 in SUDHL1 results in 
upregulation of BLIMP1α, but not BLIMP1β, mRNA expression whilst Karpas-299 and 
DEL demonstrate reduction in both BLIMP1 isoforms. Taken together, these data 
suggest that a subset of ALK+ ALCLs may exist that would benefit from Lenalidomide 
treatment. This could be investigated further by conducing gene expression profiling of 
SUDHL1 vs. Karpas-299 and DEL and investigating any important differences between 
the cell lines. In addition, published data could be investigated for alterations between 
specific ALK+ ALCLs.  
From this body of research, two key areas for future work are particularly 
evident. It is important to investigate if BCL6 and IRF4 promote proliferation across 
other PTCL subsets, particularly AITL whereby expression of BCL6 is high. Therefore 
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knockdown or CRISPR-mediated knockouts of BCL6 and/or IRF4 should be undertaken 
in other cell lines and proliferation/survival should be assessed. For AITL, due to the 
lack of cell line availability, either primary cell cultures or xenograft mouse models 
would be required to investigate this. It is also of interest to elucidate any BCL6 and 
IRF4 targets in T-cell lymphoma and assess how these contribute to proliferation. This 
would involve taking cell lines which are sensitive and insensitive to BCL6/IRF4 
inhibition or knockdown and assessing the changes in gene expression. Targets 
important for proliferation could potentially be identified by analysing the gene 
expression differences between sensitive and insensitive lines. As cell lines appear to 
exhibit heterogeneity in the sensitivities of either BCL6/IRF4 knockdown or BLIMP1 
overexpression it would be beneficial to understand the molecular events contributing 
to these sensitivities. Therefore further investigation into how the interactions of BCL6, 
IRF4, and BLIMP1 differ between both PTCL cell lines and normal T-cells, and the 
molecular mechanisms which perturb these interactions, should also be undertaken. 
This could be achieved through CRISPR-mediated knockout studies in conjunction with 
gene expression profiling. 
The data presented in this project has demonstrated that the interactions 
between the BCL6-IRF4-BLIMP1 transcription factor axis varies between cell lines 
(figure 7.1). However, it is clear the axis plays a vital role in the survival of ALCL and 
highlights potential therapeutic avenues which could be exploited for the future 
treatment of these patients. Therapeutic options should focus on downregulating 
BCL6, IRF4, and NPM-ALK activity whilst promoting BLIMP1 activity. As direct targeting 
of IRF4 is not an option currently, indirect inhibition through targeting of BRD4, c-MYC, 
and NF-κB ǁould eǆeƌt aŶti-tumour effects on those malignancies sensitive to IRF4 
knockdown. The use of metabolic inhibitors, STAT3 inhibitors, or ALK inhibitors (for 
ALK-driven malignancies) may yield a mechanism of targeting both BCL6 and IRF4 
pathways simultaneously. The treatment of PTCL will improve only with greater 
understanding of the underlying mechanisms that drive it; this project provides the 
foundations for that work. 
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Figure 7.1: Summary of the interactions between the BCL6-IRF4-BLIMP1 transcription factor axis in ALK+ ALCL cell 
lines 
Suggested interaction network of the BCL6-IRF4-BLIMP1 axis in the ALK+ ALCL based upon experiments conducted 
and published data. Arrow thickness indicates the magnitude of the interaction, dashed lines indicate the 
interaction has not been interrogated in this project.  
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